drTarget portfolio target-disease associations for reproductive system DrTarget’s AI-Powered Indication Expansion for Reproductive System Disorders

AI-Powered Discovery for Reproductive System Disorders

DrTarget leverages AI, bioinformatics, and data-driven models to identify novel targets and therapeutic opportunities for reproductive system diseases. Our platform integrates large-scale datasets from Open Targets, PubChem, and ChEMBL to accelerate drug discovery and repurposing.

We focus on the following areas:

✔ Female Reproductive Disorders – Endometriosis, Polycystic Ovary Syndrome (PCOS), Infertility
✔ Male Reproductive Disorders – Hypogonadism, Erectile Dysfunction, Sperm Quality Deficiencies
✔ Hormonal & Endocrine Dysfunctions – Estrogen, Testosterone, and Progesterone-Related Disorders
✔ Gynecological & Urological Cancers – Ovarian, Prostate, and Cervical Cancer

Target-disease associations for reproductive system diseases.

Check best scored target-disease associations in table:

BioAssay Name	program	diseaseName	assayType	associationScore	numberOfEvidences	testedCompounds	activeCompounds
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	azoospermia	targetBased	0.623836516059577	139	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	azoospermia	targetBased	0.623836516059577	139	296501	2737
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	azoospermia	pathwayBased	0.106534191164914	110	376029	3978
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	azoospermia	targetBased	0.107648708654455	149	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	azoospermia	targetBased	0.107648708654455	149	290726	2649
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	azoospermia	targetBased	0.383181213920299	103	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	azoospermia	targetBased	0.383181213920299	103	86095	1151
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	azoospermia	targetBased	0.124377576440203	74	315412	318
Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33	STK33	azoospermia	targetBased	0.121668081074759	72	37341	2812
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine Kinase 33 Activity	STK33	azoospermia	targetBased	0.121668081074759	72	321808	235
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	azoospermia	targetBased	0.619951507505911	67	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	azoospermia	targetBased	0.619951507505911	67	64908	359
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)	PAFAH1B2	azoospermia	targetBased	0.104030125995573	39	335239	4158
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	azoospermia	targetBased	0.126789838736536	74	369953	1596
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	reproductive system disease	targetBased	0.319289825498114	593	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	reproductive system disease	targetBased	0.319289825498114	593	296501	2737
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	reproductive system disease	targetBased	0.191333226758021	52	336894	489
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	reproductive system disease	targetBased	0.191400098979507	13	290355	265
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	reproductive system disease	targetBased	0.556069929669968	1974	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	reproductive system disease	targetBased	0.556069929669968	1974	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	reproductive system disease	targetBased	0.211088327023387	109	217959	2390
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	reproductive system disease	targetBased	0.269321032402017	195	46715	2829
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	reproductive system disease	pathwayBased	0.119055722557289	886	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	reproductive system disease	pathwayBased	0.119055722557289	886	359244	3094
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	reproductive system disease	targetBased	0.285336745279937	43	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	reproductive system disease	targetBased	0.285336745279937	43	335239	695
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	reproductive system disease	targetBased	0.1066502151652	35	363803	458
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	reproductive system disease	targetBased	0.504093319777361	503	86095	1114
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	reproductive system disease	targetBased	0.304941491250553	1495	356517	1139
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	reproductive system disease	targetBased	0.292553432530574	191	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	reproductive system disease	targetBased	0.292553432530574	191	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	reproductive system disease	targetBased	0.292553432530574	191	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	reproductive system disease	targetBased	0.292553432530574	191	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	reproductive system disease	targetBased	0.292553432530574	191	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	reproductive system disease	targetBased	0.292553432530574	191	336308	6862
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	reproductive system disease	targetBased	0.105357543793805	220	330392	1295
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	reproductive system disease	pathwayBased	0.226060392229629	506	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	reproductive system disease	pathwayBased	0.226060392229629	506	194666	1722
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	reproductive system disease	targetBased	0.207745789058526	55	324747	1043
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	reproductive system disease	targetBased	0.20546132876003	51	316642	617
uHTS identification of small molecule modulators of NR3A	GRIN3A	reproductive system disease	targetBased	0.236795387863165	5	339772	8480
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	reproductive system disease	pathwayBased	0.268428148224606	694	43989	342
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	infertility	targetBased	0.330935935958526	161	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	infertility	targetBased	0.330935935958526	161	296501	2737
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	infertility	targetBased	0.673498662347584	318	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	infertility	targetBased	0.673498662347584	318	86095	1151
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	infertility	targetBased	0.527380594556525	28	394050	3624
qHTS Assay for Activators of ClpP	Bacillus subtilis (strain 168)	infertility	targetBased	0.29220705263531	51	338378	6439
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	infertility	targetBased	0.537453046426094	68	86095	1114
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	infertility	targetBased	0.622704166546388	26	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	infertility	targetBased	0.622704166546388	26	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	infertility	targetBased	0.622704166546388	26	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	infertility	targetBased	0.622704166546388	26	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	infertility	targetBased	0.622704166546388	26	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	infertility	targetBased	0.622704166546388	26	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	infertility	targetBased	0.311429203538357	6375	322361	619
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	infertility	targetBased	0.60466648961276	9	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	infertility	targetBased	0.60466648961276	9	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	infertility	targetBased	0.60466648961276	9	407539	2380
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	infertility	targetBased	0.369401818624704	9	324747	1043
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	polycystic ovary syndrome	targetBased	0.691019361968048	297	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	polycystic ovary syndrome	targetBased	0.691019361968048	297	86095	1151
qHTS for Inhibitors of TGF-b	TGFB1	polycystic ovary syndrome	pathwayBased	0.115655032229183	314	403345	4970
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	polycystic ovary syndrome	targetBased	0.593532835555096	107	394050	3624
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	polycystic ovary syndrome	targetBased	0.602415032685796	174	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	polycystic ovary syndrome	targetBased	0.602415032685796	174	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	polycystic ovary syndrome	targetBased	0.602415032685796	174	405130	6428
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	polycystic ovary syndrome	targetBased	0.615267644013478	263	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	polycystic ovary syndrome	targetBased	0.615267644013478	263	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	polycystic ovary syndrome	targetBased	0.615267644013478	263	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	polycystic ovary syndrome	targetBased	0.615267644013478	263	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	polycystic ovary syndrome	targetBased	0.615267644013478	263	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	polycystic ovary syndrome	targetBased	0.615267644013478	263	196177	519
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	polycystic ovary syndrome	targetBased	0.515572552941364	60	639428	9218
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	polycystic ovary syndrome	targetBased	0.30567130515714	96	86095	1114
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	polycystic ovary syndrome	targetBased	0.108780772437343	383	356517	1139
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	polycystic ovary syndrome	pathwayBased	0.102849715814516	60	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	polycystic ovary syndrome	pathwayBased	0.102849715814516	60	194666	1722
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	polycystic ovary syndrome	targetBased	0.115163759783392	213	128695	1039
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	polycystic ovary syndrome	targetBased	0.115163759783392	213	127961	1153
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	infertility	targetBased	0.301877027830789	147	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	infertility	targetBased	0.301877027830789	147	64908	359
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	AIDS	targetBased	0.406065542559402	5	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	AIDS	targetBased	0.406065542559402	5	86095	1151
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	AIDS	targetBased	0.406110621508939	6	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	AIDS	targetBased	0.406110621508939	6	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	AIDS	targetBased	0.406110621508939	6	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	AIDS	targetBased	0.406110621508939	6	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	AIDS	targetBased	0.406110621508939	6	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	AIDS	targetBased	0.406110621508939	6	196177	519
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	AIDS	targetBased	0.102772326379821	81	330392	1295
HCS assay for microtubule stabilizers	TUBB	AIDS	targetBased	0.101782633185553	6	195821	1625
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	leprosy	targetBased	0.468432065851697	26	363803	1383
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	leprosy	targetBased	0.109625402278737	36	394050	3624
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	leprosy	targetBased	0.310549999897436	5	75924	1804
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	leprosy	targetBased	0.114460492164223	6	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	leprosy	targetBased	0.114460492164223	6	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	leprosy	targetBased	0.114460492164223	6	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	leprosy	targetBased	0.114460492164223	6	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	leprosy	targetBased	0.114460492164223	6	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	leprosy	targetBased	0.114460492164223	6	196177	519
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	leprosy	targetBased	0.484694014611609	101	292323	1836
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	endometriosis	targetBased	0.608846056713265	568	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	endometriosis	targetBased	0.608846056713265	568	86095	1151
qHTS for Inhibitors of TGF-b	TGFB1	endometriosis	pathwayBased	0.120269037141279	313	403345	4970
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	endometriosis	targetBased	0.106184305848052	33	57013	201
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	endometriosis	targetBased	0.41772389634928	35	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	endometriosis	targetBased	0.286370501857062	14	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	endometriosis	targetBased	0.286370501857062	14	335239	695
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	endometriosis	pathwayBased	0.225583452560254	353	362051	17187
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	endometriosis	targetBased	0.100173391369645	68	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	endometriosis	targetBased	0.100173391369645	68	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	endometriosis	targetBased	0.100173391369645	68	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	endometriosis	targetBased	0.100173391369645	68	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	endometriosis	targetBased	0.100173391369645	68	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	endometriosis	targetBased	0.100173391369645	68	196177	519
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	endometriosis	targetBased	0.452546152126542	290	86095	1114
qHTS assay for re-activators of p53 using a Luc reporter	TP53	endometriosis	pathwayBased	0.104624342924314	227	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endometriosis	targetBased	0.104624342924314	227	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endometriosis	targetBased	0.104624342924314	227	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endometriosis	targetBased	0.104624342924314	227	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endometriosis	targetBased	0.104624342924314	227	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	endometriosis	targetBased	0.13312524504618	260	356517	1139
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	endometriosis	targetBased	0.115938890607992	21	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	endometriosis	targetBased	0.115938890607992	21	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	endometriosis	targetBased	0.115938890607992	21	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	endometriosis	targetBased	0.115938890607992	21	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	endometriosis	targetBased	0.115938890607992	21	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	endometriosis	targetBased	0.115938890607992	21	336308	6862
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	endometriosis	targetBased	0.16602832769995	37	193542	587
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	endometriosis	pathwayBased	0.103876464971322	69	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	endometriosis	pathwayBased	0.103876464971322	69	194666	1722
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	endometriosis	targetBased	0.442740330846156	12	31324	362
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	endometriosis	targetBased	0.100906063040182	19	324747	1043
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	endometriosis	targetBased	0.262042215580954	18	369953	2602
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	hysterectomy	pathwayBased	0.341601122370423	5	376029	3978
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	hypospadias	targetBased	0.507138182289749	5	359207	1432
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	hypospadias	targetBased	0.142479897194459	54	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	hypospadias	targetBased	0.142479897194459	54	64908	359
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	bacterial vaginosis	targetBased	0.406623394559921	5	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	bacterial vaginosis	targetBased	0.406623394559921	5	86095	1151
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	erectile dysfunction	targetBased	0.105281886643352	6	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	erectile dysfunction	targetBased	0.105281886643352	6	86095	1151
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	erectile dysfunction	targetBased	0.614214142126277	12	250190	1304
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	erectile dysfunction	targetBased	0.614214142126277	12	255537	2141
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	erectile dysfunction	targetBased	0.105172006703856	9	59788	212
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	erectile dysfunction	targetBased	0.103050478641277	5	86095	1114
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	erectile dysfunction	targetBased	0.409860626623537	8	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	erectile dysfunction	targetBased	0.409860626623537	8	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	erectile dysfunction	targetBased	0.409860626623537	8	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	erectile dysfunction	targetBased	0.409860626623537	8	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	erectile dysfunction	targetBased	0.409860626623537	8	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	erectile dysfunction	targetBased	0.409860626623537	8	336308	6862
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	male infertility	targetBased	0.457284103225698	272	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	male infertility	targetBased	0.457284103225698	272	296501	2737
Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity	RAD54L	primary ovarian insufficiency	targetBased	0.478332733535692	5	358498	505
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	primary ovarian insufficiency	targetBased	0.660662625776492	198	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	primary ovarian insufficiency	targetBased	0.660662625776492	198	86095	1151
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	primary ovarian insufficiency	targetBased	0.307655737529293	11	363803	458
qHTS Assay for Activators of ClpP	Bacillus subtilis (strain 168)	primary ovarian insufficiency	targetBased	0.29147959289562	38	338378	6439
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	primary ovarian insufficiency	targetBased	0.768831049962756	66	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	primary ovarian insufficiency	targetBased	0.768831049962756	66	64908	359
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	primary ovarian insufficiency	targetBased	0.575632336673213	51	86095	1114
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	male infertility	targetBased	0.484854883538712	153	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	male infertility	targetBased	0.484854883538712	153	86095	1151
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	male infertility	targetBased	0.579314160133462	144	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	male infertility	targetBased	0.579314160133462	144	64908	359
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	pelvic organ prolapse	targetBased	0.449247372927582	39	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	pelvic organ prolapse	targetBased	0.449247372927582	39	86095	1151
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	pelvic organ prolapse	targetBased	0.28463975711316	4	394050	3624
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	pelvic organ prolapse	targetBased	0.153363995798365	7	86095	1114
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	sex hormone-binding globulin measurement	pathwayBased	0.341192509250402	11	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	sex hormone-binding globulin measurement	pathwayBased	0.341192509250402	11	64908	278
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	sex hormone-binding globulin measurement	targetBased	0.431273525326439	8	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	sex hormone-binding globulin measurement	targetBased	0.431273525326439	8	86095	1151
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	sexual dysfunction	targetBased	0.547899973728238	18	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	sexual dysfunction	targetBased	0.547899973728238	18	86095	1151
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	sexual dysfunction	targetBased	0.41000733601855	21	363803	2412
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	sexual dysfunction	targetBased	0.516153972197123	6	86095	1114
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	sexual dysfunction	targetBased	0.509695304165687	17	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	sexual dysfunction	targetBased	0.509695304165687	17	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	sexual dysfunction	targetBased	0.509695304165687	17	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	sexual dysfunction	targetBased	0.509695304165687	17	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	sexual dysfunction	targetBased	0.509695304165687	17	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	sexual dysfunction	targetBased	0.509695304165687	17	336308	6862
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	sexual dysfunction	targetBased	0.595062731184444	18	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	sexual dysfunction	targetBased	0.595062731184444	18	356160	1703
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	sexual dysfunction	targetBased	0.443101680304658	35	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	sexual dysfunction	targetBased	0.443101680304658	35	61606	416
Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity	KDM4C	sex hormone-binding globulin measurement	targetBased	0.145743829237082	12	326066	228
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	sex hormone-binding globulin measurement	targetBased	0.286069709767535	6	362098	692
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	sex hormone-binding globulin measurement	targetBased	0.503853378066006	11	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	sex hormone-binding globulin measurement	pathwayBased	0.503853378066006	11	403871	1243
uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay	TNFRSF10B	sex hormone-binding globulin measurement	targetBased	0.117555162230808	6	363840	3764
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	sex hormone-binding globulin measurement	targetBased	0.527559111681462	30	217035	883
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	sex hormone-binding globulin measurement	targetBased	0.334380493986892	12	369953	3123
uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay	UBE2M	sex hormone-binding globulin measurement	targetBased	0.117467890850134	6	363840	2123
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone-binding globulin measurement	targetBased	0.517365234928652	33	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone-binding globulin measurement	targetBased	0.517365234928652	33	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone-binding globulin measurement	targetBased	0.517365234928652	33	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone-binding globulin measurement	targetBased	0.517365234928652	33	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone-binding globulin measurement	targetBased	0.517365234928652	33	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone-binding globulin measurement	targetBased	0.517365234928652	33	196177	519
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	sex hormone-binding globulin measurement	targetBased	0.512797449636891	11	639428	9218
uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7)	SENP7	sex hormone-binding globulin measurement	targetBased	0.320943237386916	6	331670	4902
qHTS assay for re-activators of p53 using a Luc reporter	TP53	sex hormone-binding globulin measurement	pathwayBased	0.29154645410492	189	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	sex hormone-binding globulin measurement	targetBased	0.29154645410492	189	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	sex hormone-binding globulin measurement	targetBased	0.29154645410492	189	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	sex hormone-binding globulin measurement	targetBased	0.29154645410492	189	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	sex hormone-binding globulin measurement	targetBased	0.29154645410492	189	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	sex hormone-binding globulin measurement	targetBased	0.329406891059075	11	356517	1139
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	sex hormone-binding globulin measurement	targetBased	0.534121828195915	12	276265	806
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	sex hormone-binding globulin measurement	targetBased	0.484651688967846	23	325630	216
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	sex hormone-binding globulin measurement	targetBased	0.366778435415114	8	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	sex hormone-binding globulin measurement	targetBased	0.366778435415114	8	356160	1703
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	sex hormone-binding globulin measurement	targetBased	0.344736953931926	5	31324	362
uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1	PHOSPHO1	sex hormone-binding globulin measurement	targetBased	0.458478523707367	39	288321	3164
uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay	UBE2N	sex hormone-binding globulin measurement	targetBased	0.198106600332585	11	330393	1538
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	sex hormone-binding globulin measurement	targetBased	0.465363666190052	27	369953	2602
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	sex hormone-binding globulin measurement	targetBased	0.266032267576797	5	189882	6790
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	sex hormone-binding globulin measurement	targetBased	0.266032267576797	5	48068	449
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	sex hormone-binding globulin measurement	targetBased	0.266032267576797	5	220571	2380
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	sex hormone-binding globulin measurement	targetBased	0.266032267576797	5	223611	305
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	sex hormone-binding globulin measurement	pathwayBased	0.131370127775605	9	43989	342
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	testosterone measurement	targetBased	0.258084505318058	5	359206	428
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	testosterone measurement	targetBased	0.442516881242747	5	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	testosterone measurement	pathwayBased	0.442516881242747	5	403871	1243
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	testosterone measurement	targetBased	0.136798160892576	6	369953	3123
qHTS assay for re-activators of p53 using a Luc reporter	TP53	testosterone measurement	pathwayBased	0.254357101486959	20	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	testosterone measurement	targetBased	0.254357101486959	20	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	testosterone measurement	targetBased	0.254357101486959	20	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	testosterone measurement	targetBased	0.254357101486959	20	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	testosterone measurement	targetBased	0.254357101486959	20	124022	1156
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	testosterone measurement	targetBased	0.449943036758141	5	276265	806
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	testosterone measurement	targetBased	0.456524060716635	15	325630	216
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	testosterone measurement	targetBased	0.263374027540936	6	193542	587
qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation	SNUPN	testosterone measurement	targetBased	0.116813497740296	6	340719	242
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	testosterone measurement	targetBased	0.452931788356395	9	55710	315
uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1	PHOSPHO1	testosterone measurement	targetBased	0.255765123660283	8	288321	3164
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	testosterone measurement	targetBased	0.281610218556399	11	369953	2602
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	ovarian disease	pathwayBased	0.573470389432472	7344	376029	3978
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	ovarian disease	targetBased	0.218348811443544	17	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	ovarian disease	targetBased	0.218348811443544	17	337446	1356
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ovarian disease	targetBased	0.281092856851015	511	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ovarian disease	targetBased	0.281092856851015	511	86095	1151
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	ovarian disease	targetBased	0.242888964436697	84	344733	7043
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	ovarian disease	targetBased	0.250162159906845	119	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	ovarian disease	targetBased	0.250162159906845	119	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	ovarian disease	targetBased	0.250162159906845	119	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	ovarian disease	targetBased	0.250162159906845	119	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	ovarian disease	targetBased	0.250162159906845	119	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	ovarian disease	targetBased	0.250162159906845	119	196177	519
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	ovarian disease	targetBased	0.172702041557414	36	639428	9218
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ovarian disease	targetBased	0.236532177108524	110	86095	1114
qHTS assay for re-activators of p53 using a Luc reporter	TP53	ovarian disease	pathwayBased	0.316651263703166	1264	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian disease	targetBased	0.316651263703166	1264	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian disease	targetBased	0.316651263703166	1264	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian disease	targetBased	0.316651263703166	1264	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ovarian disease	targetBased	0.316651263703166	1264	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	ovarian disease	targetBased	0.26411307663705	340	356517	1139
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	ovarian disease	targetBased	0.226336248602659	30	347933	673
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	ovarian disease	pathwayBased	0.224131879990636	149	43989	342
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	breast adenosis	pathwayBased	0.205858657928793	6	376029	3978
qHTS assay for re-activators of p53 using a Luc reporter	TP53	breast adenosis	pathwayBased	0.310834852945599	8	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast adenosis	targetBased	0.310834852945599	8	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast adenosis	targetBased	0.310834852945599	8	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast adenosis	targetBased	0.310834852945599	8	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast adenosis	targetBased	0.310834852945599	8	124022	1156
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	placenta disease	targetBased	0.107152161341315	28	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	placenta disease	targetBased	0.107152161341315	28	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	placenta disease	targetBased	0.107152161341315	28	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	placenta disease	targetBased	0.107152161341315	28	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	placenta disease	targetBased	0.107152161341315	28	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	placenta disease	targetBased	0.107152161341315	28	196177	519
qHTS assay for re-activators of p53 using a Luc reporter	TP53	placenta disease	pathwayBased	0.125032607362292	26	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	placenta disease	targetBased	0.125032607362292	26	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	placenta disease	targetBased	0.125032607362292	26	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	placenta disease	targetBased	0.125032607362292	26	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	placenta disease	targetBased	0.125032607362292	26	124022	1156
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ovarian dysfunction	targetBased	0.233864740847807	139	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ovarian dysfunction	targetBased	0.233864740847807	139	86095	1151
qHTS Assay for Activators of ClpP	Bacillus subtilis (strain 168)	ovarian dysfunction	targetBased	0.296605881780465	51	338378	6439
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	ovarian dysfunction	targetBased	0.303037762218972	69	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	ovarian dysfunction	targetBased	0.303037762218972	69	64908	359
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ovarian dysfunction	targetBased	0.214388430119637	34	86095	1114
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ovarian dysfunction	targetBased	0.31261346753294	6370	322361	619
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	hyperandrogenism	targetBased	0.431211144097936	9	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	hyperandrogenism	targetBased	0.431211144097936	9	86095	1151
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Estrogen resistance syndrome	targetBased	0.62458590288883	44	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Estrogen resistance syndrome	targetBased	0.62458590288883	44	86095	1151
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	female infertility	targetBased	0.621559948320993	104	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	female infertility	targetBased	0.621559948320993	104	86095	1151
qHTS Assay for Activators of ClpP	Bacillus subtilis (strain 168)	female infertility	targetBased	0.29870929519137	50	338378	6439
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	female infertility	targetBased	0.288600100945177	32	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	female infertility	targetBased	0.288600100945177	32	64908	359
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	female infertility	targetBased	0.170428124260373	27	86095	1114
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	female infertility	targetBased	0.311531471935535	6370	322361	619
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	female reproductive system disease	pathwayBased	0.33960025512159	7817	376029	3978
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	female reproductive system disease	targetBased	0.311966328288251	1312	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	female reproductive system disease	targetBased	0.311966328288251	1312	86095	1151
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	female reproductive system disease	targetBased	0.223625112103761	186	57013	201
qHTS of IL-2 Activators	IL2	female reproductive system disease	targetBased	0.119412254187224	187	364617	238
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	female reproductive system disease	targetBased	0.211507299570284	96	394050	3624
E3 Ligase HTS_1536	MDM2	female reproductive system disease	targetBased	0.231520009997958	109	207811	220
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	female reproductive system disease	targetBased	0.247724095151054	286	86095	1114
qHTS assay for re-activators of p53 using a Luc reporter	TP53	female reproductive system disease	pathwayBased	0.317562642130861	2934	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	female reproductive system disease	targetBased	0.317562642130861	2934	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	female reproductive system disease	targetBased	0.317562642130861	2934	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	female reproductive system disease	targetBased	0.317562642130861	2934	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	female reproductive system disease	targetBased	0.317562642130861	2934	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	female reproductive system disease	targetBased	0.29337869919885	1178	356517	1139
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	female reproductive system disease	targetBased	0.113498712230823	56	93798	679
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	female reproductive system disease	targetBased	0.145842945606043	32	325630	216
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	female reproductive system disease	targetBased	0.112853633095926	121	330392	1295
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	female reproductive system disease	targetBased	0.193811522293884	10	369953	2353
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	female reproductive system disease	targetBased	0.443326655339969	6	305610	3794
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	female reproductive system disease	targetBased	0.442263037458515	4	339674	2841
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	female reproductive system disease	pathwayBased	0.263315617844261	543	43989	342
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	breast disease	pathwayBased	0.339913054276184	10133	376029	3978
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	breast disease	targetBased	0.146948979000517	63	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	breast disease	targetBased	0.146948979000517	63	290726	2649
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	breast disease	targetBased	0.330257744808382	6798	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	breast disease	targetBased	0.330257744808382	6798	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	breast disease	targetBased	0.198509829154069	146	217959	2390
qHTS for Inhibitors of TGF-b	TGFB1	breast disease	pathwayBased	0.122438711395797	860	403345	4970
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	breast disease	targetBased	0.405373886820768	19	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	breast disease	targetBased	0.405373886820768	19	335239	695
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	breast disease	targetBased	0.104560228152914	22	353950	4145
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	breast disease	targetBased	0.150500703114953	128	359244	2975
qHTS assay for re-activators of p53 using a Luc reporter	TP53	breast disease	pathwayBased	0.319112425661383	2613	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast disease	targetBased	0.319112425661383	2613	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast disease	targetBased	0.319112425661383	2613	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast disease	targetBased	0.319112425661383	2613	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	breast disease	targetBased	0.319112425661383	2613	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	breast disease	targetBased	0.311237297517874	1510	356517	1139
uHTS for 14-3-3/Bad interaction inhibitors	YWHAZ	breast disease	targetBased	0.112733571454394	24	217332	1549
Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation	WEE1	breast disease	targetBased	0.112397601701504	86	217959	2616
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	breast disease	pathwayBased	0.189184905516342	594	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	breast disease	pathwayBased	0.189184905516342	594	194666	1722
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	breast disease	targetBased	0.24213653419951	134	194628	267
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	breast disease	targetBased	0.119634773583359	40	343468	734
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	postpartum hemorrhage	targetBased	0.430098257531244	5	369953	760
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	postpartum hemorrhage	targetBased	0.430098257531244	5	369953	498
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	postpartum hemorrhage	targetBased	0.656394447196096	89	324747	1043
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	testicular disease	pathwayBased	0.119277022184985	4	376029	3978
qHTS assay for re-activators of p53 using a Luc reporter	TP53	testicular disease	pathwayBased	0.163422277212559	32	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	testicular disease	targetBased	0.163422277212559	32	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	testicular disease	targetBased	0.163422277212559	32	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	testicular disease	targetBased	0.163422277212559	32	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	testicular disease	targetBased	0.163422277212559	32	124022	1156
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	prostate disease	targetBased	0.204980648156427	104	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	prostate disease	targetBased	0.204980648156427	104	86095	1151
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	prostate disease	targetBased	0.178295426802775	99	86095	1114
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	genetic non-acquired premature ovarian failure	targetBased	0.535151368505697	11	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	genetic non-acquired premature ovarian failure	targetBased	0.535151368505697	11	64908	359
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	age at first sexual intercourse measurement	targetBased	0.47937039752395	11	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	age at first sexual intercourse measurement	targetBased	0.47937039752395	11	86095	1151
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	age at first sexual intercourse measurement	targetBased	0.200286268674481	8	335531	328
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	age at first sexual intercourse measurement	targetBased	0.426039194347116	5	339674	2841
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	amenorrhea	targetBased	0.357322254323866	33	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	amenorrhea	targetBased	0.357322254323866	33	86095	1151
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Menstrual disorder	targetBased	0.440874502390741	16	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Menstrual disorder	targetBased	0.440874502390741	16	86095	1151
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	male infertility with azoospermia or oligozoospermia due to single gene mutation	targetBased	0.305521847953183	5	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	male infertility with azoospermia or oligozoospermia due to single gene mutation	targetBased	0.305521847953183	5	296501	2737
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	male infertility with azoospermia or oligozoospermia due to single gene mutation	targetBased	0.71262050292756	170	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	male infertility with azoospermia or oligozoospermia due to single gene mutation	targetBased	0.71262050292756	170	64908	359
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	premature ejaculation	targetBased	0.575894850070855	11	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	premature ejaculation	targetBased	0.575894850070855	11	335239	695
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	Ovarian Endometriosis	targetBased	0.307519465253223	11	356517	1139
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	Ovarian Endometriosis	targetBased	0.406807260325345	11	193542	587
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Atrophic Vaginitis	targetBased	0.600186219790317	30	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Atrophic Vaginitis	targetBased	0.600186219790317	30	86095	1151
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	Atrophic Vaginitis	targetBased	0.519892362582376	12	86095	1114
Thrombin 1536 HTS	F2_modulation	habitual abortion	targetBased	0.438268817134801	5	217233	557
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	acromegaly	targetBased	0.161126351620516	56	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	acromegaly	targetBased	0.161126351620516	56	337446	1356
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	acromegaly	targetBased	0.117790720566965	27	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	acromegaly	targetBased	0.117790720566965	27	86095	1151
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	acromegaly	targetBased	0.485357463597691	74	263421	615
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	acromegaly	targetBased	0.625090953855627	21	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	acromegaly	targetBased	0.625090953855627	21	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	acromegaly	targetBased	0.625090953855627	21	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	acromegaly	targetBased	0.625090953855627	21	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	acromegaly	targetBased	0.625090953855627	21	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	acromegaly	targetBased	0.625090953855627	21	336308	6862
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	acromegaly	targetBased	0.60466648961276	9	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	acromegaly	targetBased	0.60466648961276	9	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	acromegaly	targetBased	0.60466648961276	9	407539	2380
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	abortion	targetBased	0.105763667916527	7	343468	734
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	Autosomal dominant polycystic kidney disease	targetBased	0.291624909389958	9	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	Autosomal dominant polycystic kidney disease	pathwayBased	0.291624909389958	9	403871	1243
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Autosomal dominant polycystic kidney disease	targetBased	0.288021768309825	21	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Autosomal dominant polycystic kidney disease	targetBased	0.288021768309825	21	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Autosomal dominant polycystic kidney disease	targetBased	0.288021768309825	21	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Autosomal dominant polycystic kidney disease	targetBased	0.288021768309825	21	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Autosomal dominant polycystic kidney disease	targetBased	0.288021768309825	21	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Autosomal dominant polycystic kidney disease	targetBased	0.288021768309825	21	196177	519
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	uterine prolapse	targetBased	0.406217684014089	5	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	uterine prolapse	targetBased	0.406217684014089	5	86095	1151
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Menorrhagia	targetBased	0.516421046023942	9	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Menorrhagia	targetBased	0.516421046023942	9	86095	1151
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ovulation	targetBased	0.519258439854514	11	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ovulation	targetBased	0.519258439854514	11	86095	1151
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	menopause	targetBased	0.662677082846212	180	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	menopause	targetBased	0.662677082846212	180	86095	1151
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	menopause	targetBased	0.647144623444855	81	86095	1114
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Premature ovarian insufficiency	targetBased	0.655812081846905	56	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Premature ovarian insufficiency	targetBased	0.655812081846905	56	86095	1151
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Dysmenorrhea	targetBased	0.603589229933955	21	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Dysmenorrhea	targetBased	0.603589229933955	21	86095	1151
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Dysmenorrhea	targetBased	0.603833765267521	17	316642	617
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	endometrial disorder	targetBased	0.264616993873113	473	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	endometrial disorder	targetBased	0.264616993873113	473	86095	1151
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	endometrial disorder	targetBased	0.196165441416274	10	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	endometrial disorder	pathwayBased	0.196165441416274	10	403871	1243
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	endometrial disorder	targetBased	0.162679445800892	34	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	endometrial disorder	targetBased	0.162679445800892	34	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	endometrial disorder	targetBased	0.162679445800892	34	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	endometrial disorder	targetBased	0.162679445800892	34	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	endometrial disorder	targetBased	0.162679445800892	34	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	endometrial disorder	targetBased	0.162679445800892	34	196177	519
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	endometrial disorder	targetBased	0.176465645249843	126	86095	1114
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	endometrial disorder	targetBased	0.213975272356689	194	356517	1139
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	disorder of sexual differentiation	targetBased	0.210507816188321	82	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	disorder of sexual differentiation	targetBased	0.210507816188321	82	86095	1151
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	disorder of sexual differentiation	targetBased	0.673726545644413	377	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	disorder of sexual differentiation	targetBased	0.673726545644413	377	64908	359
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	disorder of sexual differentiation	targetBased	0.196200557246514	19	86095	1114
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	disorder of sexual differentiation	targetBased	0.115818031174396	27	369953	2602
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	hypogonadism	targetBased	0.669694218698102	233	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	hypogonadism	targetBased	0.669694218698102	233	86095	1151
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	hypogonadism	targetBased	0.482911594690573	17	394050	3624
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	hypogonadism	targetBased	0.298861598515349	88	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	hypogonadism	targetBased	0.298861598515349	88	64908	359
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	hypogonadism	targetBased	0.555819857005913	19	86095	1114
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	hypogonadism	targetBased	0.626709780417037	43	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	hypogonadism	targetBased	0.626709780417037	43	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	hypogonadism	targetBased	0.626709780417037	43	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	hypogonadism	targetBased	0.626709780417037	43	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	hypogonadism	targetBased	0.626709780417037	43	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	hypogonadism	targetBased	0.626709780417037	43	336308	6862
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	hypogonadism	targetBased	0.619285523949174	12	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	hypogonadism	targetBased	0.619285523949174	12	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	hypogonadism	targetBased	0.619285523949174	12	407539	2380
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	hypogonadism	targetBased	0.308663658698556	372	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	hypogonadism	targetBased	0.308663658698556	372	343468	3417
qHTS assay for re-activators of p53 using a Luc reporter	TP53	vulvar disease	pathwayBased	0.166733730912751	70	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vulvar disease	targetBased	0.166733730912751	70	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vulvar disease	targetBased	0.166733730912751	70	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vulvar disease	targetBased	0.166733730912751	70	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vulvar disease	targetBased	0.166733730912751	70	124022	1156
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	vaginitis	targetBased	0.202040808995142	8	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	vaginitis	targetBased	0.202040808995142	8	86095	1151
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	postmenopausal atrophic vaginitis	targetBased	0.588528225678562	8	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	postmenopausal atrophic vaginitis	targetBased	0.588528225678562	8	86095	1151
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	gonadal disorder	targetBased	0.31721432974024	349	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	gonadal disorder	targetBased	0.31721432974024	349	64908	359
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	gonadal disorder	targetBased	0.102210154046711	35	330392	1295
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	gonadal disorder	targetBased	0.302295066199781	412	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	gonadal disorder	targetBased	0.302295066199781	412	343468	3417
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	gonadal disorder	targetBased	0.219826330585973	22	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	gonadal disorder	targetBased	0.219826330585973	22	331360	2760
HCS assay for microtubule stabilizers	TUBB	fallopian tube mucinous adenocarcinoma	targetBased	0.406645934034689	9	195821	1625
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	anovulation	targetBased	0.565777313387203	23	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	anovulation	targetBased	0.565777313387203	23	86095	1151
HCS assay for microtubule stabilizers	TUBB	fallopian tube transitional cell carcinoma	targetBased	0.406645934034689	9	195821	1625
HCS assay for microtubule stabilizers	TUBB	invasive tubular breast carcinoma	targetBased	0.394463347922351	8	195821	1625
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	uterine disorder	targetBased	0.507476068058557	607	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	uterine disorder	targetBased	0.507476068058557	607	86095	1151
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	uterine disorder	targetBased	0.211059646763489	54	57013	201
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	uterine disorder	targetBased	0.226954212912419	301	356517	1139
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	uterine disorder	pathwayBased	0.251133386575398	195	43989	342
HCS assay for microtubule stabilizers	TUBB	fallopian tube clear cell adenocarcinoma	targetBased	0.391431788565997	9	195821	1625
HCS assay for microtubule stabilizers	TUBB	fallopian tube endometrioid adenocarcinoma	targetBased	0.417844890568294	12	195821	1625
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	congenital bilateral aplasia of vas deferens from CFTR mutation	targetBased	0.869751101269822	953	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	congenital bilateral aplasia of vas deferens from CFTR mutation	targetBased	0.869751101269822	953	296501	2737
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ovarian hyperstimulation syndrome	targetBased	0.414662098236083	5	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ovarian hyperstimulation syndrome	targetBased	0.414662098236083	5	86095	1151
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	ovarian hyperstimulation syndrome	targetBased	0.401803639651204	20	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	ovarian hyperstimulation syndrome	targetBased	0.401803639651204	20	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	ovarian hyperstimulation syndrome	targetBased	0.401803639651204	20	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	ovarian hyperstimulation syndrome	targetBased	0.401803639651204	20	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	ovarian hyperstimulation syndrome	targetBased	0.401803639651204	20	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	ovarian hyperstimulation syndrome	targetBased	0.401803639651204	20	336308	6862
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	premature ovarian failure 7	targetBased	0.830926945955708	29	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	premature ovarian failure 7	targetBased	0.830926945955708	29	64908	359
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY sex reversal 3	targetBased	0.87124875351183	101	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY sex reversal 3	targetBased	0.87124875351183	101	64908	359
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	spermatogenic failure 8	targetBased	0.816032599202828	24	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	spermatogenic failure 8	targetBased	0.816032599202828	24	64908	359
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	partial chromosome Y deletion	targetBased	0.459244052354306	5	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	partial chromosome Y deletion	targetBased	0.459244052354306	5	296501	2737
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY partial gonadal dysgenesis	targetBased	0.63355396095555	57	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY partial gonadal dysgenesis	targetBased	0.63355396095555	57	64908	359
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	Mayer-Rokitansky-Kuster-Hauser syndrome	targetBased	0.203756851906637	6	353950	4145
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XX ovotesticular disorder of sex development	targetBased	0.42211118073766	15	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XX ovotesticular disorder of sex development	targetBased	0.42211118073766	15	64908	359
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	male infertility with teratozoospermia due to single gene mutation	targetBased	0.112589091249349	14	315412	318
Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33	STK33	male infertility with teratozoospermia due to single gene mutation	targetBased	0.109751895338892	11	37341	2812
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine Kinase 33 Activity	STK33	male infertility with teratozoospermia due to single gene mutation	targetBased	0.109751895338892	11	321808	235
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	congenital bilateral absence of vas deferens	targetBased	0.773298478345554	346	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	congenital bilateral absence of vas deferens	targetBased	0.773298478345554	346	296501	2737
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	hypogonadotropic hypogonadism	targetBased	0.458089325560593	118	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	hypogonadotropic hypogonadism	targetBased	0.458089325560593	118	86095	1151
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	hypogonadotropic hypogonadism	targetBased	0.183185739476449	34	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	hypogonadotropic hypogonadism	targetBased	0.183185739476449	34	64908	359
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	hypogonadotropic hypogonadism	targetBased	0.113612449125214	8	86095	1114
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	hypogonadotropic hypogonadism	targetBased	0.341638748312673	228	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	hypogonadotropic hypogonadism	targetBased	0.341638748312673	228	343468	3417
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	male infertility with teratozoospermia due to single gene mutation	targetBased	0.10863057189828	13	369953	1596
qHTS assay for re-activators of p53 using a Luc reporter	TP53	cervical intraepithelial neoplasia	pathwayBased	0.213492344568534	251	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervical intraepithelial neoplasia	targetBased	0.213492344568534	251	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervical intraepithelial neoplasia	targetBased	0.213492344568534	251	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervical intraepithelial neoplasia	targetBased	0.213492344568534	251	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervical intraepithelial neoplasia	targetBased	0.213492344568534	251	124022	1156
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	cervical intraepithelial neoplasia	targetBased	0.307974878085738	17	193542	587
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY disorder of sex development	targetBased	0.697883070713665	226	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY disorder of sex development	targetBased	0.697883070713665	226	64908	359
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	46,XY disorder of sex development	targetBased	0.208008782099005	6	86095	1114
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	46,XY disorder of sex development	targetBased	0.289644247605735	7	369953	2602
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	infective vaginitis	targetBased	0.138057100391	4	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	infective vaginitis	targetBased	0.138057100391	4	86095	1151
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	menstrual cycle-dependent periodic fever	targetBased	0.504703919014759	5	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	menstrual cycle-dependent periodic fever	targetBased	0.504703919014759	5	61606	416
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XX testicular disorder of sex development	targetBased	0.615040310401099	39	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XX testicular disorder of sex development	targetBased	0.615040310401099	39	64908	359
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XX gonadal dysgenesis	targetBased	0.426543976619464	27	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XX gonadal dysgenesis	targetBased	0.426543976619464	27	64908	359
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	46,XX gonadal dysgenesis	targetBased	0.384300551160077	17	86095	1114
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	Cytomegalic congenital adrenal hypoplasia	targetBased	0.848222789812202	44	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	Cytomegalic congenital adrenal hypoplasia	targetBased	0.848222789812202	44	343468	3417
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	Non-acquired premature ovarian failure	targetBased	0.156967290960506	8	86095	1114
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	Male infertility with spermatogenesis disorder due to single gene mutation	targetBased	0.105052772882331	6	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	Male infertility with spermatogenesis disorder due to single gene mutation	targetBased	0.105052772882331	6	290726	2649
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	Rare genetic female infertility	targetBased	0.102709858341997	5	319204	3065
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	Rare genetic female infertility	targetBased	0.102709858341997	5	316970	306
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Rare genetic female infertility	targetBased	0.241496984332482	75	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Rare genetic female infertility	targetBased	0.241496984332482	75	86095	1151
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	Rare genetic female infertility	targetBased	0.172160913299916	13	86095	1114
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	Female infertility due to fertilization defect	targetBased	0.107382283948335	6	319204	3065
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	Female infertility due to fertilization defect	targetBased	0.107382283948335	6	316970	306
qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)	RECQL	reproductive system disease	targetBased	0.119776800964695	7	234915	1245
Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).	PPP5C	reproductive system disease	targetBased	0.104125292278505	5	314999	564
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	reproductive system disease	pathwayBased	0.338209173161851	7958	376029	3978
ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity	TACC3	reproductive system disease	targetBased	0.112774417658636	14	391179	2589
USP28 deubiquitinase inhibition: Primary qHTS	USP28	reproductive system disease	targetBased	0.103130663947078	10	47480	1413
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	reproductive system disease	targetBased	0.126781163554025	12	290915	2982
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	reproductive system disease	targetBased	0.126781163554025	12	359244	1307
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	reproductive system disease	pathwayBased	0.20842611709695	21	358556	3721
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	reproductive system disease	targetBased	0.140222209105158	220	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	reproductive system disease	targetBased	0.140222209105158	220	290726	2649
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	reproductive system disease	targetBased	0.111318370584328	33	359206	428
Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity	RAD54L	reproductive system disease	targetBased	0.167866747171187	21	358498	505
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	reproductive system disease	targetBased	0.102798274668201	9	218528	711
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	reproductive system disease	targetBased	0.102798274668201	9	218528	770
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	reproductive system disease	targetBased	0.102798274668201	9	218528	750
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	reproductive system disease	targetBased	0.288435267404242	171	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	reproductive system disease	targetBased	0.288435267404242	171	337446	1356
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	reproductive system disease	targetBased	0.160217970569164	42	385746	932
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	reproductive system disease	targetBased	0.230693717757537	70	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	reproductive system disease	pathwayBased	0.257800105513137	84	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	reproductive system disease	pathwayBased	0.257800105513137	84	131324	544
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	reproductive system disease	targetBased	0.231193344498684	35	143816	859
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	reproductive system disease	targetBased	0.106162307780943	11	335214	1652
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	reproductive system disease	targetBased	0.200053405339436	8	363803	2412
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	reproductive system disease	targetBased	0.167840790779871	32	290726	671
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	reproductive system disease	targetBased	0.174068225585961	18	363803	1383
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	reproductive system disease	targetBased	0.171487677917859	91	315412	318
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	reproductive system disease	targetBased	0.233440587361855	246	57013	201
HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails	HP1-betaChromodomainInteractionsInhibitors	reproductive system disease	targetBased	0.122790342180537	9	383363	2142
qHTS Assay for Inhibitors of GCN5L2	KAT2A	reproductive system disease	targetBased	0.111256940426053	13	381571	792
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	reproductive system disease	targetBased	0.172291242873878	68	343468	285
qHTS of IL-2 Activators	IL2	reproductive system disease	targetBased	0.119799166648673	564	364617	238
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	reproductive system disease	targetBased	0.20448576102732	18	309684	1662
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	reproductive system disease	targetBased	0.125651931406789	83	338328	2501
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	reproductive system disease	targetBased	0.22525160031532	199	394050	3624
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	reproductive system disease	targetBased	0.146719609437002	1036	67275	2509
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	reproductive system disease	targetBased	0.211185861092394	89	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	reproductive system disease	targetBased	0.211185861092394	89	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	reproductive system disease	targetBased	0.211185861092394	89	405130	6428
uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay	CCR6_antagonists	reproductive system disease	targetBased	0.104079116244159	6	340696	1654
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	reproductive system disease	pathwayBased	0.115498053612955	92	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	reproductive system disease	targetBased	0.115498053612955	92	195980	695
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	reproductive system disease	targetBased	0.10662794725619	8	75924	1804
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	reproductive system disease	targetBased	0.206704208050605	34	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	reproductive system disease	targetBased	0.260605058604777	116	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	reproductive system disease	pathwayBased	0.260605058604777	116	403871	1243
uHTS Fluorescent assay for identification of activators of Apaf-1	APAF1_activators	reproductive system disease	targetBased	0.108469035976906	20	331671	1041
uHTS Fluorescent assay for identification of inhibitors of Apaf-1	APAF1_inhibitors	reproductive system disease	targetBased	0.108469035976906	20	331671	2353
Antagonist identification of Pyk2 oligomerization: high-throughput screening cellular assay	Pyk2Ã‚Â	reproductive system disease	targetBased	0.115327197329489	21	98749	818
qHTS for Inhibitors of Polymerase Kappa	POLK	reproductive system disease	targetBased	0.219198842423735	32	395295	2034
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	reproductive system disease	targetBased	0.188810273622289	22	369953	3123
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	reproductive system disease	targetBased	0.222497771196412	64	250190	1304
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	reproductive system disease	targetBased	0.222497771196412	64	255537	2141
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	reproductive system disease	targetBased	0.20383184325884	169	353950	4145
qHTS Assay for Activators of ClpP	Bacillus subtilis (strain 168)	reproductive system disease	targetBased	0.290874399632922	60	338378	6439
Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1)	PRMT1	reproductive system disease	targetBased	0.109222873073748	13	369953	4757
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	reproductive system disease	targetBased	0.206160316611006	21	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	reproductive system disease	targetBased	0.262481289974443	167	344733	7043
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	reproductive system disease	targetBased	0.145051358149185	26	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	reproductive system disease	targetBased	0.145051358149185	26	335180	1022
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	reproductive system disease	targetBased	0.262918891763136	295	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	reproductive system disease	targetBased	0.262918891763136	295	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	reproductive system disease	targetBased	0.262918891763136	295	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	reproductive system disease	targetBased	0.262918891763136	295	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	reproductive system disease	targetBased	0.262918891763136	295	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	reproductive system disease	targetBased	0.262918891763136	295	196177	519
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	reproductive system disease	targetBased	0.138664858545235	4	205582	727
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	reproductive system disease	targetBased	0.231688677943018	301	263421	615
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	reproductive system disease	targetBased	0.105821007552912	19	59788	212
qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy	CGA_integrin_activators	reproductive system disease	targetBased	0.103205259321781	65	345855	222
E3 Ligase HTS_1536	MDM2	reproductive system disease	targetBased	0.237476786505948	143	207811	220
Image-Based HTS for Selective Antagonists for GPR55	GPR55	reproductive system disease	targetBased	0.10288301532721	8	291657	370
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	reproductive system disease	targetBased	0.247156429288894	17	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	reproductive system disease	targetBased	0.247156429288894	17	194628	521
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	reproductive system disease	targetBased	0.314805925865947	564	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	reproductive system disease	targetBased	0.314805925865947	564	64908	359
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	reproductive system disease	targetBased	0.185229270796182	138	639428	9218
USP8 deubiquitinase inhibition: Primary qHTS	USP8	reproductive system disease	targetBased	0.257900780814483	75	47480	2010
VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2	Caspase6Inhibitors	reproductive system disease	targetBased	0.106935275969145	14	344318	1854
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	reproductive system disease	targetBased	0.23450192925203	60	368927	620
qHTS assay for re-activators of p53 using a Luc reporter	TP53	reproductive system disease	pathwayBased	0.317107083754121	3605	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	reproductive system disease	targetBased	0.317107083754121	3605	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	reproductive system disease	targetBased	0.317107083754121	3605	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	reproductive system disease	targetBased	0.317107083754121	3605	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	reproductive system disease	targetBased	0.317107083754121	3605	124022	1156
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	reproductive system disease	targetBased	0.112518972087181	76	93798	679
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	reproductive system disease	targetBased	0.337360115383818	13672	322361	619
qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)	PIP4K2A	reproductive system disease	targetBased	0.10568789580558	7	328860	4078
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	reproductive system disease	targetBased	0.133521119648414	26	276265	806
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	reproductive system disease	targetBased	0.24322751930273	22	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	reproductive system disease	targetBased	0.24322751930273	22	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	reproductive system disease	targetBased	0.24322751930273	22	407539	2380
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	reproductive system disease	targetBased	0.19904371363197	44	325630	216
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	reproductive system disease	targetBased	0.110801792449735	10	335239	2035
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	reproductive system disease	targetBased	0.110801792449735	10	335239	279
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	reproductive system disease	targetBased	0.248896342677537	30	335531	328
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	reproductive system disease	targetBased	0.136687411270991	9	310014	1321
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	reproductive system disease	targetBased	0.203852370798737	48	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	reproductive system disease	targetBased	0.203852370798737	48	218234	1620
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	reproductive system disease	targetBased	0.12583939043555	8	195560	517
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	reproductive system disease	targetBased	0.204963307186337	36	71016	346
Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3	procaspase3Activators	reproductive system disease	targetBased	0.107739238323082	330	326024	350
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	reproductive system disease	targetBased	0.266243205039575	65	369953	2353
qHTS for Inhibitors of WRN Helicase	WRN	reproductive system disease	targetBased	0.252984138877056	28	364011	1678
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	reproductive system disease	targetBased	0.18343822125048	43	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	reproductive system disease	targetBased	0.18343822125048	43	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	reproductive system disease	targetBased	0.18343822125048	43	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	reproductive system disease	targetBased	0.18343822125048	43	72026	1794
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	reproductive system disease	targetBased	0.140838283748468	4	324747	813
Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation	WEE1	reproductive system disease	targetBased	0.112359682235888	115	217959	2616
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	reproductive system disease	targetBased	0.105078806494806	60	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	reproductive system disease	targetBased	0.105078806494806	60	356160	1703
HTS of Smad transcription factor inhibitors	SMAD3	reproductive system disease	targetBased	0.211740618841489	74	88033	251
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	reproductive system disease	targetBased	0.171167186811099	57	292323	1836
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	reproductive system disease	targetBased	0.31196170617853	401	193542	587
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)	PAFAH1B2	reproductive system disease	targetBased	0.107599316530507	50	335239	4158
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	reproductive system disease	targetBased	0.172548705886465	19	386270	1331
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	reproductive system disease	targetBased	0.117435823012851	6	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	reproductive system disease	targetBased	0.117435823012851	6	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	reproductive system disease	targetBased	0.117435823012851	6	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	reproductive system disease	targetBased	0.117435823012851	6	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	reproductive system disease	targetBased	0.117435823012851	6	359207	4555
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	reproductive system disease	targetBased	0.210546784372985	36	339297	1446
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	reproductive system disease	targetBased	0.314360879202853	489	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	reproductive system disease	targetBased	0.314360879202853	489	343468	3417
Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	reproductive system disease	targetBased	0.137044580007499	119	96879	811
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	reproductive system disease	targetBased	0.187883057297541	6	305610	3794
HTS for 14-3-3 protein interaction modulators	YWHAG	reproductive system disease	targetBased	0.108801886192594	11	157962	312
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	reproductive system disease	targetBased	0.104259721208743	17	55710	315
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	reproductive system disease	targetBased	0.187058899422124	5	339674	2841
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	reproductive system disease	targetBased	0.102805385243605	8	369953	760
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	reproductive system disease	targetBased	0.102805385243605	8	369953	498
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	reproductive system disease	targetBased	0.118741086957146	63	318291	483
Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity	MLLT3	reproductive system disease	targetBased	0.106361140327115	6	344459	1627
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	reproductive system disease	targetBased	0.149333733036698	14	31324	362
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	reproductive system disease	targetBased	0.263978768589709	102	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	reproductive system disease	targetBased	0.15729289211569	50	218654	8241
uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay	UBE2N	reproductive system disease	targetBased	0.101826384206614	8	330393	1538
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	reproductive system disease	targetBased	0.189579999635371	12	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	reproductive system disease	targetBased	0.189579999635371	12	61606	416
Thrombin 1536 HTS	F2_modulation	reproductive system disease	targetBased	0.168732084051759	60	217233	557
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	reproductive system disease	targetBased	0.119986518197656	85	369953	2602
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	reproductive system disease	pathwayBased	0.113394671915538	213	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	reproductive system disease	targetBased	0.113394671915538	213	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	reproductive system disease	pathwayBased	0.113394671915538	213	271402	1048
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	reproductive system disease	targetBased	0.240330619085262	82	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	reproductive system disease	targetBased	0.240330619085262	82	331360	2760
HCS assay for microtubule stabilizers	TUBB	reproductive system disease	targetBased	0.220917566729385	821	195821	1625
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	reproductive system disease	targetBased	0.255363328968277	48	347933	673
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	reproductive system disease	targetBased	0.22956485391035	26	331671	10022
qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a	EHMT2_inhibitors	reproductive system disease	targetBased	0.1028143392411	26	348338	30875
qHTS for Inhibitors of Vif-A3G Interactions: qHTS	APOBEC3G_inhibitors	reproductive system disease	targetBased	0.207184255418106	77	402348	311
uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay	APOBEC3G_inhibitors	reproductive system disease	targetBased	0.207184255418106	77	331753	931
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	reproductive system disease	targetBased	0.1283632761092	92	343468	734
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	infertility	targetBased	0.155873548253344	9	363803	1383
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	infertility	targetBased	0.16129420860864	34	292323	1836
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	primary ovarian insufficiency	targetBased	0.309638094168041	6367	322361	619
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	male infertility	targetBased	0.155873548253344	9	363803	1383
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	male infertility	targetBased	0.16129420860864	34	292323	1836
qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)	RECQL	ovarian disease	targetBased	0.119526988452678	5	234915	1245
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	ovarian disease	pathwayBased	0.153171548029199	11	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	ovarian disease	targetBased	0.165922615977534	12	336894	489
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	ovarian disease	targetBased	0.123193905181936	15	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	ovarian disease	targetBased	0.123193905181936	15	290726	2649
Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity	RAD54L	ovarian disease	targetBased	0.16752865504966	20	358498	505
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	ovarian disease	targetBased	0.187109739789636	22	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ovarian disease	targetBased	0.177068434722322	22	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	ovarian disease	pathwayBased	0.167835062113661	22	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	ovarian disease	pathwayBased	0.167835062113661	22	131324	544
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	ovarian disease	targetBased	0.109741544821088	7	143816	859
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	ovarian disease	targetBased	0.238576427934588	74	46715	2829
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	ovarian disease	targetBased	0.102111178481684	5	335214	1652
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	ovarian disease	targetBased	0.105100026473785	8	315412	318
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	ovarian disease	targetBased	0.193059369757167	54	57013	201
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	ovarian disease	targetBased	0.140670832146846	5	343468	285
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	ovarian disease	pathwayBased	0.102310976132231	159	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	ovarian disease	pathwayBased	0.102310976132231	159	359244	3094
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	ovarian disease	targetBased	0.17777635065689	4	309684	1662
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	ovarian disease	targetBased	0.102092846546072	22	338328	2501
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	ovarian disease	targetBased	0.20105080504481	52	394050	3624
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	ovarian disease	targetBased	0.200535143379845	61	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	ovarian disease	targetBased	0.200535143379845	61	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	ovarian disease	targetBased	0.200535143379845	61	405130	6428
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	ovarian disease	targetBased	0.171575006825805	8	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	ovarian disease	targetBased	0.186038407057675	21	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	ovarian disease	pathwayBased	0.186038407057675	21	403871	1243
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	ovarian disease	targetBased	0.103021439582637	9	363803	458
Antagonist identification of Pyk2 oligomerization: high-throughput screening cellular assay	Pyk2Ã‚Â	ovarian disease	targetBased	0.112300217648847	8	98749	818
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	ovarian disease	targetBased	0.149049790064521	4	369953	3123
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	ovarian disease	targetBased	0.115885481035294	91	353950	4145
qHTS Assay for Activators of ClpP	Bacillus subtilis (strain 168)	ovarian disease	targetBased	0.290774912015882	44	338378	6439
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	ovarian disease	targetBased	0.153406678778734	5	364053	2026
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	ovarian disease	targetBased	0.106134699139874	21	263421	615
E3 Ligase HTS_1536	MDM2	ovarian disease	targetBased	0.192324351278751	27	207811	220
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	ovarian disease	targetBased	0.29516475705659	71	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	ovarian disease	targetBased	0.29516475705659	71	64908	359
USP8 deubiquitinase inhibition: Primary qHTS	USP8	ovarian disease	targetBased	0.18277907056128	4	47480	2010
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	ovarian disease	targetBased	0.181342721661777	6	368927	620
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	ovarian disease	targetBased	0.107844618640805	17	93798	679
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	ovarian disease	targetBased	0.142673572711871	36	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	ovarian disease	targetBased	0.142673572711871	36	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	ovarian disease	targetBased	0.142673572711871	36	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	ovarian disease	targetBased	0.142673572711871	36	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	ovarian disease	targetBased	0.142673572711871	36	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	ovarian disease	targetBased	0.142673572711871	36	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ovarian disease	targetBased	0.331323086885875	13500	322361	619
qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)	PIP4K2A	ovarian disease	targetBased	0.103710957231796	5	328860	4078
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	ovarian disease	targetBased	0.12073744154567	7	325630	216
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	ovarian disease	targetBased	0.183776534805662	12	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	ovarian disease	targetBased	0.183776534805662	12	218234	1620
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	ovarian disease	targetBased	0.100040631301396	30	330392	1295
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	ovarian disease	targetBased	0.168718027111592	14	71016	346
qHTS for Inhibitors of WRN Helicase	WRN	ovarian disease	targetBased	0.219231979229739	15	364011	1678
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	ovarian disease	targetBased	0.177968262742487	16	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	ovarian disease	targetBased	0.177968262742487	16	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	ovarian disease	targetBased	0.177968262742487	16	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	ovarian disease	targetBased	0.177968262742487	16	72026	1794
HTS of Smad transcription factor inhibitors	SMAD3	ovarian disease	targetBased	0.181005662948273	20	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	ovarian disease	targetBased	0.289777185777101	90	193542	587
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	ovarian disease	pathwayBased	0.2074338192207	98	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	ovarian disease	pathwayBased	0.2074338192207	98	194666	1722
Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	ovarian disease	targetBased	0.132697050868738	46	96879	811
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	ovarian disease	targetBased	0.13900024592979	4	305610	3794
HTS for 14-3-3 protein interaction modulators	YWHAG	ovarian disease	targetBased	0.104387141474849	5	157962	312
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	ovarian disease	targetBased	0.107971857884083	17	318291	483
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	ovarian disease	targetBased	0.154988624235893	23	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	ovarian disease	targetBased	0.136466729556742	16	218654	8241
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	ovarian disease	targetBased	0.217191190755374	13	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	ovarian disease	targetBased	0.217191190755374	13	331360	2760
HCS assay for microtubule stabilizers	TUBB	ovarian disease	targetBased	0.211274596335597	223	195821	1625
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	ovarian disease	targetBased	0.136605172394068	9	316642	617
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	ovarian disease	targetBased	0.177239935405991	8	331671	10022
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	placenta disease	targetBased	0.10500903597205	7	336894	489
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	ovarian dysfunction	targetBased	0.102663329842827	5	363803	458
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	testicular disease	targetBased	0.130564912087865	6	46715	2829
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	testicular disease	targetBased	0.132691766251331	4	344733	7043
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	testicular disease	targetBased	0.187014142891	5	193542	587
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	testicular disease	pathwayBased	0.127171003650238	4	43989	342
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	prostate disease	pathwayBased	0.219101712313477	28	376029	3978
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	prostate disease	targetBased	0.128300456730884	4	385746	932
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	prostate disease	targetBased	0.139640835508274	9	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	prostate disease	targetBased	0.154379346821327	20	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	prostate disease	pathwayBased	0.160891494529133	6	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	prostate disease	pathwayBased	0.160891494529133	6	131324	544
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	prostate disease	targetBased	0.128439080061664	12	143816	859
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	prostate disease	targetBased	0.127365240767913	8	46715	2829
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	prostate disease	targetBased	0.170850312534732	50	57013	201
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	prostate disease	targetBased	0.130231591783222	7	309684	1662
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	prostate disease	targetBased	0.108492313194675	12	338328	2501
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	prostate disease	targetBased	0.149100667127976	45	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	prostate disease	targetBased	0.158847662180568	4	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	prostate disease	targetBased	0.158847662180568	4	335239	695
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	prostate disease	targetBased	0.13510750959122	4	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	prostate disease	pathwayBased	0.13510750959122	4	403871	1243
qHTS for Inhibitors of Polymerase Kappa	POLK	prostate disease	targetBased	0.20229423634741	32	395295	2034
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	prostate disease	targetBased	0.161576483332133	7	344733	7043
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	prostate disease	targetBased	0.154157340457911	34	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	prostate disease	targetBased	0.154157340457911	34	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	prostate disease	targetBased	0.154157340457911	34	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	prostate disease	targetBased	0.154157340457911	34	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	prostate disease	targetBased	0.154157340457911	34	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	prostate disease	targetBased	0.154157340457911	34	196177	519
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	prostate disease	targetBased	0.128240763538566	5	263421	615
E3 Ligase HTS_1536	MDM2	prostate disease	targetBased	0.162095581373436	17	207811	220
qHTS assay for re-activators of p53 using a Luc reporter	TP53	prostate disease	pathwayBased	0.287115606746164	353	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate disease	targetBased	0.287115606746164	353	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate disease	targetBased	0.287115606746164	353	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate disease	targetBased	0.287115606746164	353	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	prostate disease	targetBased	0.287115606746164	353	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	prostate disease	targetBased	0.229210534545983	157	356517	1139
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	prostate disease	targetBased	0.279387397714469	41	322361	619
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	prostate disease	targetBased	0.171822488335158	6	325630	216
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	prostate disease	targetBased	0.191692598036833	4	335531	328
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	prostate disease	targetBased	0.127453709442047	6	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	prostate disease	targetBased	0.127453709442047	6	218234	1620
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	prostate disease	targetBased	0.133661281825626	5	369953	2353
HTS of Smad transcription factor inhibitors	SMAD3	prostate disease	targetBased	0.134976521050629	11	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	prostate disease	targetBased	0.247433390889098	38	193542	587
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	prostate disease	pathwayBased	0.131476648789344	58	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	prostate disease	pathwayBased	0.131476648789344	58	194666	1722
qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)	RECQL	breast disease	targetBased	0.122317901085434	17	234915	1245
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	prostate disease	targetBased	0.194327579690223	16	194628	267
Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).	PPP5C	breast disease	targetBased	0.10574355637852	9	314999	564
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	breast disease	targetBased	0.102426840251028	11	290915	2982
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	breast disease	targetBased	0.102426840251028	11	359244	1307
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	breast disease	pathwayBased	0.149517588244894	10	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	breast disease	targetBased	0.173371462586208	26	336894	489
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	breast disease	targetBased	0.147006637353781	17	359206	428
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selectiveÃ‚Â compounds	breast disease	targetBased	0.122716011554122	137	396029	13426
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selectiveÃ‚Â compounds	breast disease	targetBased	0.122716011554122	137	395981	5516
Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity	RAD54L	breast disease	targetBased	0.160200383974338	23	358498	505
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	breast disease	targetBased	0.196092401623749	19	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	breast disease	targetBased	0.196092401623749	19	337446	1356
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	breast disease	targetBased	0.1468673910023	9	385746	932
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	breast disease	targetBased	0.206876641022598	108	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	breast disease	pathwayBased	0.218636651896102	78	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	breast disease	pathwayBased	0.218636651896102	78	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	breast disease	targetBased	0.168291710284675	36	46715	2829
Identification of Molecular Probes that Activate MRP-1	ABCC1_activators	breast disease	targetBased	0.182078161171106	36	138717	842
HCS assay for microtubule stabilizers	TUBB	prostate disease	targetBased	0.218689089034275	365	195821	1625
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	prostate disease	targetBased	0.17033417590208	9	331671	10022
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	prostate disease	pathwayBased	0.175328715075311	51	43989	342
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	breast disease	targetBased	0.111738690883994	9	315412	318
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	breast disease	targetBased	0.169575736519415	9	343468	285
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	breast disease	pathwayBased	0.118389025564413	717	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	breast disease	pathwayBased	0.118389025564413	717	359244	3094
qHTS of IL-2 Activators	IL2	breast disease	targetBased	0.18991549294118	143	364617	238
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	breast disease	targetBased	0.194681776785556	13	309684	1662
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	breast disease	targetBased	0.15454699994889	87	394050	3624
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	breast disease	targetBased	0.210587896877429	44	363840	2624
uHTS identification of SUMO1-mediated protein-protein interactions	SUMO1	breast disease	targetBased	0.110824025335197	12	363840	1202
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	breast disease	targetBased	0.16782829506779	53	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	breast disease	pathwayBased	0.16782829506779	53	403871	1243
uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay	TNFRSF10B	breast disease	targetBased	0.105255890920665	37	363840	3764
Antagonist identification of Pyk2 oligomerization: high-throughput screening cellular assay	Pyk2Ã‚Â	breast disease	targetBased	0.104319040203969	34	98749	818
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	breast disease	targetBased	0.164296159315644	114	217035	883
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	breast disease	targetBased	0.183470387509613	29	369953	3123
Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1)	PRMT1	breast disease	targetBased	0.107515994756271	14	369953	4757
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	breast disease	targetBased	0.153700593782356	21	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	breast disease	targetBased	0.18257271406876	39	344733	7043
uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay	APOBEC3A_inhibitors	breast disease	targetBased	0.148064608380062	10	331753	1372
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	breast disease	targetBased	0.169853660655128	131	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	breast disease	targetBased	0.169853660655128	131	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	breast disease	targetBased	0.169853660655128	131	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	breast disease	targetBased	0.169853660655128	131	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	breast disease	targetBased	0.169853660655128	131	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	breast disease	targetBased	0.169853660655128	131	196177	519
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	breast disease	targetBased	0.185407003866209	26	263421	615
E3 Ligase HTS_1536	MDM2	breast disease	targetBased	0.223983449577019	128	207811	220
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	breast disease	targetBased	0.166726943992371	10	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	breast disease	targetBased	0.166726943992371	10	194628	521
Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling	ARRB1_inhibitors	breast disease	targetBased	0.109597403304455	16	338373	1061
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	breast disease	targetBased	0.101868524266852	12	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	breast disease	targetBased	0.101868524266852	12	305610	3253
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	breast disease	targetBased	0.101272098591819	21	369953	2294
USP8 deubiquitinase inhibition: Primary qHTS	USP8	breast disease	targetBased	0.212561733415683	11	47480	2010
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	breast disease	targetBased	0.230720908656892	418	86095	1114
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	breast disease	targetBased	0.218691159362837	12	368927	620
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	breast disease	pathwayBased	0.102401624002059	38	193714	1590
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	breast disease	pathwayBased	0.102401624002059	38	193400	1987
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	breast disease	targetBased	0.102401624002059	38	404343	257
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	breast disease	targetBased	0.110293420424757	60	93798	679
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	breast disease	targetBased	0.303991667469897	2184	322361	619
qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)	PIP4K2A	breast disease	targetBased	0.106180590552735	9	328860	4078
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	breast disease	targetBased	0.159354007940332	29	325630	216
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	breast disease	targetBased	0.223998353050167	10	335531	328
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	breast disease	targetBased	0.157585958955324	9	369953	2353
qHTS for Inhibitors of WRN Helicase	WRN	breast disease	targetBased	0.210750268899659	20	364011	1678
Fluorescence polarization assay for PLK1 inhibitors	PLK1	breast disease	targetBased	0.107352941978298	94	97099	518
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	breast disease	targetBased	0.107352941978298	94	364065	10181
HTS of Smad transcription factor inhibitors	SMAD3	breast disease	targetBased	0.174964957044736	69	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	breast disease	targetBased	0.188765344453778	120	193542	587
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	breast disease	targetBased	0.117901380894759	18	386270	1331
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	breast disease	targetBased	0.20897547053003	9	305610	3794
HTS for 14-3-3 protein interaction modulators	YWHAG	breast disease	targetBased	0.105577062799589	8	157962	312
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	breast disease	targetBased	0.206193476993776	4	339674	2841
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	breast disease	targetBased	0.112524761319786	99	314998	2199
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	breast disease	targetBased	0.111595369620265	14	369953	760
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	breast disease	targetBased	0.111595369620265	14	369953	498
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	breast disease	targetBased	0.155806514589496	58	318291	483
Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity	MLLT3	breast disease	targetBased	0.105994297342229	6	344459	1627
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	breast disease	targetBased	0.136107722480658	29	218654	8241
qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	breast disease	targetBased	0.126598891916406	6	330109	4174
qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	breast disease	targetBased	0.126598891916406	6	330107	7652
Thrombin 1536 HTS	F2_modulation	breast disease	targetBased	0.101713520122631	12	217233	557
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	breast disease	pathwayBased	0.100568698975053	29	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	breast disease	targetBased	0.100568698975053	29	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	breast disease	pathwayBased	0.100568698975053	29	271402	1048
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	breast disease	targetBased	0.213214327153229	15	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	breast disease	targetBased	0.213214327153229	15	331360	2760
HCS assay for microtubule stabilizers	TUBB	breast disease	targetBased	0.242646114623037	1149	195821	1625
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	breast disease	targetBased	0.109322523023291	14	316642	617
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	breast disease	targetBased	0.223410680400475	44	347933	673
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	breast disease	targetBased	0.197050938270862	42	331671	10022
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	breast disease	pathwayBased	0.216007799557554	720	43989	342
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	fallopian tube disease	pathwayBased	0.159328802963136	19	376029	3978
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	fallopian tube disease	targetBased	0.136446467089839	5	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	fallopian tube disease	targetBased	0.136446467089839	5	86095	1151
qHTS assay for re-activators of p53 using a Luc reporter	TP53	fallopian tube disease	pathwayBased	0.127100027315711	11	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	fallopian tube disease	targetBased	0.127100027315711	11	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	fallopian tube disease	targetBased	0.127100027315711	11	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	fallopian tube disease	targetBased	0.127100027315711	11	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	fallopian tube disease	targetBased	0.127100027315711	11	124022	1156
HCS assay for microtubule stabilizers	TUBB	fallopian tube disease	targetBased	0.193819717488268	69	195821	1625
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	female reproductive system disease	targetBased	0.118740279818899	65	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	female reproductive system disease	targetBased	0.118740279818899	65	296501	2737
qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)	RECQL	female reproductive system disease	targetBased	0.119776800964695	7	234915	1245
ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity	TACC3	female reproductive system disease	targetBased	0.107328017629229	11	391179	2589
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	female reproductive system disease	targetBased	0.120797655192818	8	290915	2982
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	female reproductive system disease	targetBased	0.120797655192818	8	359244	1307
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	breast disease	targetBased	0.130596636703118	19	335214	1652
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	female reproductive system disease	pathwayBased	0.195243846855942	17	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	female reproductive system disease	targetBased	0.187137655580034	43	336894	489
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	female reproductive system disease	targetBased	0.136926202615087	41	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	female reproductive system disease	targetBased	0.136926202615087	41	290726	2649
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	female reproductive system disease	targetBased	0.11780882584243	4	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	female reproductive system disease	targetBased	0.108631799078871	16	359206	428
Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity	RAD54L	female reproductive system disease	targetBased	0.16752865504966	20	358498	505
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	female reproductive system disease	targetBased	0.10080414867211	5	218528	711
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	female reproductive system disease	targetBased	0.10080414867211	5	218528	770
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	female reproductive system disease	targetBased	0.10080414867211	5	218528	750
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	female reproductive system disease	targetBased	0.251960477173034	43	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	female reproductive system disease	targetBased	0.251960477173034	43	337446	1356
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	female reproductive system disease	targetBased	0.153071356197299	7	385746	932
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	female reproductive system disease	targetBased	0.207592483778536	86	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	female reproductive system disease	targetBased	0.19437372731512	44	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	female reproductive system disease	pathwayBased	0.252546120364829	71	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	female reproductive system disease	pathwayBased	0.252546120364829	71	131324	544
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	female reproductive system disease	targetBased	0.129852246574674	16	143816	859
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	female reproductive system disease	targetBased	0.257889023541951	138	46715	2829
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	female reproductive system disease	targetBased	0.105705088380779	10	335214	1652
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	female reproductive system disease	targetBased	0.14236931752855	4	363803	2412
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	female reproductive system disease	targetBased	0.160995899898862	22	290726	671
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	breast disease	targetBased	0.20173737926032	239	57013	201
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	breast disease	targetBased	0.110287908706233	74	338328	2501
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	breast disease	targetBased	0.104014425035891	22	369953	3080
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	breast disease	targetBased	0.202282768256875	59	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	breast disease	targetBased	0.202282768256875	59	218234	1620
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	breast disease	targetBased	0.187501388540466	18	71016	346
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	breast disease	targetBased	0.103777010790712	11	217959	923
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	breast disease	targetBased	0.12090641737036	8	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	breast disease	targetBased	0.12090641737036	8	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	breast disease	targetBased	0.12090641737036	8	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	breast disease	targetBased	0.12090641737036	8	72026	1794
Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	breast disease	targetBased	0.117419583855518	229	96879	811
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	breast disease	targetBased	0.100254124781827	15	386663	3977
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	female reproductive system disease	targetBased	0.11395712031094	13	315412	318
HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails	HP1-betaChromodomainInteractionsInhibitors	female reproductive system disease	targetBased	0.122738453817343	7	383363	2142
qHTS Assay for Inhibitors of GCN5L2	KAT2A	female reproductive system disease	targetBased	0.109687891175867	10	381571	792
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	female reproductive system disease	targetBased	0.166535576327148	15	343468	285
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	female reproductive system disease	pathwayBased	0.114308960140849	576	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	female reproductive system disease	pathwayBased	0.114308960140849	576	359244	3094
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	female reproductive system disease	targetBased	0.198579452457019	9	309684	1662
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	female reproductive system disease	targetBased	0.116492011406234	60	338328	2501
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	female reproductive system disease	targetBased	0.208830980169785	10	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	female reproductive system disease	targetBased	0.208830980169785	10	335239	695
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	female reproductive system disease	targetBased	0.202298867785089	68	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	female reproductive system disease	targetBased	0.202298867785089	68	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	female reproductive system disease	targetBased	0.202298867785089	68	405130	6428
uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay	CCR6_antagonists	female reproductive system disease	targetBased	0.102378046912433	4	340696	1654
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	female reproductive system disease	pathwayBased	0.113194387939215	59	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	female reproductive system disease	targetBased	0.113194387939215	59	195980	695
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	female reproductive system disease	targetBased	0.203867653819859	29	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	female reproductive system disease	targetBased	0.258278273669527	70	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	female reproductive system disease	pathwayBased	0.258278273669527	70	403871	1243
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	female reproductive system disease	targetBased	0.105222960561101	16	363803	458
uHTS Fluorescent assay for identification of activators of Apaf-1	APAF1_activators	female reproductive system disease	targetBased	0.107155604784645	14	331671	1041
uHTS Fluorescent assay for identification of inhibitors of Apaf-1	APAF1_inhibitors	female reproductive system disease	targetBased	0.107155604784645	14	331671	2353
Antagonist identification of Pyk2 oligomerization: high-throughput screening cellular assay	Pyk2Ã‚Â	female reproductive system disease	targetBased	0.113223457885023	11	98749	818
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	female reproductive system disease	targetBased	0.186141696315585	21	369953	3123
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	female reproductive system disease	targetBased	0.112192703707313	17	250190	1304
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	female reproductive system disease	targetBased	0.112192703707313	17	255537	2141
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	female reproductive system disease	targetBased	0.197523198093513	155	353950	4145
qHTS Assay for Activators of ClpP	Bacillus subtilis (strain 168)	female reproductive system disease	targetBased	0.290775566150394	49	338378	6439
Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1)	PRMT1	female reproductive system disease	targetBased	0.107413155133366	11	369953	4757
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	female reproductive system disease	targetBased	0.178335878674342	15	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	female reproductive system disease	targetBased	0.258949503496759	149	344733	7043
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	female reproductive system disease	targetBased	0.252524235857846	202	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	female reproductive system disease	targetBased	0.252524235857846	202	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	female reproductive system disease	targetBased	0.252524235857846	202	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	female reproductive system disease	targetBased	0.252524235857846	202	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	female reproductive system disease	targetBased	0.252524235857846	202	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	female reproductive system disease	targetBased	0.252524235857846	202	196177	519
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	female reproductive system disease	targetBased	0.173826895332114	44	263421	615
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	female reproductive system disease	targetBased	0.102628527430793	13	59788	212
qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy	CGA_integrin_activators	female reproductive system disease	targetBased	0.102633187140817	22	345855	222
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	female reproductive system disease	targetBased	0.230359974537758	14	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	female reproductive system disease	targetBased	0.230359974537758	14	194628	521
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	female reproductive system disease	targetBased	0.296712587614208	104	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	female reproductive system disease	targetBased	0.296712587614208	104	64908	359
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	female reproductive system disease	targetBased	0.185192626067092	121	639428	9218
USP8 deubiquitinase inhibition: Primary qHTS	USP8	female reproductive system disease	targetBased	0.212246222586367	17	47480	2010
VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2	Caspase6Inhibitors	female reproductive system disease	targetBased	0.104566048981036	10	344318	1854
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	female reproductive system disease	targetBased	0.223119348274683	15	368927	620
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	female reproductive system disease	targetBased	0.204714103633038	59	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	female reproductive system disease	targetBased	0.204714103633038	59	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	female reproductive system disease	targetBased	0.204714103633038	59	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	female reproductive system disease	targetBased	0.204714103633038	59	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	female reproductive system disease	targetBased	0.204714103633038	59	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	female reproductive system disease	targetBased	0.204714103633038	59	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	female reproductive system disease	targetBased	0.333417244155734	13597	322361	619
qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)	PIP4K2A	female reproductive system disease	targetBased	0.105081208276396	6	328860	4078
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	female reproductive system disease	targetBased	0.130336543577627	7	276265	806
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	female reproductive system disease	targetBased	0.128130058666925	5	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	female reproductive system disease	targetBased	0.128130058666925	5	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	female reproductive system disease	targetBased	0.128130058666925	5	407539	2380
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	female reproductive system disease	targetBased	0.235292341351517	20	335531	328
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	female reproductive system disease	targetBased	0.200624034399356	38	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	female reproductive system disease	targetBased	0.200624034399356	38	218234	1620
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	female reproductive system disease	targetBased	0.202807971044838	24	71016	346
Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3	procaspase3Activators	female reproductive system disease	targetBased	0.104261387684401	229	326024	350
qHTS for Inhibitors of WRN Helicase	WRN	female reproductive system disease	targetBased	0.239114763531375	23	364011	1678
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	female reproductive system disease	targetBased	0.182021109314348	24	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	female reproductive system disease	targetBased	0.182021109314348	24	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	female reproductive system disease	targetBased	0.182021109314348	24	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	female reproductive system disease	targetBased	0.182021109314348	24	72026	1794
Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation	WEE1	female reproductive system disease	targetBased	0.112304986637119	78	217959	2616
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	female reproductive system disease	targetBased	0.306078813946493	314	193542	587
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	female reproductive system disease	targetBased	0.124024116263439	15	386270	1331
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	female reproductive system disease	pathwayBased	0.221483037953794	388	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	female reproductive system disease	pathwayBased	0.221483037953794	388	194666	1722
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	female reproductive system disease	targetBased	0.283152477816219	33	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	female reproductive system disease	targetBased	0.283152477816219	33	343468	3417
Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	female reproductive system disease	targetBased	0.137038968884367	103	96879	811
HTS for 14-3-3 protein interaction modulators	YWHAG	female reproductive system disease	targetBased	0.108801886192594	11	157962	312
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	female reproductive system disease	targetBased	0.103676358616879	12	55710	315
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	female reproductive system disease	targetBased	0.102802625307919	7	369953	760
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	female reproductive system disease	targetBased	0.102802625307919	7	369953	498
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	female reproductive system disease	targetBased	0.118374377142379	40	318291	483
Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity	MLLT3	female reproductive system disease	targetBased	0.102464903086793	4	344459	1627
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	female reproductive system disease	targetBased	0.147517434571374	10	31324	362
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	female reproductive system disease	targetBased	0.246108996084288	67	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	female reproductive system disease	targetBased	0.152550628645428	42	218654	8241
uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay	UBE2N	female reproductive system disease	targetBased	0.101802924867331	7	330393	1538
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	female reproductive system disease	targetBased	0.17880993958174	5	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	female reproductive system disease	targetBased	0.17880993958174	5	61606	416
Thrombin 1536 HTS	F2_modulation	female reproductive system disease	targetBased	0.164428242681268	50	217233	557
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	female reproductive system disease	targetBased	0.1943071474518	30	324747	1043
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	female reproductive system disease	targetBased	0.230177138841128	35	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	female reproductive system disease	targetBased	0.230177138841128	35	331360	2760
HCS assay for microtubule stabilizers	TUBB	female reproductive system disease	targetBased	0.215920262050755	443	195821	1625
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	female reproductive system disease	targetBased	0.177328260141263	32	316642	617
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	female reproductive system disease	targetBased	0.243856104413148	43	347933	673
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	female reproductive system disease	targetBased	0.1957229648964	15	331671	10022
qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a	EHMT2_inhibitors	female reproductive system disease	targetBased	0.100405792478326	17	348338	30875
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	female reproductive system disease	targetBased	0.117487306207858	45	343468	734
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	male reproductive system disease	targetBased	0.308308934368707	484	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	male reproductive system disease	targetBased	0.308308934368707	484	296501	2737
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	male reproductive system disease	pathwayBased	0.230005391996766	141	376029	3978
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	male reproductive system disease	pathwayBased	0.133643212984012	5	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	male reproductive system disease	targetBased	0.128120087769096	16	336894	489
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	male reproductive system disease	targetBased	0.105803322716523	169	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	male reproductive system disease	targetBased	0.105803322716523	169	290726	2649
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	male reproductive system disease	targetBased	0.159771391419648	19	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	male reproductive system disease	targetBased	0.159771391419648	19	337446	1356
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	male reproductive system disease	targetBased	0.133291837501927	36	385746	932
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	male reproductive system disease	targetBased	0.240407616694986	286	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	male reproductive system disease	targetBased	0.240407616694986	286	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	male reproductive system disease	targetBased	0.140715360200009	53	217959	2390
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	male reproductive system disease	pathwayBased	0.166244527117031	31	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	male reproductive system disease	pathwayBased	0.166244527117031	31	131324	544
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	male reproductive system disease	targetBased	0.128529237960737	13	143816	859
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	male reproductive system disease	targetBased	0.154381580568837	32	46715	2829
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	male reproductive system disease	targetBased	0.101398724304095	19	290726	671
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	male reproductive system disease	targetBased	0.161005149958417	12	363803	1383
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	male reproductive system disease	targetBased	0.179987738531216	124	57013	201
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	male reproductive system disease	targetBased	0.15343191464913	32	343468	285
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	male reproductive system disease	targetBased	0.14785793384725	10	309684	1662
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	male reproductive system disease	targetBased	0.113081606425761	34	338328	2501
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	male reproductive system disease	targetBased	0.16392868839361	13	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	male reproductive system disease	targetBased	0.16392868839361	13	335239	695
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	male reproductive system disease	targetBased	0.12989997184571	8	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	male reproductive system disease	targetBased	0.141693762624851	44	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	male reproductive system disease	pathwayBased	0.141693762624851	44	403871	1243
qHTS for Inhibitors of Polymerase Kappa	POLK	male reproductive system disease	targetBased	0.20229423634741	32	395295	2034
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	male reproductive system disease	targetBased	0.127795328318428	4	369953	3123
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	male reproductive system disease	targetBased	0.219698192584722	40	250190	1304
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	male reproductive system disease	targetBased	0.219698192584722	40	255537	2141
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	male reproductive system disease	targetBased	0.146696525162998	9	353950	4145
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	male reproductive system disease	targetBased	0.142060046577855	4	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	male reproductive system disease	targetBased	0.183556135401063	16	344733	7043
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	male reproductive system disease	targetBased	0.130195771618903	22	263421	615
E3 Ligase HTS_1536	MDM2	male reproductive system disease	targetBased	0.178040524491268	43	207811	220
USP8 deubiquitinase inhibition: Primary qHTS	USP8	male reproductive system disease	targetBased	0.142992269818415	8	47480	2010
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	male reproductive system disease	targetBased	0.179598305079434	163	86095	1114
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	male reproductive system disease	targetBased	0.168364124198154	39	368927	620
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	male reproductive system disease	targetBased	0.23449317273105	726	356517	1139
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	male reproductive system disease	targetBased	0.187517230341239	16	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	male reproductive system disease	targetBased	0.187517230341239	16	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	male reproductive system disease	targetBased	0.187517230341239	16	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	male reproductive system disease	targetBased	0.187517230341239	16	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	male reproductive system disease	targetBased	0.187517230341239	16	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	male reproductive system disease	targetBased	0.187517230341239	16	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	male reproductive system disease	targetBased	0.283091938334947	75	322361	619
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	male reproductive system disease	targetBased	0.197392997129676	15	335531	328
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	male reproductive system disease	targetBased	0.134761791506931	14	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	male reproductive system disease	targetBased	0.134761791506931	14	218234	1620
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	male reproductive system disease	targetBased	0.127647525712634	4	71016	346
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	male reproductive system disease	targetBased	0.133668531448357	5	369953	2353
HTS of Smad transcription factor inhibitors	SMAD3	male reproductive system disease	targetBased	0.148259199127439	25	88033	251
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	male reproductive system disease	targetBased	0.165064269653221	42	292323	1836
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	male reproductive system disease	targetBased	0.259775887173518	75	193542	587
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	male reproductive system disease	pathwayBased	0.136999987040117	238	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	male reproductive system disease	pathwayBased	0.136999987040117	238	194666	1722
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	male reproductive system disease	targetBased	0.175977773463788	17	339297	1446
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	male reproductive system disease	targetBased	0.167519520383769	34	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	male reproductive system disease	targetBased	0.167519520383769	34	331360	2760
HCS assay for microtubule stabilizers	TUBB	male reproductive system disease	targetBased	0.218711141264653	373	195821	1625
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	male reproductive system disease	targetBased	0.161331182449403	5	347933	673
HTS of Smad transcription factor inhibitors	SMAD3	female reproductive system disease	targetBased	0.208399348980695	46	88033	251
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	female reproductive system disease	targetBased	0.161468426524039	24	339297	1446
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	male reproductive system disease	targetBased	0.167782858204981	23	359207	1432
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	male reproductive system disease	targetBased	0.153195763803487	73	394050	3624
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	male reproductive system disease	targetBased	0.158809016087091	57	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	male reproductive system disease	targetBased	0.158809016087091	57	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	male reproductive system disease	targetBased	0.158809016087091	57	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	male reproductive system disease	targetBased	0.158809016087091	57	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	male reproductive system disease	targetBased	0.158809016087091	57	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	male reproductive system disease	targetBased	0.158809016087091	57	196177	519
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	male reproductive system disease	targetBased	0.286069567870116	142	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	male reproductive system disease	targetBased	0.286069567870116	142	64908	359
qHTS assay for re-activators of p53 using a Luc reporter	TP53	male reproductive system disease	pathwayBased	0.289275069257719	741	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	male reproductive system disease	targetBased	0.289275069257719	741	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	male reproductive system disease	targetBased	0.289275069257719	741	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	male reproductive system disease	targetBased	0.289275069257719	741	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	male reproductive system disease	targetBased	0.289275069257719	741	124022	1156
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	male reproductive system disease	targetBased	0.174563057575011	16	325630	216
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	male reproductive system disease	targetBased	0.102054877433075	10	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	male reproductive system disease	targetBased	0.102054877433075	10	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	male reproductive system disease	targetBased	0.102054877433075	10	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	male reproductive system disease	targetBased	0.102054877433075	10	72026	1794
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	male reproductive system disease	targetBased	0.283249352797804	59	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	male reproductive system disease	targetBased	0.283249352797804	59	343468	3417
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	male reproductive system disease	targetBased	0.224581657884406	27	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	male reproductive system disease	targetBased	0.130028851256686	18	218654	8241
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	male reproductive system disease	targetBased	0.170357292663396	11	331671	10022
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	male reproductive system disease	pathwayBased	0.195236418844547	259	43989	342
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	sex hormone measurement	pathwayBased	0.128518245075307	5	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	sex hormone measurement	pathwayBased	0.128518245075307	5	64908	278
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	sex hormone measurement	targetBased	0.156279965694572	4	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	sex hormone measurement	targetBased	0.156279965694572	4	86095	1151
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	sex hormone measurement	targetBased	0.175768059625549	5	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	sex hormone measurement	pathwayBased	0.175768059625549	5	403871	1243
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	sex hormone measurement	targetBased	0.176018029450373	11	217035	883
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone measurement	targetBased	0.17263244587617	12	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone measurement	targetBased	0.17263244587617	12	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone measurement	targetBased	0.17263244587617	12	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone measurement	targetBased	0.17263244587617	12	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone measurement	targetBased	0.17263244587617	12	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone measurement	targetBased	0.17263244587617	12	196177	519
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	sex hormone measurement	targetBased	0.171861856636956	5	639428	9218
qHTS assay for re-activators of p53 using a Luc reporter	TP53	sex hormone measurement	pathwayBased	0.103563977521843	70	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	sex hormone measurement	targetBased	0.103563977521843	70	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	sex hormone measurement	targetBased	0.103563977521843	70	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	sex hormone measurement	targetBased	0.103563977521843	70	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	sex hormone measurement	targetBased	0.103563977521843	70	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	sex hormone measurement	targetBased	0.111319591435167	5	356517	1139
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	sex hormone measurement	targetBased	0.180738404263492	6	276265	806
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	sex hormone measurement	targetBased	0.165396446099997	13	325630	216
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	sex hormone measurement	targetBased	0.160221399397579	4	55710	315
uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1	PHOSPHO1	sex hormone measurement	targetBased	0.154288951447895	16	288321	3164
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	sex hormone measurement	targetBased	0.155773113346406	13	369953	2602
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	sex hormone measurement	targetBased	0.112580586589997	6	369953	3123
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	dysplasia of cervix	targetBased	0.104447177505913	13	193542	587
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Abnormality of the genital system	targetBased	0.226117676974408	162	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Abnormality of the genital system	targetBased	0.226117676974408	162	86095	1151
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Abnormality of the genital system	targetBased	0.198200066394977	5	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Abnormality of the genital system	targetBased	0.198200066394977	5	335239	695
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	Abnormality of the genital system	targetBased	0.171314495377213	32	86095	1114
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Abnormality of the genital system	targetBased	0.170062929167428	4	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Abnormality of the genital system	targetBased	0.170062929167428	4	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Abnormality of the genital system	targetBased	0.170062929167428	4	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Abnormality of the genital system	targetBased	0.170062929167428	4	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Abnormality of the genital system	targetBased	0.170062929167428	4	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Abnormality of the genital system	targetBased	0.170062929167428	4	336308	6862
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Abnormality of the genital system	targetBased	0.201328655240741	9	316642	617
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	penile disorder	targetBased	0.204467573678204	4	250190	1304
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	penile disorder	targetBased	0.204467573678204	4	255537	2141
qHTS assay for re-activators of p53 using a Luc reporter	TP53	penile disorder	pathwayBased	0.16241462529665	44	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	penile disorder	targetBased	0.16241462529665	44	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	penile disorder	targetBased	0.16241462529665	44	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	penile disorder	targetBased	0.16241462529665	44	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	penile disorder	targetBased	0.16241462529665	44	124022	1156
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	penile disorder	targetBased	0.127277371188249	4	194628	267
HCS assay for microtubule stabilizers	TUBB	penile disorder	targetBased	0.108859380870519	5	195821	1625
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	endometrial disorder	pathwayBased	0.236240684293198	39	376029	3978
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	endometrial disorder	pathwayBased	0.161041034818971	4	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	endometrial disorder	targetBased	0.102426623279281	6	336894	489
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	endometrial disorder	targetBased	0.121651544352107	7	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	endometrial disorder	targetBased	0.121651544352107	7	290726	2649
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	endometrial disorder	targetBased	0.170937579264425	14	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	endometrial disorder	targetBased	0.16659225514969	8	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	endometrial disorder	pathwayBased	0.136764953703116	9	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	endometrial disorder	pathwayBased	0.136764953703116	9	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	endometrial disorder	targetBased	0.199603347749987	14	46715	2829
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	endometrial disorder	targetBased	0.187018940435692	35	57013	201
qHTS Assay for Inhibitors of GCN5L2	KAT2A	endometrial disorder	targetBased	0.102139900705402	4	381571	792
qHTS of IL-2 Activators	IL2	endometrial disorder	targetBased	0.102116782561792	32	364617	238
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	endometrial disorder	targetBased	0.145766988868619	14	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	endometrial disorder	targetBased	0.111576368123933	5	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	endometrial disorder	targetBased	0.111576368123933	5	335239	695
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	endometrial disorder	pathwayBased	0.107739974466869	7	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	endometrial disorder	targetBased	0.107739974466869	7	195980	695
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	endometrial disorder	targetBased	0.152556764480107	14	369953	3123
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	endometrial disorder	targetBased	0.135999151280191	4	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	endometrial disorder	targetBased	0.200403682251898	22	344733	7043
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	endometrial disorder	targetBased	0.118865676770461	4	263421	615
E3 Ligase HTS_1536	MDM2	endometrial disorder	targetBased	0.182716318327384	23	207811	220
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	endometrial disorder	targetBased	0.130477048098182	7	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	endometrial disorder	targetBased	0.130477048098182	7	194628	521
qHTS assay for re-activators of p53 using a Luc reporter	TP53	endometrial disorder	pathwayBased	0.274336682884845	403	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endometrial disorder	targetBased	0.274336682884845	403	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endometrial disorder	targetBased	0.274336682884845	403	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endometrial disorder	targetBased	0.274336682884845	403	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	endometrial disorder	targetBased	0.274336682884845	403	124022	1156
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	endometrial disorder	targetBased	0.252586832216947	27	322361	619
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	endometrial disorder	targetBased	0.153854161040899	5	335531	328
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	endometrial disorder	targetBased	0.177749566165603	8	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	endometrial disorder	targetBased	0.177749566165603	8	218234	1620
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	endometrial disorder	targetBased	0.152601710761696	5	71016	346
Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation	WEE1	endometrial disorder	targetBased	0.104901925275093	9	217959	2616
HTS of Smad transcription factor inhibitors	SMAD3	endometrial disorder	targetBased	0.17108048152452	9	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	endometrial disorder	targetBased	0.27290358046923	106	193542	587
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	endometrial disorder	pathwayBased	0.164733303027072	48	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	endometrial disorder	pathwayBased	0.164733303027072	48	194666	1722
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	endometrial disorder	targetBased	0.100899201365958	5	369953	760
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	endometrial disorder	targetBased	0.100899201365958	5	369953	498
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	endometrial disorder	targetBased	0.10252428102439	8	318291	483
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	endometrial disorder	targetBased	0.147309636584831	4	31324	362
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	endometrial disorder	targetBased	0.126844968997739	5	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	endometrial disorder	targetBased	0.119528786968175	5	218654	8241
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	endometrial disorder	targetBased	0.191118050129079	5	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	endometrial disorder	targetBased	0.191118050129079	5	331360	2760
HCS assay for microtubule stabilizers	TUBB	endometrial disorder	targetBased	0.150453493669177	42	195821	1625
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	endometrial disorder	targetBased	0.206063064849997	8	347933	673
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	endometrial disorder	pathwayBased	0.224549238701253	101	43989	342
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	vaginal disorder	targetBased	0.200736314950677	9	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	vaginal disorder	targetBased	0.200736314950677	9	86095	1151
qHTS assay for re-activators of p53 using a Luc reporter	TP53	vaginal disorder	pathwayBased	0.198019104555726	8	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vaginal disorder	targetBased	0.198019104555726	8	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vaginal disorder	targetBased	0.198019104555726	8	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vaginal disorder	targetBased	0.198019104555726	8	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vaginal disorder	targetBased	0.198019104555726	8	124022	1156
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	gonadal dysgenesis	targetBased	0.206260176531234	46	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	gonadal dysgenesis	targetBased	0.206260176531234	46	86095	1151
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	gonadal dysgenesis	targetBased	0.29552195751918	56	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	gonadal dysgenesis	targetBased	0.29552195751918	56	64908	359
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	gonadal dysgenesis	targetBased	0.237963243093854	128	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	gonadal dysgenesis	targetBased	0.237963243093854	128	343468	3417
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	cervix disorder	pathwayBased	0.129741959696899	20	376029	3978
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	cervix disorder	targetBased	0.15223364780017	5	336894	489
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	cervix disorder	targetBased	0.180193396277543	7	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	cervix disorder	targetBased	0.180193396277543	7	337446	1356
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	cervix disorder	targetBased	0.112371273248956	59	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	cervix disorder	targetBased	0.112371273248956	59	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	cervix disorder	targetBased	0.129938746695902	5	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	cervix disorder	targetBased	0.13315194719452	4	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	cervix disorder	pathwayBased	0.202819801109159	11	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	cervix disorder	pathwayBased	0.202819801109159	11	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	cervix disorder	targetBased	0.14276786558855	7	46715	2829
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	cervix disorder	targetBased	0.135884932491802	4	290726	671
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	cervix disorder	targetBased	0.121430844403718	14	57013	201
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	cervix disorder	targetBased	0.133892275026185	4	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	cervix disorder	targetBased	0.191941195028862	18	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	cervix disorder	pathwayBased	0.191941195028862	18	403871	1243
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	cervix disorder	targetBased	0.16601450025093	12	353950	4145
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	cervix disorder	targetBased	0.127651691703518	6	344733	7043
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	cervix disorder	targetBased	0.103525122147911	5	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	cervix disorder	targetBased	0.103525122147911	5	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	cervix disorder	targetBased	0.103525122147911	5	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	cervix disorder	targetBased	0.103525122147911	5	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	cervix disorder	targetBased	0.103525122147911	5	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	cervix disorder	targetBased	0.103525122147911	5	196177	519
E3 Ligase HTS_1536	MDM2	cervix disorder	targetBased	0.103052747851954	14	207811	220
USP8 deubiquitinase inhibition: Primary qHTS	USP8	cervix disorder	targetBased	0.102814705193778	5	47480	2010
qHTS assay for re-activators of p53 using a Luc reporter	TP53	cervix disorder	pathwayBased	0.240193439270232	474	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervix disorder	targetBased	0.240193439270232	474	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervix disorder	targetBased	0.240193439270232	474	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervix disorder	targetBased	0.240193439270232	474	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cervix disorder	targetBased	0.240193439270232	474	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	cervix disorder	targetBased	0.157006559147765	58	356517	1139
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	cervix disorder	targetBased	0.148102638246012	17	322361	619
qHTS for Inhibitors of WRN Helicase	WRN	cervix disorder	targetBased	0.119083689840159	4	364011	1678
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	cervix disorder	targetBased	0.188963968354571	34	193542	587
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	cervix disorder	pathwayBased	0.108695611890028	39	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	cervix disorder	pathwayBased	0.108695611890028	39	194666	1722
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	cervix disorder	targetBased	0.196973106821807	23	194628	267
HCS assay for microtubule stabilizers	TUBB	cervix disorder	targetBased	0.194292745124793	68	195821	1625
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	cervix disorder	targetBased	0.118344226021693	4	347933	673
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	cervix disorder	pathwayBased	0.17861386914038	32	43989	342
qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)	RECQL	gonadal disorder	targetBased	0.119526988452678	5	234915	1245
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	gonadal disorder	pathwayBased	0.329791354578158	7355	376029	3978
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	gonadal disorder	pathwayBased	0.153171548029199	11	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	gonadal disorder	targetBased	0.165924951554178	12	336894	489
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	gonadal disorder	targetBased	0.124359186371945	35	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	gonadal disorder	targetBased	0.124359186371945	35	290726	2649
Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity	RAD54L	gonadal disorder	targetBased	0.16752865504966	20	358498	505
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	gonadal disorder	targetBased	0.219723980393433	23	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	gonadal disorder	targetBased	0.219723980393433	23	337446	1356
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	gonadal disorder	targetBased	0.272883634254307	722	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	gonadal disorder	targetBased	0.272883634254307	722	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	gonadal disorder	targetBased	0.187110832839925	23	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	gonadal disorder	targetBased	0.179576245058738	23	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	gonadal disorder	pathwayBased	0.167835903541685	22	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	gonadal disorder	pathwayBased	0.167835903541685	22	131324	544
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	gonadal disorder	targetBased	0.109741544821088	7	143816	859
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	gonadal disorder	targetBased	0.239903995448924	81	46715	2829
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	gonadal disorder	targetBased	0.102126204798196	6	335214	1652
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	gonadal disorder	targetBased	0.118373192701858	4	363803	2412
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	gonadal disorder	targetBased	0.106037361389645	10	315412	318
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	gonadal disorder	targetBased	0.193064094955463	57	57013	201
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	gonadal disorder	targetBased	0.153240345909376	7	343468	285
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	gonadal disorder	pathwayBased	0.103315886474151	169	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	gonadal disorder	pathwayBased	0.103315886474151	169	359244	3094
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	gonadal disorder	targetBased	0.185833273741823	5	309684	1662
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	gonadal disorder	targetBased	0.103753228112831	24	338328	2501
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	gonadal disorder	targetBased	0.210963970116023	64	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	gonadal disorder	targetBased	0.106234471630695	4	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	gonadal disorder	targetBased	0.106234471630695	4	335239	695
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	gonadal disorder	targetBased	0.205565011593548	74	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	gonadal disorder	targetBased	0.205565011593548	74	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	gonadal disorder	targetBased	0.205565011593548	74	405130	6428
uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay	CCR6_antagonists	gonadal disorder	targetBased	0.102501187576251	4	340696	1654
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	gonadal disorder	targetBased	0.172178491008802	9	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	gonadal disorder	targetBased	0.186647940665242	27	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	gonadal disorder	pathwayBased	0.186647940665242	27	403871	1243
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	gonadal disorder	targetBased	0.103498737659759	20	363803	458
Antagonist identification of Pyk2 oligomerization: high-throughput screening cellular assay	Pyk2Ã‚Â	gonadal disorder	targetBased	0.113436023856114	10	98749	818
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	gonadal disorder	targetBased	0.149049790064521	4	369953	3123
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	gonadal disorder	targetBased	0.116104211613976	95	353950	4145
qHTS Assay for Activators of ClpP	Bacillus subtilis (strain 168)	gonadal disorder	targetBased	0.290832637437638	47	338378	6439
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	gonadal disorder	targetBased	0.156599809171732	10	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	gonadal disorder	targetBased	0.243175555772075	88	344733	7043
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gonadal disorder	targetBased	0.249273062188396	122	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gonadal disorder	targetBased	0.249273062188396	122	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gonadal disorder	targetBased	0.249273062188396	122	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gonadal disorder	targetBased	0.249273062188396	122	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gonadal disorder	targetBased	0.249273062188396	122	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gonadal disorder	targetBased	0.249273062188396	122	196177	519
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	gonadal disorder	targetBased	0.106222262551229	39	263421	615
E3 Ligase HTS_1536	MDM2	gonadal disorder	targetBased	0.198786996315959	31	207811	220
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	gonadal disorder	targetBased	0.171620146768529	35	639428	9218
USP8 deubiquitinase inhibition: Primary qHTS	USP8	gonadal disorder	targetBased	0.18277907056128	4	47480	2010
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	gonadal disorder	targetBased	0.248834890642323	138	86095	1114
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	gonadal disorder	targetBased	0.182722089123978	15	368927	620
qHTS assay for re-activators of p53 using a Luc reporter	TP53	gonadal disorder	pathwayBased	0.306593205080055	1317	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gonadal disorder	targetBased	0.306593205080055	1317	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gonadal disorder	targetBased	0.306593205080055	1317	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gonadal disorder	targetBased	0.306593205080055	1317	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gonadal disorder	targetBased	0.306593205080055	1317	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	gonadal disorder	targetBased	0.261208152210668	352	356517	1139
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	gonadal disorder	targetBased	0.107848293246061	18	93798	679
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	gonadal disorder	targetBased	0.219680173536037	77	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	gonadal disorder	targetBased	0.219680173536037	77	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	gonadal disorder	targetBased	0.219680173536037	77	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	gonadal disorder	targetBased	0.219680173536037	77	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	gonadal disorder	targetBased	0.219680173536037	77	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	gonadal disorder	targetBased	0.219680173536037	77	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	gonadal disorder	targetBased	0.33149537987595	13512	322361	619
qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)	PIP4K2A	gonadal disorder	targetBased	0.103710957231796	5	328860	4078
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	gonadal disorder	targetBased	0.229503728197977	8	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	gonadal disorder	targetBased	0.229503728197977	8	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	gonadal disorder	targetBased	0.229503728197977	8	407539	2380
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	gonadal disorder	targetBased	0.12073744154567	7	325630	216
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	gonadal disorder	targetBased	0.183778603574616	13	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	gonadal disorder	targetBased	0.183778603574616	13	218234	1620
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	gonadal disorder	targetBased	0.101441068315321	4	195560	517
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	gonadal disorder	targetBased	0.16877785907893	22	71016	346
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	gonadal disorder	targetBased	0.171360564295638	4	369953	2353
qHTS for Inhibitors of WRN Helicase	WRN	gonadal disorder	targetBased	0.227627640734767	16	364011	1678
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	gonadal disorder	targetBased	0.179014153350841	22	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	gonadal disorder	targetBased	0.179014153350841	22	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	gonadal disorder	targetBased	0.179014153350841	22	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	gonadal disorder	targetBased	0.179014153350841	22	72026	1794
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	gonadal disorder	targetBased	0.102708046816829	45	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	gonadal disorder	targetBased	0.102708046816829	45	356160	1703
HTS of Smad transcription factor inhibitors	SMAD3	gonadal disorder	targetBased	0.184263920355275	21	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	gonadal disorder	targetBased	0.292814050181884	97	193542	587
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	gonadal disorder	pathwayBased	0.207433897628151	102	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	gonadal disorder	pathwayBased	0.207433897628151	102	194666	1722
Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	gonadal disorder	targetBased	0.132697113965317	47	96879	811
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	gonadal disorder	targetBased	0.139043745966119	4	305610	3794
HTS for 14-3-3 protein interaction modulators	YWHAG	gonadal disorder	targetBased	0.104387141474849	5	157962	312
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	gonadal disorder	targetBased	0.107971857884083	17	318291	483
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	gonadal disorder	targetBased	0.196874882707434	25	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	gonadal disorder	targetBased	0.136466729556742	16	218654	8241
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	gonadal disorder	targetBased	0.11413315254802	30	324747	1043
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	gonadal disorder	targetBased	0.102672413749294	51	369953	2602
HCS assay for microtubule stabilizers	TUBB	gonadal disorder	targetBased	0.211275505672569	225	195821	1625
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	gonadal disorder	targetBased	0.136605172394068	9	316642	617
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	gonadal disorder	targetBased	0.223631661893612	29	347933	673
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	gonadal disorder	targetBased	0.17729203590024	10	331671	10022
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	gonadal disorder	pathwayBased	0.222180302289357	156	43989	342
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	gonadal dysgenesis	targetBased	0.164943194170421	6	86095	1114
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	physiological sexual disorder	targetBased	0.204467573678204	4	250190	1304
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	physiological sexual disorder	targetBased	0.204467573678204	4	255537	2141
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	hypogonadism	targetBased	0.113120091454521	13	324747	1043
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	uterine disorder	targetBased	0.101327109568645	10	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	uterine disorder	targetBased	0.101327109568645	10	296501	2737
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	uterine disorder	pathwayBased	0.246238868407285	95	376029	3978
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	uterine disorder	pathwayBased	0.172310772203188	5	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	uterine disorder	targetBased	0.171038575630078	21	336894	489
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	uterine disorder	targetBased	0.12914624943016	11	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	uterine disorder	targetBased	0.12914624943016	11	290726	2649
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	uterine disorder	targetBased	0.23645044831403	16	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	uterine disorder	targetBased	0.23645044831403	16	337446	1356
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	uterine disorder	targetBased	0.186834025964783	22	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	uterine disorder	targetBased	0.188540520738708	17	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	uterine disorder	pathwayBased	0.236771246821749	23	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	uterine disorder	pathwayBased	0.236771246821749	23	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	uterine disorder	targetBased	0.225545520330605	32	46715	2829
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	uterine disorder	targetBased	0.153273567455286	8	290726	671
qHTS Assay for Inhibitors of GCN5L2	KAT2A	uterine disorder	targetBased	0.102224423735784	5	381571	792
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	uterine disorder	targetBased	0.157551778004607	5	343468	285
qHTS of IL-2 Activators	IL2	uterine disorder	targetBased	0.103802064995839	62	364617	238
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	uterine disorder	targetBased	0.180706482376786	4	309684	1662
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	uterine disorder	targetBased	0.148811697929748	21	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	uterine disorder	targetBased	0.17581508282668	6	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	uterine disorder	targetBased	0.17581508282668	6	335239	695
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	uterine disorder	pathwayBased	0.107867846502814	18	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	uterine disorder	targetBased	0.107867846502814	18	195980	695
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	uterine disorder	targetBased	0.18818624598229	17	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	uterine disorder	targetBased	0.236872481169491	38	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	uterine disorder	pathwayBased	0.236872481169491	38	403871	1243
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	uterine disorder	targetBased	0.174954792544636	16	369953	3123
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	uterine disorder	targetBased	0.173878499996215	44	353950	4145
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	uterine disorder	targetBased	0.136188781385203	7	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	uterine disorder	targetBased	0.220349621797791	52	344733	7043
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	uterine disorder	targetBased	0.190073192600543	67	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	uterine disorder	targetBased	0.190073192600543	67	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	uterine disorder	targetBased	0.190073192600543	67	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	uterine disorder	targetBased	0.190073192600543	67	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	uterine disorder	targetBased	0.190073192600543	67	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	uterine disorder	targetBased	0.190073192600543	67	196177	519
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	uterine disorder	targetBased	0.156842719551229	6	263421	615
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	uterine disorder	targetBased	0.101872505343319	6	59788	212
E3 Ligase HTS_1536	MDM2	uterine disorder	targetBased	0.209389154453941	46	207811	220
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	uterine disorder	targetBased	0.176953020571194	10	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	uterine disorder	targetBased	0.176953020571194	10	194628	521
USP8 deubiquitinase inhibition: Primary qHTS	USP8	uterine disorder	targetBased	0.196090811963261	8	47480	2010
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	uterine disorder	targetBased	0.17849315427173	140	86095	1114
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	uterine disorder	targetBased	0.212580334595751	7	368927	620
qHTS assay for re-activators of p53 using a Luc reporter	TP53	uterine disorder	pathwayBased	0.295872950798814	1101	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	uterine disorder	targetBased	0.295872950798814	1101	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	uterine disorder	targetBased	0.295872950798814	1101	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	uterine disorder	targetBased	0.295872950798814	1101	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	uterine disorder	targetBased	0.295872950798814	1101	124022	1156
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	uterine disorder	targetBased	0.122549162707371	14	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	uterine disorder	targetBased	0.122549162707371	14	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	uterine disorder	targetBased	0.122549162707371	14	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	uterine disorder	targetBased	0.122549162707371	14	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	uterine disorder	targetBased	0.122549162707371	14	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	uterine disorder	targetBased	0.122549162707371	14	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	uterine disorder	targetBased	0.260658089564191	58	322361	619
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	uterine disorder	targetBased	0.126426046319396	4	276265	806
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	uterine disorder	targetBased	0.216280727792673	9	335531	328
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	uterine disorder	targetBased	0.192290664658195	15	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	uterine disorder	targetBased	0.192290664658195	15	218234	1620
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	uterine disorder	targetBased	0.196010959180914	10	71016	346
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	uterine disorder	targetBased	0.168169838681627	4	369953	2353
qHTS for Inhibitors of WRN Helicase	WRN	uterine disorder	targetBased	0.198467817521782	7	364011	1678
HTS of Smad transcription factor inhibitors	SMAD3	uterine disorder	targetBased	0.192445394555893	15	88033	251
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	uterine disorder	targetBased	0.101517600582035	9	386270	1331
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	uterine disorder	pathwayBased	0.208637239255762	98	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	uterine disorder	pathwayBased	0.208637239255762	98	194666	1722
HTS for 14-3-3 protein interaction modulators	YWHAG	uterine disorder	targetBased	0.100777748268793	4	157962	312
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	uterine disorder	targetBased	0.100914227682471	5	369953	760
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	uterine disorder	targetBased	0.100914227682471	5	369953	498
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	uterine disorder	targetBased	0.105597926119177	11	318291	483
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	uterine disorder	targetBased	0.14735137102897	5	31324	362
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	uterine disorder	targetBased	0.201618235650747	35	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	uterine disorder	targetBased	0.140865987494922	13	218654	8241
uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay	UBE2N	uterine disorder	targetBased	0.101648110086976	5	330393	1538
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	uterine disorder	targetBased	0.149879761519293	12	324747	1043
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	uterine disorder	targetBased	0.210105963348681	10	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	uterine disorder	targetBased	0.210105963348681	10	331360	2760
HCS assay for microtubule stabilizers	TUBB	uterine disorder	targetBased	0.195166929639395	138	195821	1625
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	uterine disorder	targetBased	0.138584089830271	19	316642	617
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	uterine disorder	targetBased	0.160521218182124	5	331671	10022
Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation	WEE1	uterine disorder	targetBased	0.111138856785893	26	217959	2616
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	uterine disorder	targetBased	0.28318325185266	167	193542	587
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	uterine disorder	targetBased	0.221553341793559	13	347933	673
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	congenital hypogonadotropic hypogonadism	targetBased	0.141756595563748	15	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	congenital hypogonadotropic hypogonadism	targetBased	0.141756595563748	15	64908	359
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	congenital hypogonadotropic hypogonadism	targetBased	0.298615367719276	217	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	congenital hypogonadotropic hypogonadism	targetBased	0.298615367719276	217	343468	3417
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	congenital hypogonadotropic hypogonadism	targetBased	0.113120091454521	13	324747	1043
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XX disorder of sex development	targetBased	0.204751514765103	15	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XX disorder of sex development	targetBased	0.204751514765103	15	64908	359
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	sex chromosome disorder of sex development	targetBased	0.20429572042001	15	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	sex chromosome disorder of sex development	targetBased	0.20429572042001	15	86095	1151
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	hypogonadotropic hypogonadism	targetBased	0.113120091454521	13	324747	1043
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	inherited primary ovarian failure	targetBased	0.206827954257339	64	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	inherited primary ovarian failure	targetBased	0.206827954257339	64	86095	1151
qHTS Assay for Activators of ClpP	Bacillus subtilis (strain 168)	inherited primary ovarian failure	targetBased	0.290397689588416	37	338378	6439
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	inherited primary ovarian failure	targetBased	0.277317762324974	26	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	inherited primary ovarian failure	targetBased	0.277317762324974	26	64908	359
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	inherited primary ovarian failure	targetBased	0.166051530973857	13	86095	1114
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	inherited primary ovarian failure	targetBased	0.309638094168041	6367	322361	619
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	reproductive system or breast disease	targetBased	0.315041861934939	610	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	reproductive system or breast disease	targetBased	0.315041861934939	610	296501	2737
qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)	RECQL	reproductive system or breast disease	targetBased	0.122357056649977	18	234915	1245
Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).	PPP5C	reproductive system or breast disease	targetBased	0.11149882496022	13	314999	564
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	reproductive system or breast disease	pathwayBased	0.339868813175177	11058	376029	3978
USP28 deubiquitinase inhibition: Primary qHTS	USP28	reproductive system or breast disease	targetBased	0.116265438534925	24	47480	1413
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	reproductive system or breast disease	targetBased	0.112394726875287	25	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	reproductive system or breast disease	targetBased	0.112394726875287	25	305610	1082
High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits	GNAI3	reproductive system or breast disease	targetBased	0.102987541603356	6	204125	876
qHTS Assay for Inhibitors of JMJD2A-Tudor Domain	KDM4A	reproductive system or breast disease	targetBased	0.105126572007807	24	384527	16920
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	reproductive system or breast disease	pathwayBased	0.103929717615172	26	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	reproductive system or breast disease	pathwayBased	0.103929717615172	26	64908	278
Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity	FGF22_inhibitors	reproductive system or breast disease	targetBased	0.184492174993101	4	339650	5128
qHTS Assay for Inhibitors of DNA Polymerase Beta	POLB	reproductive system or breast disease	targetBased	0.107397352758111	13	334457	4509
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	reproductive system or breast disease	targetBased	0.130988159296554	23	290915	2982
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	reproductive system or breast disease	targetBased	0.130988159296554	23	359244	1307
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	reproductive system or breast disease	pathwayBased	0.214045589413412	30	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	reproductive system or breast disease	targetBased	0.194602880134546	76	336894	489
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	reproductive system or breast disease	targetBased	0.113987953445681	64	368927	3838
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	reproductive system or breast disease	targetBased	0.145648810475709	280	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	reproductive system or breast disease	targetBased	0.145648810475709	280	290726	2649
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	reproductive system or breast disease	targetBased	0.165813970130848	16	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	reproductive system or breast disease	targetBased	0.149387333578254	50	359206	428
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selectiveÃ‚Â compounds	reproductive system or breast disease	targetBased	0.123151604770649	273	396029	13426
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selectiveÃ‚Â compounds	reproductive system or breast disease	targetBased	0.123151604770649	273	395981	5516
Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity	RAD54L	reproductive system or breast disease	targetBased	0.181210441854174	25	358498	505
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	reproductive system or breast disease	targetBased	0.108425491234728	13	218528	711
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	reproductive system or breast disease	targetBased	0.108425491234728	13	218528	770
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	reproductive system or breast disease	targetBased	0.108425491234728	13	218528	750
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	reproductive system or breast disease	targetBased	0.290015482100919	190	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	reproductive system or breast disease	targetBased	0.290015482100919	190	337446	1356
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	reproductive system or breast disease	targetBased	0.165736390229891	51	385746	932
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	reproductive system or breast disease	targetBased	0.325862177682374	8730	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	reproductive system or breast disease	targetBased	0.325862177682374	8730	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	reproductive system or breast disease	targetBased	0.217034917925751	252	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	reproductive system or breast disease	targetBased	0.239464552546762	177	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	reproductive system or breast disease	pathwayBased	0.270278401206253	162	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	reproductive system or breast disease	pathwayBased	0.270278401206253	162	131324	544
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	reproductive system or breast disease	targetBased	0.233019713021094	41	143816	859
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	reproductive system or breast disease	targetBased	0.269745214643302	230	46715	2829
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	reproductive system or breast disease	targetBased	0.134703638850045	29	335214	1652
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	reproductive system or breast disease	targetBased	0.201156007395051	15	363803	2412
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	reproductive system or breast disease	targetBased	0.16917350779093	78	290726	671
Identification of Molecular Probes that Activate MRP-1	ABCC1_activators	reproductive system or breast disease	targetBased	0.182499678223829	55	138717	842
qHTS for Inhibitors of TGF-b	TGFB1	reproductive system or breast disease	pathwayBased	0.119053706669912	1992	403345	4970
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	reproductive system or breast disease	targetBased	0.173298891362732	100	315412	318
uHTS luminescence assay for the identification of compounds that inhibit NOD1	NOD1	reproductive system or breast disease	targetBased	0.104674178000611	36	289422	2997
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	reproductive system or breast disease	targetBased	0.255073450047621	485	57013	201
HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails	HP1-betaChromodomainInteractionsInhibitors	reproductive system or breast disease	targetBased	0.125197522946858	16	383363	2142
qHTS Assay for Inhibitors of GCN5L2	KAT2A	reproductive system or breast disease	targetBased	0.114893524623229	16	381571	792
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	reproductive system or breast disease	targetBased	0.184551843119238	76	343468	285
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	reproductive system or breast disease	pathwayBased	0.124748398848968	1599	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	reproductive system or breast disease	pathwayBased	0.124748398848968	1599	359244	3094
Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3)	MAPK10	reproductive system or breast disease	targetBased	0.115347718066026	15	59788	366
qHTS of IL-2 Activators	IL2	reproductive system or breast disease	targetBased	0.193172370186606	706	364617	238
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	reproductive system or breast disease	targetBased	0.215976898925072	31	309684	1662
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	reproductive system or breast disease	targetBased	0.128065488445728	157	338328	2501
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	reproductive system or breast disease	targetBased	0.22640156121364	285	394050	3624
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	reproductive system or breast disease	targetBased	0.147531269136379	1336	67275	2509
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	reproductive system or breast disease	targetBased	0.237706138176421	58	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	reproductive system or breast disease	targetBased	0.237706138176421	58	335239	695
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	reproductive system or breast disease	targetBased	0.21129425567878	93	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	reproductive system or breast disease	targetBased	0.21129425567878	93	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	reproductive system or breast disease	targetBased	0.21129425567878	93	405130	6428
uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay	CCR6_antagonists	reproductive system or breast disease	targetBased	0.104100403525885	7	340696	1654
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	reproductive system or breast disease	pathwayBased	0.119664455518231	197	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	reproductive system or breast disease	targetBased	0.119664455518231	197	195980	695
qHTS for Inhibitors of Glutaminase (GLS)	GLS	reproductive system or breast disease	targetBased	0.107380420619916	80	405291	844
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	reproductive system or breast disease	targetBased	0.108059323287828	12	75924	1804
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	reproductive system or breast disease	targetBased	0.230577809047963	77	363840	2624
uHTS identification of SUMO1-mediated protein-protein interactions	SUMO1	reproductive system or breast disease	targetBased	0.111332208598825	17	363840	1202
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	reproductive system or breast disease	targetBased	0.265650659657604	169	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	reproductive system or breast disease	pathwayBased	0.265650659657604	169	403871	1243
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	reproductive system or breast disease	targetBased	0.105839702007131	42	363803	458
Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE)	IDE	reproductive system or breast disease	targetBased	0.103606701361454	44	335239	245
Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE)	IDE	reproductive system or breast disease	targetBased	0.103606701361454	44	324747	1316
uHTS Fluorescent assay for identification of activators of Apaf-1	APAF1_activators	reproductive system or breast disease	targetBased	0.111063611588845	29	331671	1041
uHTS Fluorescent assay for identification of inhibitors of Apaf-1	APAF1_inhibitors	reproductive system or breast disease	targetBased	0.111063611588845	29	331671	2353
uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay	TNFRSF10B	reproductive system or breast disease	targetBased	0.113527527038118	71	363840	3764
Antagonist identification of Pyk2 oligomerization: high-throughput screening cellular assay	Pyk2Ã‚Â	reproductive system or breast disease	targetBased	0.137582912913681	54	98749	818
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	reproductive system or breast disease	targetBased	0.102288559608012	10	326024	5748
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	reproductive system or breast disease	targetBased	0.102288559608012	10	326024	1387
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	reproductive system or breast disease	targetBased	0.169206271174044	241	217035	883
qHTS for Inhibitors of Polymerase Kappa	POLK	reproductive system or breast disease	targetBased	0.226525195743405	35	395295	2034
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	reproductive system or breast disease	targetBased	0.192949048024399	51	369953	3123
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	reproductive system or breast disease	targetBased	0.222505753927059	65	250190	1304
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	reproductive system or breast disease	targetBased	0.222505753927059	65	255537	2141
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	reproductive system or breast disease	targetBased	0.204726419469314	190	353950	4145
qHTS Assay for Activators of ClpP	Bacillus subtilis (strain 168)	reproductive system or breast disease	targetBased	0.29148492887276	69	338378	6439
Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1)	PRMT1	reproductive system or breast disease	targetBased	0.115248241563321	27	369953	4757
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	reproductive system or breast disease	targetBased	0.217726697830515	42	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	reproductive system or breast disease	targetBased	0.265477798460451	206	344733	7043
qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore)	GNAI1	reproductive system or breast disease	targetBased	0.100299178327605	14	229888	1007
uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay	APOBEC3A_inhibitors	reproductive system or breast disease	targetBased	0.148785059951875	24	331753	1372
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	reproductive system or breast disease	targetBased	0.153942910342574	271	359244	2975
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	reproductive system or breast disease	targetBased	0.161812496632852	45	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	reproductive system or breast disease	targetBased	0.161812496632852	45	335180	1022
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	reproductive system or breast disease	targetBased	0.26565064297067	425	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	reproductive system or breast disease	targetBased	0.26565064297067	425	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	reproductive system or breast disease	targetBased	0.26565064297067	425	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	reproductive system or breast disease	targetBased	0.26565064297067	425	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	reproductive system or breast disease	targetBased	0.26565064297067	425	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	reproductive system or breast disease	targetBased	0.26565064297067	425	196177	519
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	reproductive system or breast disease	targetBased	0.145117664843821	5	205582	727
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	reproductive system or breast disease	targetBased	0.237712518982076	317	263421	615
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	reproductive system or breast disease	targetBased	0.120577976673738	27	59788	212
qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy	CGA_integrin_activators	reproductive system or breast disease	targetBased	0.105660065791412	66	345855	222
E3 Ligase HTS_1536	MDM2	reproductive system or breast disease	targetBased	0.248732298892986	270	207811	220
Image-Based HTS for Selective Antagonists for GPR55	GPR55	reproductive system or breast disease	targetBased	0.105559367172299	11	291657	370
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	reproductive system or breast disease	targetBased	0.253385745175792	27	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	reproductive system or breast disease	targetBased	0.253385745175792	27	194628	521
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	reproductive system or breast disease	targetBased	0.314805936282202	566	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	reproductive system or breast disease	targetBased	0.314805936282202	566	64908	359
Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling	ARRB1_inhibitors	reproductive system or breast disease	targetBased	0.110823601053235	21	338373	1061
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	reproductive system or breast disease	targetBased	0.106077377668013	22	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	reproductive system or breast disease	targetBased	0.106077377668013	22	305610	3253
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	reproductive system or breast disease	targetBased	0.189448044442927	229	639428	9218
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	reproductive system or breast disease	targetBased	0.108139530945602	42	369953	2294
USP8 deubiquitinase inhibition: Primary qHTS	USP8	reproductive system or breast disease	targetBased	0.265883288728466	85	47480	2010
VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2	Caspase6Inhibitors	reproductive system or breast disease	targetBased	0.110262441768979	22	344318	1854
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	reproductive system or breast disease	targetBased	0.271674611375097	913	86095	1114
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	reproductive system or breast disease	targetBased	0.24993867239302	72	368927	620
qHTS assay for re-activators of p53 using a Luc reporter	TP53	reproductive system or breast disease	pathwayBased	0.324145529515924	6113	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	reproductive system or breast disease	targetBased	0.324145529515924	6113	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	reproductive system or breast disease	targetBased	0.324145529515924	6113	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	reproductive system or breast disease	targetBased	0.324145529515924	6113	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	reproductive system or breast disease	targetBased	0.324145529515924	6113	124022	1156
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	reproductive system or breast disease	pathwayBased	0.10743784790666	77	193714	1590
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	reproductive system or breast disease	pathwayBased	0.10743784790666	77	193400	1987
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	reproductive system or breast disease	targetBased	0.10743784790666	77	404343	257
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	reproductive system or breast disease	targetBased	0.320391454803785	2999	356517	1139
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	reproductive system or breast disease	pathwayBased	0.102086618277437	32	7671	874
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	reproductive system or breast disease	targetBased	0.102086618277437	32	304060	10600
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	reproductive system or breast disease	pathwayBased	0.102086618277437	32	305439	16717
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	reproductive system or breast disease	targetBased	0.115032633411498	136	93798	679
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	reproductive system or breast disease	targetBased	0.241596907640811	202	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	reproductive system or breast disease	targetBased	0.241596907640811	202	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	reproductive system or breast disease	targetBased	0.241596907640811	202	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	reproductive system or breast disease	targetBased	0.241596907640811	202	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	reproductive system or breast disease	targetBased	0.241596907640811	202	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	reproductive system or breast disease	targetBased	0.241596907640811	202	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	reproductive system or breast disease	targetBased	0.339512616804793	15595	322361	619
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).	PLCB3	reproductive system or breast disease	targetBased	0.104060229831466	6	369953	662
qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)	PIP4K2A	reproductive system or breast disease	targetBased	0.109021463392111	16	328860	4078
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	reproductive system or breast disease	targetBased	0.138034149143747	34	276265	806
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	reproductive system or breast disease	targetBased	0.243802245590322	22	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	reproductive system or breast disease	targetBased	0.243802245590322	22	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	reproductive system or breast disease	targetBased	0.243802245590322	22	407539	2380
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	reproductive system or breast disease	targetBased	0.104564190549598	55	369953	3080
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	reproductive system or breast disease	targetBased	0.205191699712703	72	325630	216
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	reproductive system or breast disease	targetBased	0.112172622062306	13	335239	2035
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	reproductive system or breast disease	targetBased	0.112172622062306	13	335239	279
Luminescent HTS for small molecule inhibitors of MT1-MMP transcription	MMP14	reproductive system or breast disease	targetBased	0.103122098618282	197	86733	537
uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay	MMP14	reproductive system or breast disease	targetBased	0.103122098618282	197	361500	222
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	reproductive system or breast disease	targetBased	0.258824475434152	40	335531	328
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	reproductive system or breast disease	targetBased	0.139389037725102	15	310014	1321
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	reproductive system or breast disease	targetBased	0.240898783657988	107	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	reproductive system or breast disease	targetBased	0.240898783657988	107	218234	1620
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	reproductive system or breast disease	targetBased	0.109207956697289	36	92518	501
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	reproductive system or breast disease	targetBased	0.125992575657322	10	195560	517
Primary HTS assay for chemical inhibitors of TNF alpha stimulated VCAM1 expression	VCAM1_expression	reproductive system or breast disease	targetBased	0.104552982745329	125	94498	457
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	reproductive system or breast disease	targetBased	0.107936646532647	297	330392	1295
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	reproductive system or breast disease	targetBased	0.211783678477218	49	71016	346
Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3	procaspase3Activators	reproductive system or breast disease	targetBased	0.110926400461654	622	326024	350
uHTS for 14-3-3/Bad interaction inhibitors	YWHAZ	reproductive system or breast disease	targetBased	0.112206507238686	41	217332	1549
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	reproductive system or breast disease	targetBased	0.267718944034859	73	369953	2353
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	reproductive system or breast disease	targetBased	0.107222075305837	20	217959	923
qHTS for Inhibitors of WRN Helicase	WRN	reproductive system or breast disease	targetBased	0.260476547988866	46	364011	1678
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	reproductive system or breast disease	targetBased	0.185260110621561	51	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	reproductive system or breast disease	targetBased	0.185260110621561	51	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	reproductive system or breast disease	targetBased	0.185260110621561	51	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	reproductive system or breast disease	targetBased	0.185260110621561	51	72026	1794
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	reproductive system or breast disease	targetBased	0.146671416339003	5	324747	813
Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation	WEE1	reproductive system or breast disease	targetBased	0.119362963869128	199	217959	2616
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	reproductive system or breast disease	targetBased	0.109857097006501	63	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	reproductive system or breast disease	targetBased	0.109857097006501	63	356160	1703
Fluorescence polarization assay for PLK1 inhibitors	PLK1	reproductive system or breast disease	targetBased	0.115480236869551	160	97099	518
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	reproductive system or breast disease	targetBased	0.115480236869551	160	364065	10181
HTS of Smad transcription factor inhibitors	SMAD3	reproductive system or breast disease	targetBased	0.230789064913118	143	88033	251
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	reproductive system or breast disease	targetBased	0.173682340270717	67	292323	1836
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	reproductive system or breast disease	targetBased	0.312629923411077	521	193542	587
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)	PAFAH1B2	reproductive system or breast disease	targetBased	0.112666418962385	53	335239	4158
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	reproductive system or breast disease	targetBased	0.175628832740176	36	386270	1331
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	reproductive system or breast disease	targetBased	0.131303258816036	9	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	reproductive system or breast disease	targetBased	0.131303258816036	9	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	reproductive system or breast disease	targetBased	0.131303258816036	9	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	reproductive system or breast disease	targetBased	0.131303258816036	9	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	reproductive system or breast disease	targetBased	0.131303258816036	9	359207	4555
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	reproductive system or breast disease	pathwayBased	0.22758712981801	1098	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	reproductive system or breast disease	pathwayBased	0.22758712981801	1098	194666	1722
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	reproductive system or breast disease	targetBased	0.214158332031498	54	339297	1446
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	reproductive system or breast disease	targetBased	0.314361866626238	500	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	reproductive system or breast disease	targetBased	0.314361866626238	500	343468	3417
Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	reproductive system or breast disease	targetBased	0.140523931327755	348	96879	811
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	reproductive system or breast disease	targetBased	0.225904993732661	15	305610	3794
HTS for 14-3-3 protein interaction modulators	YWHAG	reproductive system or breast disease	targetBased	0.111388584561696	18	157962	312
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	reproductive system or breast disease	targetBased	0.111323626818137	35	55710	315
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	reproductive system or breast disease	targetBased	0.223954155608764	9	339674	2841
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	reproductive system or breast disease	targetBased	0.118132066889252	238	314998	2199
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	reproductive system or breast disease	targetBased	0.113613874955796	21	369953	760
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	reproductive system or breast disease	targetBased	0.113613874955796	21	369953	498
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	reproductive system or breast disease	targetBased	0.158467887601642	120	318291	483
Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity	MLLT3	reproductive system or breast disease	targetBased	0.111233855071717	12	344459	1627
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	reproductive system or breast disease	targetBased	0.277896347118708	234	194628	267
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	reproductive system or breast disease	targetBased	0.157113464278031	43	31324	362
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	reproductive system or breast disease	targetBased	0.160613491293648	78	218654	8241
qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	reproductive system or breast disease	targetBased	0.127694726144649	9	330109	4174
qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	reproductive system or breast disease	targetBased	0.127694726144649	9	330107	7652
uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay	UBE2N	reproductive system or breast disease	targetBased	0.101903368110771	12	330393	1538
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	reproductive system or breast disease	targetBased	0.189960088317977	16	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	reproductive system or breast disease	targetBased	0.189960088317977	16	61606	416
Thrombin 1536 HTS	F2_modulation	reproductive system or breast disease	targetBased	0.17080259510773	72	217233	557
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	reproductive system or breast disease	targetBased	0.206997518397451	61	324747	1043
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	reproductive system or breast disease	targetBased	0.120869673378419	90	369953	2602
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	reproductive system or breast disease	pathwayBased	0.129269593122487	242	267412	5703
qHTS Assay for Tau Filament Binding	MAPT	reproductive system or breast disease	targetBased	0.129269593122487	242	69668	1391
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	reproductive system or breast disease	pathwayBased	0.129269593122487	242	271402	1048
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	reproductive system or breast disease	targetBased	0.246696565681118	96	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	reproductive system or breast disease	targetBased	0.246696565681118	96	331360	2760
HCS assay for microtubule stabilizers	TUBB	reproductive system or breast disease	targetBased	0.243143899823142	1967	195821	1625
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	reproductive system or breast disease	targetBased	0.206823289226062	64	316642	617
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	reproductive system or breast disease	targetBased	0.262162020659698	81	347933	673
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	reproductive system or breast disease	targetBased	0.246633690045256	67	331671	10022
uHTS identification of small molecule modulators of NR3A	GRIN3A	reproductive system or breast disease	targetBased	0.208952854263136	7	339772	8480
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	reproductive system or breast disease	pathwayBased	0.271554766936928	1411	43989	342
qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a	EHMT2_inhibitors	reproductive system or breast disease	targetBased	0.103364273641413	36	348338	30875
qHTS for Inhibitors of Vif-A3G Interactions: qHTS	APOBEC3G_inhibitors	reproductive system or breast disease	targetBased	0.207185574162041	79	402348	311
uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay	APOBEC3G_inhibitors	reproductive system or breast disease	targetBased	0.207185574162041	79	331753	931
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	reproductive system or breast disease	targetBased	0.139406871586366	131	343468	734
Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).	NPBWR1	reproductive system or breast disease	targetBased	0.102078992114647	5	290726	3127
ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity	TACC3	reproductive system or breast disease	targetBased	0.112993440227902	29	391179	2589
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	reproductive system or breast disease	targetBased	0.174226469670181	32	363803	1383
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3)	NCOA3	reproductive system or breast disease	targetBased	0.111162862754501	97	359207	620
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	reproductive system or breast disease	targetBased	0.1097103537135	24	386663	3977
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	Genetic disorder of sex development of gynecological interest	targetBased	0.142147811481263	14	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	Genetic disorder of sex development of gynecological interest	targetBased	0.142147811481263	14	64908	359
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	Genetic disorder of sex development of gynecological interest	targetBased	0.127906012380124	7	86095	1114
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	Hypogonadotropic hypogonadism associated with other endocrinopathies	targetBased	0.282470456240179	15	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	Hypogonadotropic hypogonadism associated with other endocrinopathies	targetBased	0.282470456240179	15	343468	3417
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	Rare female infertility due to a congenital hypogonadotropic hypogonadism	targetBased	0.282470456240179	15	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	Rare female infertility due to a congenital hypogonadotropic hypogonadism	targetBased	0.282470456240179	15	343468	3417
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	Female infertility due to gonadal dysgenesis	targetBased	0.1419108518426	9	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	Female infertility due to gonadal dysgenesis	targetBased	0.1419108518426	9	64908	359
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	Female infertility due to gonadal dysgenesis	targetBased	0.127829710022805	6	86095	1114
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	Rare genetic male infertility	targetBased	0.282983268582679	18	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	Rare genetic male infertility	targetBased	0.282983268582679	18	343468	3417
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	Rare male infertility due to hypothalamic-pituitary-gonadal axis disorder of genetic origin	targetBased	0.282779093776079	16	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	Rare male infertility due to hypothalamic-pituitary-gonadal axis disorder of genetic origin	targetBased	0.282779093776079	16	343468	3417
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	Rare genetic female infertility	targetBased	0.142258196207136	15	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	Rare genetic female infertility	targetBased	0.142258196207136	15	64908	359
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	Rare genetic female infertility	targetBased	0.282779093776079	16	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	Rare genetic female infertility	targetBased	0.282779093776079	16	343468	3417
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Rare female infertility due to hypothalamic-pituitary-gonadal axis disorder of genetic origin	targetBased	0.207970332385383	25	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Rare female infertility due to hypothalamic-pituitary-gonadal axis disorder of genetic origin	targetBased	0.207970332385383	25	86095	1151
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	Rare female infertility due to hypothalamic-pituitary-gonadal axis disorder of genetic origin	targetBased	0.282779093776079	16	368927	4094
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	Rare female infertility due to hypothalamic-pituitary-gonadal axis disorder of genetic origin	targetBased	0.282779093776079	16	343468	3417
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	Non-acquired premature ovarian failure	targetBased	0.142229290955506	12	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	Non-acquired premature ovarian failure	targetBased	0.142229290955506	12	64908	359
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	Non-acquired premature ovarian failure	targetBased	0.321588853348576	6829	322361	619
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	Gonadal dysgenesis of gynecological interest	targetBased	0.1419108518426	9	64908	1225
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	Gonadal dysgenesis of gynecological interest	targetBased	0.1419108518426	9	64908	359
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	Gonadal dysgenesis of gynecological interest	targetBased	0.127829710022805	6	86095	1114

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	sexual dysfunction	BUSPIRONE	targetBased	2	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02101203	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	sexual dysfunction	BUSPIRONE	targetBased	2	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02101203	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	sexual dysfunction	BUSPIRONE	targetBased	2	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01743235	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	sexual dysfunction	BUSPIRONE	targetBased	2	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01743235	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	erectile dysfunction	APOMORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BE07	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	erectile dysfunction	APOMORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BE07	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	erectile dysfunction	APOMORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BE07	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	erectile dysfunction	APOMORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BE07	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	erectile dysfunction	APOMORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BE07	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	erectile dysfunction	APOMORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BE07	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	erectile dysfunction	APOMORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BE07	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	erectile dysfunction	APOMORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BE07	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	erectile dysfunction	APOMORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BE07	1	GoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	HIV wasting syndrome	THALIDOMIDE	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00002127	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	AIDS	THALIDOMIDE	targetBased	2	Completed	01/06/1995	https://clinicaltrials.gov/study/NCT00001475	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypogonadotropic hypogonadism	NALOXONE	targetBased	2	Enrolling by invitation	31/08/2024	https://clinicaltrials.gov/study/NCT04975334	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypogonadotropic hypogonadism	NALOXONE	targetBased	2	Enrolling by invitation	31/08/2024	https://clinicaltrials.gov/study/NCT04975334	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	hypogonadotropic hypogonadism	NALOXONE	targetBased	2	Enrolling by invitation	31/08/2024	https://clinicaltrials.gov/study/NCT04975334	0.2	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	RALOXIFENE	targetBased	2	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00149604	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	polycystic ovary syndrome	RALOXIFENE	targetBased	3	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00427700	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	TAMOXIFEN	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00171704	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	TAMOXIFEN	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00171704	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	TAMOXIFEN	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02479256	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	TAMOXIFEN	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02479256	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	TAMOXIFEN	targetBased	3	Recruiting	21/07/2016	https://clinicaltrials.gov/study/NCT03011684	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	TAMOXIFEN	targetBased	3	Recruiting	21/07/2016	https://clinicaltrials.gov/study/NCT03011684	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	TAMOXIFEN	targetBased	4	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT02690870	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	TAMOXIFEN	targetBased	4	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT02690870	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	male infertility	TAMOXIFEN	targetBased	2	Recruiting	15/10/2021	https://clinicaltrials.gov/study/NCT05200663	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	male infertility	TAMOXIFEN	targetBased	2	Recruiting	15/10/2021	https://clinicaltrials.gov/study/NCT05200663	0.2		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04351126	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04351126	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04351126	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02846493	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02846493	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02846493	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04351126	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04351126	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04351126	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04351126	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04351126	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04351126	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02846493	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02846493	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02846493	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02846493	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02846493	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	BROMOCRIPTINE	targetBased	2	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02846493	0.2	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	invasive tubular breast carcinoma	PACLITAXEL	targetBased	3	Recruiting	27/07/2017	https://clinicaltrials.gov/study/NCT03201861	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	invasive tubular breast carcinoma	PACLITAXEL	targetBased	2	Active, not recruiting	01/09/2013	https://clinicaltrials.gov/study/NCT02221999	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	invasive tubular breast carcinoma	PACLITAXEL	targetBased	2	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT02199418	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube transitional cell carcinoma	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube transitional cell carcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	27/09/2010	https://clinicaltrials.gov/study/NCT01167712	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube transitional cell carcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube endometrioid adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube endometrioid adenocarcinoma	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube endometrioid adenocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	27/09/2010	https://clinicaltrials.gov/study/NCT01167712	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube endometrioid adenocarcinoma	PACLITAXEL	targetBased	3	Completed	11/08/2009	https://clinicaltrials.gov/study/NCT00951496	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	cervical intraepithelial neoplasia	PACLITAXEL	targetBased	2	Withdrawn	01/10/2017	https://clinicaltrials.gov/study/NCT03143491	0.2	LoF	protect	Study never initiated
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube clear cell adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube clear cell adenocarcinoma	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube mucinous adenocarcinoma	PACLITAXEL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262847	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube mucinous adenocarcinoma	PACLITAXEL	targetBased	3	Active, not recruiting	27/09/2010	https://clinicaltrials.gov/study/NCT01167712	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube mucinous adenocarcinoma	PACLITAXEL	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	LoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	sexual dysfunction	ALPROSTADIL	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00324948	0.2	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	sexual dysfunction	ALPROSTADIL	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00324948	0.2	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dec1dbd-c63b-4a1b-81cb-c8d29696cc40	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dec1dbd-c63b-4a1b-81cb-c8d29696cc40	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	2	Terminated	01/02/2013	https://clinicaltrials.gov/study/NCT01810575	0.2	GoF	protect	Re-assessment of study
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	2	Terminated	01/02/2013	https://clinicaltrials.gov/study/NCT01810575	0.2	GoF	protect	Re-assessment of study
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a295fc1e-d82c-4f44-bc2d-a552bf594c98	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a295fc1e-d82c-4f44-bc2d-a552bf594c98	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BE01	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=G04BE01	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8f85a7e-becb-4e15-9829-40e8f359140a	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8f85a7e-becb-4e15-9829-40e8f359140a	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c55f3f9-c4cf-11df-851a-0800200c9a66	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c55f3f9-c4cf-11df-851a-0800200c9a66	1	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4	Withdrawn	01/12/2013	https://clinicaltrials.gov/study/NCT01776320	1	GoF	protect	No medication
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4	Withdrawn	01/12/2013	https://clinicaltrials.gov/study/NCT01776320	1	GoF	protect	No medication
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8b8ec8d-1318-43e4-a182-446e9f9579de	1	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	erectile dysfunction	ALPROSTADIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8b8ec8d-1318-43e4-a182-446e9f9579de	1	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	invasive tubular breast carcinoma	DOCETAXEL	targetBased	3	Recruiting	27/07/2017	https://clinicaltrials.gov/study/NCT03201861	0.7	LoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	fetal growth restriction	DINOPROSTONE	targetBased	3	Recruiting	27/03/2023	https://clinicaltrials.gov/study/NCT05774236	0.7	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	fetal growth restriction	DINOPROSTONE	targetBased	3	Recruiting	27/03/2023	https://clinicaltrials.gov/study/NCT05774236	0.7	GoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	incomplete abortion	DINOPROSTONE	targetBased	2	Recruiting	11/11/2021	https://clinicaltrials.gov/study/NCT05342467	0.2	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	incomplete abortion	DINOPROSTONE	targetBased	2	Recruiting	11/11/2021	https://clinicaltrials.gov/study/NCT05342467	0.2	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pelvic organ prolapse	ACETAMINOPHEN	targetBased	4	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02155738	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Dysmenorrhea	ACETAMINOPHEN	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01462370	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Dysmenorrhea	ACETAMINOPHEN	targetBased	4	Completed	25/04/2018	https://clinicaltrials.gov/study/NCT03509740	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Dysmenorrhea	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e4219a-a4ef-f090-f6a4-2fd2e213d397	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Dysmenorrhea	ACETAMINOPHEN	targetBased	4	Unknown status	01/01/2015	https://clinicaltrials.gov/study/NCT02373514	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Dysmenorrhea	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd7b5ba3-652a-443f-b0b9-17abda148e67	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Dysmenorrhea	ACETAMINOPHEN	targetBased	4	Completed	05/04/2018	https://clinicaltrials.gov/study/NCT03448536	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	hypospadias	ACETAMINOPHEN	targetBased	3	Recruiting	01/07/2020	https://clinicaltrials.gov/study/NCT04423107	0.7		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	sexual dysfunction	ROPINIROLE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00334048	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	sexual dysfunction	ROPINIROLE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00334048	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	sexual dysfunction	ROPINIROLE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00334048	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	sexual dysfunction	ROPINIROLE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00334048	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	sexual dysfunction	ROPINIROLE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00334048	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	sexual dysfunction	ROPINIROLE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00334048	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	sexual dysfunction	ROPINIROLE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00334048	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	sexual dysfunction	ROPINIROLE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00334048	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	sexual dysfunction	ROPINIROLE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00334048	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	X-linked adrenoleukodystrophy	PIOGLITAZONE	targetBased	2	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT03864523	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	X-linked adrenoleukodystrophy	PIOGLITAZONE	targetBased	2	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT03864523	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	X-linked adrenoleukodystrophy	PIOGLITAZONE	targetBased	2	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT03864523	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	X-linked adrenoleukodystrophy	PIOGLITAZONE	targetBased	2	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT03864523	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	X-linked adrenoleukodystrophy	PIOGLITAZONE	targetBased	2	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT03864523	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	X-linked adrenoleukodystrophy	PIOGLITAZONE	targetBased	2	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT03864523	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04113889	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04113889	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04113889	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04113889	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04113889	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Completed	15/10/2019	https://clinicaltrials.gov/study/NCT04113889	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Recruiting	24/05/2022	https://clinicaltrials.gov/study/NCT05394142	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Recruiting	24/05/2022	https://clinicaltrials.gov/study/NCT05394142	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Recruiting	24/05/2022	https://clinicaltrials.gov/study/NCT05394142	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Recruiting	24/05/2022	https://clinicaltrials.gov/study/NCT05394142	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Recruiting	24/05/2022	https://clinicaltrials.gov/study/NCT05394142	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Recruiting	24/05/2022	https://clinicaltrials.gov/study/NCT05394142	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	4	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00145340	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	4	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00145340	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	4	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00145340	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	4	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00145340	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	4	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00145340	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	4	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00145340	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Completed	03/05/2021	https://clinicaltrials.gov/study/NCT04867252	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Completed	03/05/2021	https://clinicaltrials.gov/study/NCT04867252	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Completed	03/05/2021	https://clinicaltrials.gov/study/NCT04867252	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Completed	03/05/2021	https://clinicaltrials.gov/study/NCT04867252	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Completed	03/05/2021	https://clinicaltrials.gov/study/NCT04867252	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	2	Completed	03/05/2021	https://clinicaltrials.gov/study/NCT04867252	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	4	Active, not recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05519813	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	4	Active, not recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05519813	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	4	Active, not recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05519813	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	4	Active, not recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05519813	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	4	Active, not recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05519813	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE	targetBased	4	Active, not recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05519813	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypospadias	FENTANYL	targetBased	2	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02752308	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypospadias	FENTANYL	targetBased	2	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02752308	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cervical incompetence	FENTANYL	targetBased	4	Completed	08/11/2016	https://clinicaltrials.gov/study/NCT02862912	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cervical incompetence	FENTANYL	targetBased	4	Completed	08/11/2016	https://clinicaltrials.gov/study/NCT02862912	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	ROSIGLITAZONE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00640224	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	ROSIGLITAZONE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00640224	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	ROSIGLITAZONE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00640224	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	ROSIGLITAZONE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00640224	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	ROSIGLITAZONE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00640224	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	ROSIGLITAZONE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00640224	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	endometriosis	NALTREXONE	targetBased	3	Terminated	16/01/2020	https://clinicaltrials.gov/study/NCT03970330	0.7	LoF	protect	Original PI left institution, lack of funding to continue
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	endometriosis	NALTREXONE	targetBased	3	Terminated	16/01/2020	https://clinicaltrials.gov/study/NCT03970330	0.7	LoF	protect	Original PI left institution, lack of funding to continue
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	endometriosis	NALTREXONE	targetBased	3	Terminated	16/01/2020	https://clinicaltrials.gov/study/NCT03970330	0.7	LoF	protect	Original PI left institution, lack of funding to continue
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	erectile dysfunction	NEBIVOLOL	targetBased	4	Unknown status	01/03/2013	https://clinicaltrials.gov/study/NCT01885988	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypospadias	OXYCODONE	targetBased	3	Recruiting	01/07/2020	https://clinicaltrials.gov/study/NCT04423107	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hypospadias	OXYCODONE	targetBased	3	Recruiting	01/07/2020	https://clinicaltrials.gov/study/NCT04423107	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Menstrual disorder	ESTRADIOL	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02027337	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Menstrual disorder	ESTRADIOL	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02027337	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac676026-14be-486a-9d64-6702bd9e51ea	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac676026-14be-486a-9d64-6702bd9e51ea	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83198ef1-11c4-11e4-9191-0800200c9a66	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83198ef1-11c4-11e4-9191-0800200c9a66	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92eafd85-0051-44af-ba5c-9194c8deffe2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92eafd85-0051-44af-ba5c-9194c8deffe2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92eafd85-0051-44af-ba5c-9194c8deffe2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92eafd85-0051-44af-ba5c-9194c8deffe2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	15/07/2017	https://clinicaltrials.gov/study/NCT03047330	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	15/07/2017	https://clinicaltrials.gov/study/NCT03047330	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=184d3092-7fc6-4375-816b-1ab06bb99cfd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=184d3092-7fc6-4375-816b-1ab06bb99cfd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02224313	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02224313	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=966ac064-9eb7-4d15-b271-a7880ed1e79a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=966ac064-9eb7-4d15-b271-a7880ed1e79a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eabc0fb3-da2a-482f-83a7-99b1e823a150	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eabc0fb3-da2a-482f-83a7-99b1e823a150	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	2	Terminated	01/02/2006	https://clinicaltrials.gov/study/NCT00302731	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	2	Terminated	01/02/2006	https://clinicaltrials.gov/study/NCT00302731	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	28/05/2004	https://clinicaltrials.gov/study/NCT00184795	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	28/05/2004	https://clinicaltrials.gov/study/NCT00184795	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	05/08/2013	https://clinicaltrials.gov/study/NCT01942668	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	05/08/2013	https://clinicaltrials.gov/study/NCT01942668	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00775242	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00775242	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03336437	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	01/02/2018	https://clinicaltrials.gov/study/NCT03336437	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00185328	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00185328	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	16/11/2012	https://clinicaltrials.gov/study/NCT01822288	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	16/11/2012	https://clinicaltrials.gov/study/NCT01822288	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa530dfd-3a48-46b9-9678-a7bc48316e41	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa530dfd-3a48-46b9-9678-a7bc48316e41	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02467673	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02467673	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86d84095-1551-458c-8358-a7610f745cad	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86d84095-1551-458c-8358-a7610f745cad	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00251082	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00251082	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc52489a-5149-411d-9665-2c75405ad15d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc52489a-5149-411d-9665-2c75405ad15d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=104be9f2-a8f6-430e-9e01-2ee7cc1861f1	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=104be9f2-a8f6-430e-9e01-2ee7cc1861f1	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01174524	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01174524	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Active, not recruiting	01/05/2007	https://clinicaltrials.gov/study/NCT00623311	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Active, not recruiting	01/05/2007	https://clinicaltrials.gov/study/NCT00623311	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00431093	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00431093	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee7025c5-4cff-4da9-9ff0-100af626612d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee7025c5-4cff-4da9-9ff0-100af626612d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac676026-14be-486a-9d64-6702bd9e51ea	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac676026-14be-486a-9d64-6702bd9e51ea	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00145522	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00145522	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Withdrawn	01/07/2016	https://clinicaltrials.gov/study/NCT02860897	1	GoF	protect	Unable to provide study medications due to cost.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Withdrawn	01/07/2016	https://clinicaltrials.gov/study/NCT02860897	1	GoF	protect	Unable to provide study medications due to cost.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00727129	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00727129	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eff2dea1-f117-11e3-ac10-0800200c9a66	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eff2dea1-f117-11e3-ac10-0800200c9a66	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0178a92c-62b1-d5cf-cf54-2c85af88a74a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0178a92c-62b1-d5cf-cf54-2c85af88a74a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	02/12/2004	https://clinicaltrials.gov/study/NCT00160173	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	02/12/2004	https://clinicaltrials.gov/study/NCT00160173	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30c7f6ba-7a9e-4853-b3e4-e00a46560224	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30c7f6ba-7a9e-4853-b3e4-e00a46560224	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00160316	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00160316	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02516202	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02516202	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Terminated	24/01/2017	https://clinicaltrials.gov/study/NCT03003949	1	GoF	protect	In-person visit restrictions due to COVID-19
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Terminated	24/01/2017	https://clinicaltrials.gov/study/NCT03003949	1	GoF	protect	In-person visit restrictions due to COVID-19
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09c472c6-a38a-4a3d-b048-6fefd52e2ad3	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09c472c6-a38a-4a3d-b048-6fefd52e2ad3	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04255160	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04255160	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70d00600-b8d3-4820-8db6-40d4536a6f9e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70d00600-b8d3-4820-8db6-40d4536a6f9e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	14/08/2001	https://clinicaltrials.gov/study/NCT01705249	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	14/08/2001	https://clinicaltrials.gov/study/NCT01705249	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Terminated	01/02/2016	https://clinicaltrials.gov/study/NCT02693002	1	GoF	protect	Enrollment goals not being met
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Terminated	01/02/2016	https://clinicaltrials.gov/study/NCT02693002	1	GoF	protect	Enrollment goals not being met
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83198ef1-11c4-11e4-9191-0800200c9a66	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83198ef1-11c4-11e4-9191-0800200c9a66	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22191eca-c98d-4a07-844e-11edb0f04b8d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22191eca-c98d-4a07-844e-11edb0f04b8d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Not yet recruiting	01/06/2020	https://clinicaltrials.gov/study/NCT04190927	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Not yet recruiting	01/06/2020	https://clinicaltrials.gov/study/NCT04190927	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00195455	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00195455	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00905723	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	3	Unknown status	01/05/2009	https://clinicaltrials.gov/study/NCT00905723	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	2	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00420342	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	2	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00420342	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01a8bfdf-0fac-4e86-a299-daf64a2e885e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01a8bfdf-0fac-4e86-a299-daf64a2e885e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=761834c2-6b61-4583-84c2-f1ca4a97c4f2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=761834c2-6b61-4583-84c2-f1ca4a97c4f2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b85df980-7df1-4973-bee3-ae51274b588f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b85df980-7df1-4973-bee3-ae51274b588f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ESTRADIOL	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00428311	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ESTRADIOL	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00428311	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ESTRADIOL	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02027337	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ESTRADIOL	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02027337	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hyperandrogenism	ESTRADIOL	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02027337	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hyperandrogenism	ESTRADIOL	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02027337	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	ovulation	ESTRADIOL	targetBased	2	Terminated	01/08/2008	https://clinicaltrials.gov/study/NCT00729404	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	ovulation	ESTRADIOL	targetBased	2	Terminated	01/08/2008	https://clinicaltrials.gov/study/NCT00729404	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	ovulation	ESTRADIOL	targetBased	2	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00915915	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	ovulation	ESTRADIOL	targetBased	2	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00915915	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	ovulation	ESTRADIOL	targetBased	4	Completed	21/01/2017	https://clinicaltrials.gov/study/NCT03077555	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	ovulation	ESTRADIOL	targetBased	4	Completed	21/01/2017	https://clinicaltrials.gov/study/NCT03077555	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e8341f1-8089-46ff-b142-1fb04209029d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e8341f1-8089-46ff-b142-1fb04209029d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf9bc807-b871-4c09-924e-6252540bf5d5	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf9bc807-b871-4c09-924e-6252540bf5d5	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7e6da3b-8485-1382-61c9-e9b369018b98	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7e6da3b-8485-1382-61c9-e9b369018b98	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8fab92c2-5827-4c62-a4f6-4f2547dc5233	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8fab92c2-5827-4c62-a4f6-4f2547dc5233	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee98f923-8961-4f9f-8fa1-dcd934df89ac	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee98f923-8961-4f9f-8fa1-dcd934df89ac	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91b78bf6-7d83-4e7d-a287-bc8717ae66c4	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91b78bf6-7d83-4e7d-a287-bc8717ae66c4	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ab0226-b494-4607-8e8b-7381082fa780	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ab0226-b494-4607-8e8b-7381082fa780	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47f3f8a4-c24c-4380-af6c-ad09b055f9ff	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47f3f8a4-c24c-4380-af6c-ad09b055f9ff	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92eafd85-0051-44af-ba5c-9194c8deffe2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92eafd85-0051-44af-ba5c-9194c8deffe2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c77e113-37e3-4c86-834a-6355bb1020e9	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c77e113-37e3-4c86-834a-6355bb1020e9	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=144db6ad-c4cf-45ea-b27c-a76a319dba38	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=144db6ad-c4cf-45ea-b27c-a76a319dba38	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11312c94-4b74-51c1-e054-00144ff88e88	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11312c94-4b74-51c1-e054-00144ff88e88	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT02847806	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT02847806	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05393315-da87-4679-9ab1-7b3a289e5638	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05393315-da87-4679-9ab1-7b3a289e5638	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37f3094c-f02d-4a9c-8e30-2c4752bc62ed	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37f3094c-f02d-4a9c-8e30-2c4752bc62ed	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22eeffba-29ad-4f1f-9a0e-ed8946f7d6be	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22eeffba-29ad-4f1f-9a0e-ed8946f7d6be	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6c0ee96-5d2a-4725-a460-5ca62f2b6c36	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6c0ee96-5d2a-4725-a460-5ca62f2b6c36	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3803ba3-4eee-4e2e-ac8c-821a4e6720cc	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3803ba3-4eee-4e2e-ac8c-821a4e6720cc	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6c4b64a-2f0c-47ce-b423-b74d705b2de8	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6c4b64a-2f0c-47ce-b423-b74d705b2de8	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a995f9d-8b3e-4475-b818-34c4bbf4eec6	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a995f9d-8b3e-4475-b818-34c4bbf4eec6	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83198ef1-11c4-11e4-9191-0800200c9a66	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83198ef1-11c4-11e4-9191-0800200c9a66	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50603fd9-08fe-4bb7-80d2-1dd1e4aa4fcd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50603fd9-08fe-4bb7-80d2-1dd1e4aa4fcd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64ae46f5-889c-4c13-ab07-92bebe8d5ef2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64ae46f5-889c-4c13-ab07-92bebe8d5ef2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6f2e7ed-41a9-4a53-ac80-0cb1fa2edcbf	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6f2e7ed-41a9-4a53-ac80-0cb1fa2edcbf	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7712c639-36c5-4c0f-aa74-fd4161540761	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7712c639-36c5-4c0f-aa74-fd4161540761	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0d4f0b8-5dcc-4ffe-9590-0203e869622f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0d4f0b8-5dcc-4ffe-9590-0203e869622f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=396686ba-ab8d-4223-80e7-9c4f7ddb7852	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=396686ba-ab8d-4223-80e7-9c4f7ddb7852	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfc1beb9-1ade-446e-97dd-55b41c2fa851	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfc1beb9-1ade-446e-97dd-55b41c2fa851	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4936878-1643-4e7f-9b0d-e4957935aef2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4936878-1643-4e7f-9b0d-e4957935aef2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1d42bc5f-c6c3-4715-a283-d2c50baa341f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1d42bc5f-c6c3-4715-a283-d2c50baa341f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10b9f708-0a6d-b216-8db8-106a98a52b99	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10b9f708-0a6d-b216-8db8-106a98a52b99	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c674e1bc-5c8e-4c59-8de5-c7fa5306706d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c674e1bc-5c8e-4c59-8de5-c7fa5306706d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=690730ea-bd69-4b57-ab9e-2e76309c8d50	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=690730ea-bd69-4b57-ab9e-2e76309c8d50	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a273ddbd-cfb2-4be4-8b29-8eb7d3f93031	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a273ddbd-cfb2-4be4-8b29-8eb7d3f93031	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e9702c4-f2d7-4ea8-b6e8-7dca31671864	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e9702c4-f2d7-4ea8-b6e8-7dca31671864	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d28bec8f-762e-4f05-a20d-96a42970d6a7	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d28bec8f-762e-4f05-a20d-96a42970d6a7	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ce4e37f-b55b-40cd-a194-ded0056ca594	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ce4e37f-b55b-40cd-a194-ded0056ca594	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac676026-14be-486a-9d64-6702bd9e51ea	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac676026-14be-486a-9d64-6702bd9e51ea	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bc58020-727f-483e-95de-15cbe327c673	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bc58020-727f-483e-95de-15cbe327c673	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4da6de7-9ab1-4fcf-88f3-fe785019e6e7	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4da6de7-9ab1-4fcf-88f3-fe785019e6e7	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ESTRADIOL	targetBased	3	Terminated	11/02/2016	https://clinicaltrials.gov/study/NCT02668783	0.7	GoF	protect	Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ESTRADIOL	targetBased	3	Terminated	11/02/2016	https://clinicaltrials.gov/study/NCT02668783	0.7	GoF	protect	Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ESTRADIOL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00212342	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ESTRADIOL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00212342	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL	targetBased	4	Unknown status	01/05/2011	https://clinicaltrials.gov/study/NCT01353846	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL	targetBased	4	Unknown status	01/05/2011	https://clinicaltrials.gov/study/NCT01353846	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL	targetBased	3	Unknown status	01/08/2017	https://clinicaltrials.gov/study/NCT03238092	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL	targetBased	3	Unknown status	01/08/2017	https://clinicaltrials.gov/study/NCT03238092	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT01489852	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT01489852	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL	targetBased	4	Active, not recruiting	20/04/2021	https://clinicaltrials.gov/study/NCT04997525	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL	targetBased	4	Active, not recruiting	20/04/2021	https://clinicaltrials.gov/study/NCT04997525	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT01980680	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT01980680	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02736032	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02736032	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	ESTRADIOL	targetBased	3	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT01973816	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	ESTRADIOL	targetBased	3	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT01973816	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	ESTRADIOL	targetBased	3	Completed	22/05/2018	https://clinicaltrials.gov/study/NCT03654274	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	ESTRADIOL	targetBased	3	Completed	22/05/2018	https://clinicaltrials.gov/study/NCT03654274	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	ESTRADIOL	targetBased	3	Recruiting	04/09/2023	https://clinicaltrials.gov/study/NCT06145438	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	ESTRADIOL	targetBased	3	Recruiting	04/09/2023	https://clinicaltrials.gov/study/NCT06145438	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	ESTRADIOL	targetBased	3	Completed	07/07/2017	https://clinicaltrials.gov/study/NCT03213457	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	ESTRADIOL	targetBased	3	Completed	07/07/2017	https://clinicaltrials.gov/study/NCT03213457	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	ESTRADIOL	targetBased	3	Terminated	27/12/2017	https://clinicaltrials.gov/study/NCT03343067	0.7	GoF	protect	The study was terminated early for business reasons, not for safety concerns.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	ESTRADIOL	targetBased	3	Terminated	27/12/2017	https://clinicaltrials.gov/study/NCT03343067	0.7	GoF	protect	The study was terminated early for business reasons, not for safety concerns.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal atrophic vaginitis	ESTRADIOL	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01779947	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal atrophic vaginitis	ESTRADIOL	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01779947	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal atrophic vaginitis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal atrophic vaginitis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal atrophic vaginitis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal atrophic vaginitis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal atrophic vaginitis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30c7f6ba-7a9e-4853-b3e4-e00a46560224	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal atrophic vaginitis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30c7f6ba-7a9e-4853-b3e4-e00a46560224	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1d42bc5f-c6c3-4715-a283-d2c50baa341f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1d42bc5f-c6c3-4715-a283-d2c50baa341f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfc1beb9-1ade-446e-97dd-55b41c2fa851	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfc1beb9-1ade-446e-97dd-55b41c2fa851	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7e6da3b-8485-1382-61c9-e9b369018b98	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7e6da3b-8485-1382-61c9-e9b369018b98	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e9702c4-f2d7-4ea8-b6e8-7dca31671864	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e9702c4-f2d7-4ea8-b6e8-7dca31671864	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37f3094c-f02d-4a9c-8e30-2c4752bc62ed	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37f3094c-f02d-4a9c-8e30-2c4752bc62ed	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ab0226-b494-4607-8e8b-7381082fa780	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ab0226-b494-4607-8e8b-7381082fa780	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4da6de7-9ab1-4fcf-88f3-fe785019e6e7	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4da6de7-9ab1-4fcf-88f3-fe785019e6e7	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ce4e37f-b55b-40cd-a194-ded0056ca594	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ce4e37f-b55b-40cd-a194-ded0056ca594	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf9bc807-b871-4c09-924e-6252540bf5d5	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf9bc807-b871-4c09-924e-6252540bf5d5	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=690730ea-bd69-4b57-ab9e-2e76309c8d50	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=690730ea-bd69-4b57-ab9e-2e76309c8d50	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d28bec8f-762e-4f05-a20d-96a42970d6a7	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d28bec8f-762e-4f05-a20d-96a42970d6a7	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7712c639-36c5-4c0f-aa74-fd4161540761	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7712c639-36c5-4c0f-aa74-fd4161540761	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91b78bf6-7d83-4e7d-a287-bc8717ae66c4	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91b78bf6-7d83-4e7d-a287-bc8717ae66c4	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11312c94-4b74-51c1-e054-00144ff88e88	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11312c94-4b74-51c1-e054-00144ff88e88	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6f2e7ed-41a9-4a53-ac80-0cb1fa2edcbf	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6f2e7ed-41a9-4a53-ac80-0cb1fa2edcbf	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64ae46f5-889c-4c13-ab07-92bebe8d5ef2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64ae46f5-889c-4c13-ab07-92bebe8d5ef2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bc58020-727f-483e-95de-15cbe327c673	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bc58020-727f-483e-95de-15cbe327c673	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=144db6ad-c4cf-45ea-b27c-a76a319dba38	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=144db6ad-c4cf-45ea-b27c-a76a319dba38	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00732693	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00732693	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e8341f1-8089-46ff-b142-1fb04209029d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e8341f1-8089-46ff-b142-1fb04209029d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=396686ba-ab8d-4223-80e7-9c4f7ddb7852	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=396686ba-ab8d-4223-80e7-9c4f7ddb7852	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83198ef1-11c4-11e4-9191-0800200c9a66	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83198ef1-11c4-11e4-9191-0800200c9a66	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c674e1bc-5c8e-4c59-8de5-c7fa5306706d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c674e1bc-5c8e-4c59-8de5-c7fa5306706d	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0d4f0b8-5dcc-4ffe-9590-0203e869622f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0d4f0b8-5dcc-4ffe-9590-0203e869622f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50603fd9-08fe-4bb7-80d2-1dd1e4aa4fcd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50603fd9-08fe-4bb7-80d2-1dd1e4aa4fcd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3803ba3-4eee-4e2e-ac8c-821a4e6720cc	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3803ba3-4eee-4e2e-ac8c-821a4e6720cc	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4936878-1643-4e7f-9b0d-e4957935aef2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4936878-1643-4e7f-9b0d-e4957935aef2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6c0ee96-5d2a-4725-a460-5ca62f2b6c36	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6c0ee96-5d2a-4725-a460-5ca62f2b6c36	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a995f9d-8b3e-4475-b818-34c4bbf4eec6	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a995f9d-8b3e-4475-b818-34c4bbf4eec6	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00140998	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00140998	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00837616	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00837616	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05393315-da87-4679-9ab1-7b3a289e5638	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05393315-da87-4679-9ab1-7b3a289e5638	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	2	Withdrawn	25/08/2006	https://clinicaltrials.gov/study/NCT00370019	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	2	Withdrawn	25/08/2006	https://clinicaltrials.gov/study/NCT00370019	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c77e113-37e3-4c86-834a-6355bb1020e9	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c77e113-37e3-4c86-834a-6355bb1020e9	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	amenorrhea	ESTRADIOL	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00946192	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	amenorrhea	ESTRADIOL	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00946192	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	sexual dysfunction	ESTRADIOL	targetBased	3	Completed	23/03/2004	https://clinicaltrials.gov/study/NCT00413764	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	sexual dysfunction	ESTRADIOL	targetBased	3	Completed	23/03/2004	https://clinicaltrials.gov/study/NCT00413764	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	sexual dysfunction	ESTRADIOL	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00698035	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	sexual dysfunction	ESTRADIOL	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00698035	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02516202	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02516202	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	18/05/2016	https://clinicaltrials.gov/study/NCT03294538	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	18/05/2016	https://clinicaltrials.gov/study/NCT03294538	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	4	Completed	15/10/2018	https://clinicaltrials.gov/study/NCT03493126	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	4	Completed	15/10/2018	https://clinicaltrials.gov/study/NCT03493126	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	29/06/2011	https://clinicaltrials.gov/study/NCT01400776	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	29/06/2011	https://clinicaltrials.gov/study/NCT01400776	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02195986	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02195986	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02995694	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02995694	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	26/10/2017	https://clinicaltrials.gov/study/NCT03332303	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	26/10/2017	https://clinicaltrials.gov/study/NCT03332303	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02668796	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02668796	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00108849	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00108849	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Menorrhagia	ESTRADIOL	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01165307	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Menorrhagia	ESTRADIOL	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01165307	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	pelvic organ prolapse	ESTRADIOL	targetBased	4	Completed	02/02/2017	https://clinicaltrials.gov/study/NCT03779633	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	pelvic organ prolapse	ESTRADIOL	targetBased	4	Completed	02/02/2017	https://clinicaltrials.gov/study/NCT03779633	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cervical intraepithelial neoplasia	EPINEPHRINE	targetBased	4	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02368054	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypospadias	EPINEPHRINE	targetBased	2	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02752308	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	AIDS	ETHINYL ESTRADIOL	targetBased	4	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00829114	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	AIDS	ETHINYL ESTRADIOL	targetBased	4	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00829114	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00948402	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00948402	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	2	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT03264638	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	2	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT03264638	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Completed	15/08/2016	https://clinicaltrials.gov/study/NCT02866786	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Completed	15/08/2016	https://clinicaltrials.gov/study/NCT02866786	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Unknown status	01/12/2012	https://clinicaltrials.gov/study/NCT01752270	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Unknown status	01/12/2012	https://clinicaltrials.gov/study/NCT01752270	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	3	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03229057	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	3	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03229057	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02729545	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	2	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02729545	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00640224	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00640224	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01511822	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01511822	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Completed	01/08/2017	https://clinicaltrials.gov/study/NCT03236740	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Completed	01/08/2017	https://clinicaltrials.gov/study/NCT03236740	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT01581814	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT01581814	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00593294	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00593294	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Recruiting	24/06/2020	https://clinicaltrials.gov/study/NCT04257500	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ETHINYL ESTRADIOL	targetBased	4	Recruiting	24/06/2020	https://clinicaltrials.gov/study/NCT04257500	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hyperandrogenism	ETHINYL ESTRADIOL	targetBased	2	Completed	01/01/1993	https://clinicaltrials.gov/study/NCT00004763	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hyperandrogenism	ETHINYL ESTRADIOL	targetBased	2	Completed	01/01/1993	https://clinicaltrials.gov/study/NCT00004763	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	ovulation	ETHINYL ESTRADIOL	targetBased	3	Suspended	01/08/2014	https://clinicaltrials.gov/study/NCT03106454	0.7	GoF	protect	Investigator leave of absence
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	ovulation	ETHINYL ESTRADIOL	targetBased	3	Suspended	01/08/2014	https://clinicaltrials.gov/study/NCT03106454	0.7	GoF	protect	Investigator leave of absence
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	ovulation	ETHINYL ESTRADIOL	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00567164	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	ovulation	ETHINYL ESTRADIOL	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00567164	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	ovulation	ETHINYL ESTRADIOL	targetBased	2	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT01250210	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	ovulation	ETHINYL ESTRADIOL	targetBased	2	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT01250210	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00902746	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00902746	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00569244	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00569244	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00196365	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00196365	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00746096	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00746096	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00909857	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00909857	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01129102	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01129102	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	4	Completed	15/01/2015	https://clinicaltrials.gov/study/NCT03124524	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	4	Completed	15/01/2015	https://clinicaltrials.gov/study/NCT03124524	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00212277	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00212277	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ETHINYL ESTRADIOL	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01501448	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ETHINYL ESTRADIOL	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01501448	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	ETHINYL ESTRADIOL	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT01056042	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	ETHINYL ESTRADIOL	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT01056042	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	bacterial vaginosis	ETHINYL ESTRADIOL	targetBased	4	Unknown status	01/10/2011	https://clinicaltrials.gov/study/NCT01448291	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	bacterial vaginosis	ETHINYL ESTRADIOL	targetBased	4	Unknown status	01/10/2011	https://clinicaltrials.gov/study/NCT01448291	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	amenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00946192	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	amenorrhea	ETHINYL ESTRADIOL	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00946192	0.7	GoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	prostate disease	DALFAMPRIDINE	targetBased	2	Withdrawn	03/10/2018	https://clinicaltrials.gov/study/NCT03658408	0.2	LoF	protect	This record should not have been created for this study. It is under another sponsor's account.
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	prostate disease	DALFAMPRIDINE	targetBased	2	Withdrawn	03/10/2018	https://clinicaltrials.gov/study/NCT03658408	0.2	LoF	protect	This record should not have been created for this study. It is under another sponsor's account.
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	prostate disease	DALFAMPRIDINE	targetBased	2	Withdrawn	03/10/2018	https://clinicaltrials.gov/study/NCT03658408	0.2	LoF	protect	This record should not have been created for this study. It is under another sponsor's account.
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	prostate disease	DALFAMPRIDINE	targetBased	2	Withdrawn	03/10/2018	https://clinicaltrials.gov/study/NCT03658408	0.2	LoF	protect	This record should not have been created for this study. It is under another sponsor's account.
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	prostate disease	DALFAMPRIDINE	targetBased	2	Withdrawn	03/10/2018	https://clinicaltrials.gov/study/NCT03658408	0.2	LoF	protect	This record should not have been created for this study. It is under another sponsor's account.
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	prostate disease	DALFAMPRIDINE	targetBased	2	Withdrawn	03/10/2018	https://clinicaltrials.gov/study/NCT03658408	0.2	LoF	protect	This record should not have been created for this study. It is under another sponsor's account.
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	prostate disease	DALFAMPRIDINE	targetBased	2	Withdrawn	03/10/2018	https://clinicaltrials.gov/study/NCT03658408	0.2	LoF	protect	This record should not have been created for this study. It is under another sponsor's account.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	AIDS	MESALAMINE	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01090102	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	AIDS	MESALAMINE	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01090102	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	AIDS	MESALAMINE	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01090102	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	AIDS	MESALAMINE	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01090102	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	AIDS	MESALAMINE	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01090102	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	AIDS	MESALAMINE	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01090102	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	acute pyelonephritis	ZIPRASIDONE	targetBased	3	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT03630081	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	acute pyelonephritis	ZIPRASIDONE	targetBased	3	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT03630081	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acute pyelonephritis	ZIPRASIDONE	targetBased	3	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT03630081	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acute pyelonephritis	ZIPRASIDONE	targetBased	3	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT03630081	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acute pyelonephritis	ZIPRASIDONE	targetBased	3	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT03630081	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acute pyelonephritis	ZIPRASIDONE	targetBased	3	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT03630081	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	acute pyelonephritis	ZIPRASIDONE	targetBased	3	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT03630081	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		reproductive system disease	KETAMINE	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02099006	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	TAMOXIFEN CITRATE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00171704	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	TAMOXIFEN CITRATE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00171704	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	TAMOXIFEN CITRATE	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02479256	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	TAMOXIFEN CITRATE	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02479256	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	TAMOXIFEN CITRATE	targetBased	3	Recruiting	21/07/2016	https://clinicaltrials.gov/study/NCT03011684	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	TAMOXIFEN CITRATE	targetBased	3	Recruiting	21/07/2016	https://clinicaltrials.gov/study/NCT03011684	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	TAMOXIFEN CITRATE	targetBased	4	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT02690870	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	TAMOXIFEN CITRATE	targetBased	4	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT02690870	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	male infertility	TAMOXIFEN CITRATE	targetBased	2	Recruiting	15/10/2021	https://clinicaltrials.gov/study/NCT05200663	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	male infertility	TAMOXIFEN CITRATE	targetBased	2	Recruiting	15/10/2021	https://clinicaltrials.gov/study/NCT05200663	0.2		protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Autosomal dominant polycystic kidney disease	BOSUTINIB	targetBased	2	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01233869	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	reproductive system disease	LOPERAMIDE	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02099006	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	reproductive system disease	LOPERAMIDE	targetBased	2	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02099006	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Klinefelter's syndrome	CALCITRIOL	targetBased	2	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02061384	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	BAZEDOXIFENE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00234819	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	BAZEDOXIFENE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00234819	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	BAZEDOXIFENE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00234819	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	endometriosis	BAZEDOXIFENE	targetBased	4	Recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT05059626	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	BAZEDOXIFENE	targetBased	4	Recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT05059626	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	endometriosis	BAZEDOXIFENE	targetBased	4	Recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT05059626	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ENCLOMIPHENE	targetBased	4	Unknown status	01/01/2007	https://clinicaltrials.gov/study/NCT00461643	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ENCLOMIPHENE	targetBased	4	Unknown status	01/01/2007	https://clinicaltrials.gov/study/NCT00461643	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ENCLOMIPHENE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02344888	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ENCLOMIPHENE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02344888	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ENCLOMIPHENE	targetBased	3	Unknown status	01/07/2017	https://clinicaltrials.gov/study/NCT03396380	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ENCLOMIPHENE	targetBased	3	Unknown status	01/07/2017	https://clinicaltrials.gov/study/NCT03396380	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ENCLOMIPHENE	targetBased	2	Completed	11/01/2016	https://clinicaltrials.gov/study/NCT02651688	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ENCLOMIPHENE	targetBased	2	Completed	11/01/2016	https://clinicaltrials.gov/study/NCT02651688	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ENCLOMIPHENE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01386567	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ENCLOMIPHENE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01386567	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00962637	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00962637	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT01067365	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT01067365	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	2	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00706719	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	2	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00706719	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01532414	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01532414	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01739582	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01739582	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	2	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01270841	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	2	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01270841	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01386606	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01386606	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01993212	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01993212	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01993225	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01993225	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01534208	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01534208	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01739595	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	ENCLOMIPHENE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01739595	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	4	Recruiting	10/10/2016	https://clinicaltrials.gov/study/NCT02330757	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	4	Recruiting	10/10/2016	https://clinicaltrials.gov/study/NCT02330757	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	2	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00796289	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	2	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00796289	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	4	Withdrawn	01/04/2012	https://clinicaltrials.gov/study/NCT01577199	1		protect	no subjects recruited
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	4	Withdrawn	01/04/2012	https://clinicaltrials.gov/study/NCT01577199	1		protect	no subjects recruited
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01219101	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01219101	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00296465	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00296465	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	2	Withdrawn	22/09/2014	https://clinicaltrials.gov/study/NCT02160704	0.2		protect	Difficult eligibility and lack of funding
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	2	Withdrawn	22/09/2014	https://clinicaltrials.gov/study/NCT02160704	0.2		protect	Difficult eligibility and lack of funding
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	2	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT01232075	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	2	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT01232075	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01921166	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01921166	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02344888	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ENCLOMIPHENE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02344888	1		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	breast disease	REMIFENTANIL	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT03764267	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	breast disease	REMIFENTANIL	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT03764267	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	hypogonadism	CHOLECALCIFEROL	targetBased	3	Terminated	01/09/2015	https://clinicaltrials.gov/study/NCT02419105	0.7	GoF	protect	Delayed recruitment mainly due to a screening to inclusion rate much lower than expected. Due to the delayed recruitment IMP reached the end of its shelf life.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	hypogonadism	CHOLECALCIFEROL	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01748370	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	AIDS	CHOLECALCIFEROL	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01092338	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	endometriosis	CHOLECALCIFEROL	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02387931	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	male infertility	CHOLECALCIFEROL	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01304927	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	polycystic ovary syndrome	CHOLECALCIFEROL	targetBased	2	Recruiting	21/09/2023	https://clinicaltrials.gov/study/NCT06101147	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	polycystic ovary syndrome	CHOLECALCIFEROL	targetBased	3	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02328404	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	AIDS	VINCRISTINE	targetBased	2	Completed	14/01/2015	https://clinicaltrials.gov/study/NCT02199184	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	sexual dysfunction	ARIPIPRAZOLE	targetBased	4	Terminated	01/06/2015	https://clinicaltrials.gov/study/NCT02472652	1	GoF	protect	Lack of adequate enrollment
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	sexual dysfunction	ARIPIPRAZOLE	targetBased	4	Terminated	01/06/2015	https://clinicaltrials.gov/study/NCT02472652	1	GoF	protect	Lack of adequate enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	sexual dysfunction	ARIPIPRAZOLE	targetBased	4	Terminated	01/06/2015	https://clinicaltrials.gov/study/NCT02472652	1	GoF	protect	Lack of adequate enrollment
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	sexual dysfunction	ARIPIPRAZOLE	targetBased	4	Terminated	01/06/2015	https://clinicaltrials.gov/study/NCT02472652	1	GoF	protect	Lack of adequate enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	sexual dysfunction	ARIPIPRAZOLE	targetBased	4	Terminated	01/06/2015	https://clinicaltrials.gov/study/NCT02472652	1	GoF	protect	Lack of adequate enrollment
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	sexual dysfunction	ARIPIPRAZOLE	targetBased	4	Terminated	01/06/2015	https://clinicaltrials.gov/study/NCT02472652	1	GoF	protect	Lack of adequate enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	sexual dysfunction	ARIPIPRAZOLE	targetBased	4	Terminated	01/06/2015	https://clinicaltrials.gov/study/NCT02472652	1	LoF	protect	Lack of adequate enrollment
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	sexual dysfunction	ARIPIPRAZOLE	targetBased	4	Terminated	01/06/2015	https://clinicaltrials.gov/study/NCT02472652	1	GoF	protect	Lack of adequate enrollment
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	sexual dysfunction	ARIPIPRAZOLE	targetBased	4	Terminated	01/06/2015	https://clinicaltrials.gov/study/NCT02472652	1	GoF	protect	Lack of adequate enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	precocious puberty	FULVESTRANT	targetBased	2	Completed	31/01/2006	https://clinicaltrials.gov/study/NCT00278915	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	precocious puberty	FULVESTRANT	targetBased	2	Completed	31/01/2006	https://clinicaltrials.gov/study/NCT00278915	0.2	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	precocious puberty	FULVESTRANT	targetBased	2	Completed	31/01/2006	https://clinicaltrials.gov/study/NCT00278915	0.2	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	endometriosis	PRINABEREL	targetBased	2	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00110487	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	AUS-131	targetBased	2	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT00962585	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTRIOL	targetBased	2	Terminated	01/02/2006	https://clinicaltrials.gov/study/NCT00302731	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRIOL	targetBased	2	Terminated	01/02/2006	https://clinicaltrials.gov/study/NCT00302731	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRIOL	targetBased	2	Terminated	01/02/2006	https://clinicaltrials.gov/study/NCT00302731	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophic Vaginitis	ESTRIOL	targetBased	2	Withdrawn	05/06/2021	https://clinicaltrials.gov/study/NCT04159493	0.2		protect	Project terminated IND withdrawn
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophic Vaginitis	ESTRIOL	targetBased	2	Completed	16/10/2015	https://clinicaltrials.gov/study/NCT02413008	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophic Vaginitis	ESTRIOL	targetBased	3	Completed	25/01/2008	https://clinicaltrials.gov/study/NCT04574999	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophic Vaginitis	ESTRIOL	targetBased	2	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02967510	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophic Vaginitis	ESTRIOL	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00816556	0.7		protect	Funding
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRIOL	targetBased	2	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02967510	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRIOL	targetBased	2	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02967510	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRIOL	targetBased	3	Completed	25/01/2008	https://clinicaltrials.gov/study/NCT04574999	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRIOL	targetBased	3	Completed	25/01/2008	https://clinicaltrials.gov/study/NCT04574999	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRIOL	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00816556	0.7		protect	Funding
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRIOL	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00816556	0.7		protect	Funding
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRIOL	targetBased	2	Completed	16/10/2015	https://clinicaltrials.gov/study/NCT02413008	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRIOL	targetBased	2	Completed	16/10/2015	https://clinicaltrials.gov/study/NCT02413008	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRIOL	targetBased	2	Withdrawn	05/06/2021	https://clinicaltrials.gov/study/NCT04159493	0.2		protect	Project terminated IND withdrawn
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRIOL	targetBased	2	Withdrawn	05/06/2021	https://clinicaltrials.gov/study/NCT04159493	0.2		protect	Project terminated IND withdrawn
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	endometriosis	ATOSIBAN	targetBased	2	Recruiting	01/02/2022	https://clinicaltrials.gov/study/NCT05382143	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	premenstrual tension	ESTRONE	targetBased	3	Unknown status	01/03/2015	https://clinicaltrials.gov/study/NCT02402049	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	premenstrual tension	ESTRONE	targetBased	3	Unknown status	01/03/2015	https://clinicaltrials.gov/study/NCT02402049	0.7	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	infertility	NIMODIPINE	targetBased	2	Terminated	01/12/2012	https://clinicaltrials.gov/study/NCT01551368	0.2	LoF	protect	small number of patients got recruited
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	pelvic organ prolapse	VASOPRESSIN	targetBased	4	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06419075	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		abortion	ESKETAMINE	targetBased	2	Completed	01/08/2022	https://clinicaltrials.gov/study/NCT05635955	0.2	LoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	EXENATIDE	targetBased	4	Completed	04/01/2021	https://clinicaltrials.gov/study/NCT04969627	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	EXENATIDE	targetBased	4	Completed	04/01/2021	https://clinicaltrials.gov/study/NCT04969627	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	EXENATIDE	targetBased	4	Completed	04/01/2021	https://clinicaltrials.gov/study/NCT04969627	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	EXENATIDE	targetBased	2	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00344851	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	EXENATIDE	targetBased	2	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00344851	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	EXENATIDE	targetBased	2	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00344851	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	sexual dysfunction	OXYTOCIN	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT02229721	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	Atrophic Vaginitis	OXYTOCIN	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01987804	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	Uterine Inertia	OXYTOCIN	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00785395	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	Uterine Inertia	OXYTOCIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18fe8365-86e3-414e-84dc-c98e097a2f36	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Completed	08/04/2018	https://clinicaltrials.gov/study/NCT03463993	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02303418	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	2	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT02079558	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02954068	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Withdrawn	01/07/2013	https://clinicaltrials.gov/study/NCT01710566	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01932060	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	2	Recruiting	03/02/2021	https://clinicaltrials.gov/study/NCT04724187	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	2	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT03006380	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	4	Completed	04/01/2018	https://clinicaltrials.gov/study/NCT03755531	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Withdrawn	01/01/2016	https://clinicaltrials.gov/study/NCT02503319	0.7	GoF	protect	Authorization denied
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	2	Unknown status	30/09/2017	https://clinicaltrials.gov/study/NCT03395730	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	4	Completed	01/11/2018	https://clinicaltrials.gov/study/NCT03676621	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	4	Unknown status	01/11/2010	https://clinicaltrials.gov/study/NCT01236482	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	2	Recruiting	20/01/2020	https://clinicaltrials.gov/study/NCT04117243	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT02053922	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06010368	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Completed	01/12/2017	https://clinicaltrials.gov/study/NCT03591679	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	2	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02562300	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02306733	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Unknown status	01/09/2015	https://clinicaltrials.gov/study/NCT02319707	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02391636	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT03344302	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02216383	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Completed	30/01/2018	https://clinicaltrials.gov/study/NCT02775773	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Completed	02/07/2017	https://clinicaltrials.gov/study/NCT03148574	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	4	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT03651882	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Recruiting	01/03/2022	https://clinicaltrials.gov/study/NCT05245227	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	4	Completed	02/09/2018	https://clinicaltrials.gov/study/NCT03680339	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	4	Completed	20/12/2022	https://clinicaltrials.gov/study/NCT05664659	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	OXYTOCIN	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT01373359	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	placenta praevia	OXYTOCIN	targetBased	4	Completed	04/05/2022	https://clinicaltrials.gov/study/NCT05340205	1	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	preterm premature rupture of the membranes	NIFEDIPINE	targetBased	3	Recruiting	07/10/2019	https://clinicaltrials.gov/study/NCT03976063	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	placenta praevia	NIFEDIPINE	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00620724	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	placenta praevia	NIFEDIPINE	targetBased	3	Completed	01/06/2018	https://clinicaltrials.gov/study/NCT03542552	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f94df9-0692-4462-a7f0-fe019a0a3f07	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f94df9-0692-4462-a7f0-fe019a0a3f07	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL VALERATE	targetBased	2	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01933204	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL VALERATE	targetBased	2	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01933204	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL VALERATE	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT01300676	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL VALERATE	targetBased	2	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT01300676	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f94df9-0692-4462-a7f0-fe019a0a3f07	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f94df9-0692-4462-a7f0-fe019a0a3f07	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ESTRADIOL VALERATE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT02352597	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	ESTRADIOL VALERATE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT02352597	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anovulation	ESTRADIOL VALERATE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02186782	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anovulation	ESTRADIOL VALERATE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02186782	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5f32941-3427-4a38-bc3d-38337b41d9d3	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5f32941-3427-4a38-bc3d-38337b41d9d3	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d29dc3b-e19a-4924-8ad4-85018f0ab395	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d29dc3b-e19a-4924-8ad4-85018f0ab395	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f94df9-0692-4462-a7f0-fe019a0a3f07	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f94df9-0692-4462-a7f0-fe019a0a3f07	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	ovarian hyperstimulation syndrome	ESTRADIOL VALERATE	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01500863	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	ovarian hyperstimulation syndrome	ESTRADIOL VALERATE	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01500863	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ESTRADIOL VALERATE	targetBased	4	Completed	15/01/2015	https://clinicaltrials.gov/study/NCT03124524	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ESTRADIOL VALERATE	targetBased	4	Completed	15/01/2015	https://clinicaltrials.gov/study/NCT03124524	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ESTRADIOL VALERATE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00909857	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Dysmenorrhea	ESTRADIOL VALERATE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00909857	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Recruiting	10/10/2016	https://clinicaltrials.gov/study/NCT02330757	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Recruiting	10/10/2016	https://clinicaltrials.gov/study/NCT02330757	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	3	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT02251925	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	3	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT02251925	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Unknown status	01/05/2011	https://clinicaltrials.gov/study/NCT01353846	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Unknown status	01/05/2011	https://clinicaltrials.gov/study/NCT01353846	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01419353	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01419353	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	3	Unknown status	01/12/2018	https://clinicaltrials.gov/study/NCT03832894	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	3	Unknown status	01/12/2018	https://clinicaltrials.gov/study/NCT03832894	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01501448	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01501448	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01218386	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01218386	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT00843570	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT00843570	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	2	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02845388	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	2	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02845388	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Completed	12/08/2020	https://clinicaltrials.gov/study/NCT04507022	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Completed	12/08/2020	https://clinicaltrials.gov/study/NCT04507022	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02186782	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTRADIOL VALERATE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02186782	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	female infertility	ESTRADIOL VALERATE	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT05197374	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	female infertility	ESTRADIOL VALERATE	targetBased	4	Completed	01/06/2020	https://clinicaltrials.gov/study/NCT05197374	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f94df9-0692-4462-a7f0-fe019a0a3f07	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f94df9-0692-4462-a7f0-fe019a0a3f07	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5f32941-3427-4a38-bc3d-38337b41d9d3	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5f32941-3427-4a38-bc3d-38337b41d9d3	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d29dc3b-e19a-4924-8ad4-85018f0ab395	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Premature ovarian insufficiency	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d29dc3b-e19a-4924-8ad4-85018f0ab395	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	male infertility	ESTRADIOL VALERATE	targetBased	4	Completed	12/08/2020	https://clinicaltrials.gov/study/NCT04507022	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	male infertility	ESTRADIOL VALERATE	targetBased	4	Completed	12/08/2020	https://clinicaltrials.gov/study/NCT04507022	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL VALERATE	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00816556	0.7	GoF	protect	Funding
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	ESTRADIOL VALERATE	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00816556	0.7	GoF	protect	Funding
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Menorrhagia	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02c91fba-9c47-43ef-ac78-e82369798834	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Menorrhagia	ESTRADIOL VALERATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02c91fba-9c47-43ef-ac78-e82369798834	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	habitual abortion	HYDROXYCHLOROQUINE	targetBased	3	Active, not recruiting	04/12/2017	https://clinicaltrials.gov/study/NCT03165136	0.7	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	infertility	ERGOCALCIFEROL	targetBased	4	Completed	06/07/2017	https://clinicaltrials.gov/study/NCT03209856	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	infertility	ERGOCALCIFEROL	targetBased	4	Recruiting	11/02/2021	https://clinicaltrials.gov/study/NCT04547530	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	menopause	ERGOCALCIFEROL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	polycystic ovary syndrome	ERGOCALCIFEROL	targetBased	3	Unknown status	01/07/2017	https://clinicaltrials.gov/study/NCT03396380	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	polycystic ovary syndrome	ERGOCALCIFEROL	targetBased	4	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT03898934	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	polycystic ovary syndrome	ERGOCALCIFEROL	targetBased	4	Unknown status	02/01/2018	https://clinicaltrials.gov/study/NCT03806036	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	hypospadias	ATROPINE	targetBased	2	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02752308	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	hypospadias	ATROPINE	targetBased	2	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02752308	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	hypospadias	ATROPINE	targetBased	2	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02752308	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	hypospadias	ATROPINE	targetBased	2	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02752308	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	hypospadias	ATROPINE	targetBased	2	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02752308	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Autosomal dominant polycystic kidney disease	CILNIDIPINE	targetBased	2	Unknown status	01/07/2009	https://clinicaltrials.gov/study/NCT00890279	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Autosomal dominant polycystic kidney disease	CILNIDIPINE	targetBased	4	Unknown status	01/12/2007	https://clinicaltrials.gov/study/NCT00541853	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRONE SULFURIC ACID	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTRONE SULFURIC ACID	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRONE SULFURIC ACID	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRONE SULFURIC ACID	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRONE SULFURIC ACID	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTRONE SULFURIC ACID	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	AIDS	VINCRISTINE SULFATE	targetBased	2	Completed	14/01/2015	https://clinicaltrials.gov/study/NCT02199184	0.2	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE HYDROCHLORIDE	targetBased	4	Active, not recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05519813	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE HYDROCHLORIDE	targetBased	4	Active, not recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05519813	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE HYDROCHLORIDE	targetBased	4	Active, not recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05519813	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE HYDROCHLORIDE	targetBased	4	Active, not recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05519813	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE HYDROCHLORIDE	targetBased	4	Active, not recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05519813	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	PIOGLITAZONE HYDROCHLORIDE	targetBased	4	Active, not recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05519813	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Dysmenorrhea	SCOPOLAMINE	targetBased	3	Not yet recruiting	30/01/2025	https://clinicaltrials.gov/study/NCT05640232	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Dysmenorrhea	SCOPOLAMINE	targetBased	3	Not yet recruiting	30/01/2025	https://clinicaltrials.gov/study/NCT05640232	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Dysmenorrhea	SCOPOLAMINE	targetBased	3	Not yet recruiting	30/01/2025	https://clinicaltrials.gov/study/NCT05640232	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Dysmenorrhea	SCOPOLAMINE	targetBased	3	Not yet recruiting	30/01/2025	https://clinicaltrials.gov/study/NCT05640232	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Dysmenorrhea	SCOPOLAMINE	targetBased	3	Not yet recruiting	30/01/2025	https://clinicaltrials.gov/study/NCT05640232	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	erectile dysfunction	PF-00446687	targetBased	2	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00862888	0.2	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	erectile dysfunction	PF-00446687	targetBased	2	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00862888	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	PF-00446687	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00479570	0.2	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	PF-00446687	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00479570	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	sexual dysfunction	BUSPIRONE HYDROCHLORIDE	targetBased	2	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01743235	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	sexual dysfunction	BUSPIRONE HYDROCHLORIDE	targetBased	2	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01743235	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86b90d68-bfb6-47f6-aa5b-a6642391ff13	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTRADIOL ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86b90d68-bfb6-47f6-aa5b-a6642391ff13	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	acromegaly	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	infertility	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	hypogonadism	BROMOCRIPTINE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822	1	GoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	female reproductive system disease	SEVOFLURANE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT01437462	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	female reproductive system disease	SEVOFLURANE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT01437462	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTROPIPATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTROPIPATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROPIPATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROPIPATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTROPIPATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTROPIPATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02134249	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02134249	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02134249	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02134249	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02134249	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02134249	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	4	Completed	23/09/2019	https://clinicaltrials.gov/study/NCT04096027	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	4	Completed	23/09/2019	https://clinicaltrials.gov/study/NCT04096027	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	4	Completed	23/09/2019	https://clinicaltrials.gov/study/NCT04096027	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	4	Completed	23/09/2019	https://clinicaltrials.gov/study/NCT04096027	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	4	Completed	23/09/2019	https://clinicaltrials.gov/study/NCT04096027	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	4	Completed	23/09/2019	https://clinicaltrials.gov/study/NCT04096027	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Unknown status	01/07/2018	https://clinicaltrials.gov/study/NCT03549741	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Unknown status	01/07/2018	https://clinicaltrials.gov/study/NCT03549741	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Unknown status	01/07/2018	https://clinicaltrials.gov/study/NCT03549741	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Unknown status	01/07/2018	https://clinicaltrials.gov/study/NCT03549741	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Unknown status	01/07/2018	https://clinicaltrials.gov/study/NCT03549741	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Unknown status	01/07/2018	https://clinicaltrials.gov/study/NCT03549741	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02271360	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02271360	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02271360	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02271360	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02271360	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	infertility	CABERGOLINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02271360	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT01278342	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT01278342	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT01278342	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT01278342	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT01278342	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT01278342	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00595140	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00595140	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00595140	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00595140	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00595140	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00595140	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00376064	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00376064	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00376064	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00376064	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00376064	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	acromegaly	CABERGOLINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00376064	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	reproductive system disease	CABERGOLINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02644304	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	reproductive system disease	CABERGOLINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02644304	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	reproductive system disease	CABERGOLINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02644304	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	reproductive system disease	CABERGOLINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02644304	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	reproductive system disease	CABERGOLINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02644304	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	reproductive system disease	CABERGOLINE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02644304	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	polycystic ovary syndrome	CABERGOLINE	targetBased	2	Completed	21/09/2022	https://clinicaltrials.gov/study/NCT05981742	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	polycystic ovary syndrome	CABERGOLINE	targetBased	2	Completed	21/09/2022	https://clinicaltrials.gov/study/NCT05981742	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	polycystic ovary syndrome	CABERGOLINE	targetBased	2	Completed	21/09/2022	https://clinicaltrials.gov/study/NCT05981742	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	polycystic ovary syndrome	CABERGOLINE	targetBased	2	Completed	21/09/2022	https://clinicaltrials.gov/study/NCT05981742	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	polycystic ovary syndrome	CABERGOLINE	targetBased	2	Completed	21/09/2022	https://clinicaltrials.gov/study/NCT05981742	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	polycystic ovary syndrome	CABERGOLINE	targetBased	2	Completed	21/09/2022	https://clinicaltrials.gov/study/NCT05981742	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	abortion	CABERGOLINE	targetBased	4	Recruiting	18/12/2023	https://clinicaltrials.gov/study/NCT06123026	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	abortion	CABERGOLINE	targetBased	4	Recruiting	18/12/2023	https://clinicaltrials.gov/study/NCT06123026	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	abortion	CABERGOLINE	targetBased	4	Recruiting	18/12/2023	https://clinicaltrials.gov/study/NCT06123026	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	abortion	CABERGOLINE	targetBased	4	Recruiting	18/12/2023	https://clinicaltrials.gov/study/NCT06123026	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	abortion	CABERGOLINE	targetBased	4	Recruiting	18/12/2023	https://clinicaltrials.gov/study/NCT06123026	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	abortion	CABERGOLINE	targetBased	4	Recruiting	18/12/2023	https://clinicaltrials.gov/study/NCT06123026	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	endometriosis	CABERGOLINE	targetBased	2	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02542410	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	endometriosis	CABERGOLINE	targetBased	2	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02542410	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	endometriosis	CABERGOLINE	targetBased	2	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02542410	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	endometriosis	CABERGOLINE	targetBased	2	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02542410	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	endometriosis	CABERGOLINE	targetBased	2	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02542410	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	endometriosis	CABERGOLINE	targetBased	2	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02542410	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	endometriosis	CABERGOLINE	targetBased	2	Recruiting	02/12/2019	https://clinicaltrials.gov/study/NCT03928288	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	endometriosis	CABERGOLINE	targetBased	2	Recruiting	02/12/2019	https://clinicaltrials.gov/study/NCT03928288	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	endometriosis	CABERGOLINE	targetBased	2	Recruiting	02/12/2019	https://clinicaltrials.gov/study/NCT03928288	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	endometriosis	CABERGOLINE	targetBased	2	Recruiting	02/12/2019	https://clinicaltrials.gov/study/NCT03928288	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	endometriosis	CABERGOLINE	targetBased	2	Recruiting	02/12/2019	https://clinicaltrials.gov/study/NCT03928288	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	endometriosis	CABERGOLINE	targetBased	2	Recruiting	02/12/2019	https://clinicaltrials.gov/study/NCT03928288	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Unknown status	20/12/2017	https://clinicaltrials.gov/study/NCT02620605	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Unknown status	20/12/2017	https://clinicaltrials.gov/study/NCT02620605	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Unknown status	20/12/2017	https://clinicaltrials.gov/study/NCT02620605	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Unknown status	20/12/2017	https://clinicaltrials.gov/study/NCT02620605	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Unknown status	20/12/2017	https://clinicaltrials.gov/study/NCT02620605	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Unknown status	20/12/2017	https://clinicaltrials.gov/study/NCT02620605	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00440258	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00440258	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00440258	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00440258	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00440258	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00440258	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	2	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02875587	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	2	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02875587	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	2	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02875587	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	2	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02875587	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	2	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02875587	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	2	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02875587	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01535859	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01535859	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01535859	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01535859	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01535859	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01535859	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	2	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT02461875	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	2	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT02461875	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	2	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT02461875	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	2	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT02461875	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	2	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT02461875	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	CABERGOLINE	targetBased	2	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT02461875	0.2	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	menopause	ARMODAFINIL	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01460628	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	menopause	LISDEXAMFETAMINE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01977625	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED SYNTHETIC A	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cd07b54-f66f-4040-9058-462324267196	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED SYNTHETIC A	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cd07b54-f66f-4040-9058-462324267196	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED SYNTHETIC A	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cd07b54-f66f-4040-9058-462324267196	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, ESTERIFIED	targetBased	2	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00141557	0.2	GoF	protect	Lack of enrollment
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, ESTERIFIED	targetBased	2	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00160342	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, ESTERIFIED	targetBased	2	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00141544	0.2	GoF	protect	Lack of enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, ESTERIFIED	targetBased	2	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00160342	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, ESTERIFIED	targetBased	2	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00160342	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, ESTERIFIED	targetBased	2	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00141544	0.2	GoF	protect	Lack of enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, ESTERIFIED	targetBased	2	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00141544	0.2	GoF	protect	Lack of enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, ESTERIFIED	targetBased	2	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00141557	0.2	GoF	protect	Lack of enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, ESTERIFIED	targetBased	2	Terminated	01/07/2004	https://clinicaltrials.gov/study/NCT00141557	0.2	GoF	protect	Lack of enrollment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	primary ovarian insufficiency	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	hypogonadism	ESTROGENS, ESTERIFIED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	SYNTHETIC CONJUGATED ESTROGENS, B	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00196378	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	SYNTHETIC CONJUGATED ESTROGENS, B	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0625060-29c7-4cda-b6f9-cfa15e59775e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	SYNTHETIC CONJUGATED ESTROGENS, B	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00196378	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	SYNTHETIC CONJUGATED ESTROGENS, B	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00196378	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	SYNTHETIC CONJUGATED ESTROGENS, B	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0625060-29c7-4cda-b6f9-cfa15e59775e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	SYNTHETIC CONJUGATED ESTROGENS, B	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0625060-29c7-4cda-b6f9-cfa15e59775e	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	uterine prolapse	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02431897	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00224094	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00149604	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	2	Unknown status		https://clinicaltrials.gov/study/NCT00005768	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01295892	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00000601	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1994	https://clinicaltrials.gov/study/NCT00000549	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00745108	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00000555	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	28/11/2000	https://clinicaltrials.gov/study/NCT00026286	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00234819	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	4	Active, not recruiting	01/05/2007	https://clinicaltrials.gov/study/NCT00623311	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	3	Recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT05586724	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTROGENS, CONJUGATED	targetBased	4	Withdrawn	01/07/2016	https://clinicaltrials.gov/study/NCT02860897	1	GoF	protect	Unable to provide study medications due to cost.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	uterine prolapse	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02431897	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	uterine prolapse	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02431897	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/11/2018	https://clinicaltrials.gov/study/NCT03568708	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/11/2018	https://clinicaltrials.gov/study/NCT03568708	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	primary ovarian insufficiency	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	sexual dysfunction	ESTROGENS, CONJUGATED	targetBased	4	Terminated	30/06/2017	https://clinicaltrials.gov/study/NCT03018106	1	GoF	protect	Obstacles with recruitment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00000555	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00000555	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	4	Active, not recruiting	01/05/2007	https://clinicaltrials.gov/study/NCT00623311	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	4	Active, not recruiting	01/05/2007	https://clinicaltrials.gov/study/NCT00623311	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00745108	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00745108	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	28/11/2000	https://clinicaltrials.gov/study/NCT00026286	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	28/11/2000	https://clinicaltrials.gov/study/NCT00026286	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00224094	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00224094	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00000601	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/07/1995	https://clinicaltrials.gov/study/NCT00000601	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01295892	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01295892	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000559	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00149604	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	2	Completed	01/03/2000	https://clinicaltrials.gov/study/NCT00149604	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT05586724	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT05586724	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	4	Withdrawn	01/07/2016	https://clinicaltrials.gov/study/NCT02860897	1	GoF	protect	Unable to provide study medications due to cost.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	4	Withdrawn	01/07/2016	https://clinicaltrials.gov/study/NCT02860897	1	GoF	protect	Unable to provide study medications due to cost.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	2	Unknown status		https://clinicaltrials.gov/study/NCT00005768	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	2	Unknown status		https://clinicaltrials.gov/study/NCT00005768	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1994	https://clinicaltrials.gov/study/NCT00000549	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1994	https://clinicaltrials.gov/study/NCT00000549	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00234819	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00234819	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	infertility	ESTROGENS, CONJUGATED	targetBased	4	Unknown status	01/11/2011	https://clinicaltrials.gov/study/NCT01237535	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	infertility	ESTROGENS, CONJUGATED	targetBased	4	Unknown status	01/07/2016	https://clinicaltrials.gov/study/NCT03120715	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	primary ovarian insufficiency	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/11/2018	https://clinicaltrials.gov/study/NCT03568708	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	primary ovarian insufficiency	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTROGENS, CONJUGATED	targetBased	4	Unknown status	01/07/2016	https://clinicaltrials.gov/study/NCT03120715	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTROGENS, CONJUGATED	targetBased	4	Unknown status	01/07/2016	https://clinicaltrials.gov/study/NCT03120715	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTROGENS, CONJUGATED	targetBased	4	Unknown status	01/11/2011	https://clinicaltrials.gov/study/NCT01237535	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	ESTROGENS, CONJUGATED	targetBased	4	Unknown status	01/11/2011	https://clinicaltrials.gov/study/NCT01237535	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal atrophic vaginitis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal atrophic vaginitis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	hypogonadism	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal atrophic vaginitis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	sexual dysfunction	ESTROGENS, CONJUGATED	targetBased	4	Terminated	30/06/2017	https://clinicaltrials.gov/study/NCT03018106	1	GoF	protect	Obstacles with recruitment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	sexual dysfunction	ESTROGENS, CONJUGATED	targetBased	4	Terminated	30/06/2017	https://clinicaltrials.gov/study/NCT03018106	1	GoF	protect	Obstacles with recruitment
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	bilateral breast carcinoma	IXABEPILONE	targetBased	2	Active, not recruiting	30/03/2009	https://clinicaltrials.gov/study/NCT00877500	0.2	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	ESTETROL	targetBased	3	Active, not recruiting	30/12/2019	https://clinicaltrials.gov/study/NCT04209543	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTETROL	targetBased	3	Active, not recruiting	30/12/2019	https://clinicaltrials.gov/study/NCT04209543	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	ESTETROL	targetBased	3	Active, not recruiting	30/12/2019	https://clinicaltrials.gov/study/NCT04209543	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature ejaculation	TRAMADOL	targetBased	4	Not yet recruiting	30/12/2021	https://clinicaltrials.gov/study/NCT05183334	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature ejaculation	TRAMADOL	targetBased	4	Not yet recruiting	30/12/2021	https://clinicaltrials.gov/study/NCT05183334	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature ejaculation	TRAMADOL	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT00983736	0.7	GoF	protect	This study was terminated because of recruitment difficulties.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature ejaculation	TRAMADOL	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT00983736	0.7	GoF	protect	This study was terminated because of recruitment difficulties.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature ejaculation	TRAMADOL	targetBased	3	Terminated	01/08/2009	https://clinicaltrials.gov/study/NCT00983151	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature ejaculation	TRAMADOL	targetBased	3	Terminated	01/08/2009	https://clinicaltrials.gov/study/NCT00983151	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Dysmenorrhea	TRAMADOL	targetBased	4	Completed	25/04/2018	https://clinicaltrials.gov/study/NCT03509740	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Dysmenorrhea	TRAMADOL	targetBased	4	Completed	25/04/2018	https://clinicaltrials.gov/study/NCT03509740	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature ejaculation	TRAMADOL HYDROCHLORIDE	targetBased	3	Terminated	01/08/2009	https://clinicaltrials.gov/study/NCT00983151	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature ejaculation	TRAMADOL HYDROCHLORIDE	targetBased	3	Terminated	01/08/2009	https://clinicaltrials.gov/study/NCT00983151	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature ejaculation	TRAMADOL HYDROCHLORIDE	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT00983736	0.7	GoF	protect	This study was terminated because of recruitment difficulties.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature ejaculation	TRAMADOL HYDROCHLORIDE	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT00983736	0.7	GoF	protect	This study was terminated because of recruitment difficulties.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature ejaculation	TRAMADOL HYDROCHLORIDE	targetBased	4	Not yet recruiting	30/12/2021	https://clinicaltrials.gov/study/NCT05183334	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	premature ejaculation	TRAMADOL HYDROCHLORIDE	targetBased	4	Not yet recruiting	30/12/2021	https://clinicaltrials.gov/study/NCT05183334	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	infertility	NOLASIBAN	targetBased	2	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02310802	0.2	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	infertility	NOLASIBAN	targetBased	3	Completed	10/01/2019	https://clinicaltrials.gov/study/NCT03758885	0.7	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	infertility	NOLASIBAN	targetBased	3	Completed	06/03/2017	https://clinicaltrials.gov/study/NCT03081208	0.7	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	pelvic organ prolapse	ALFACALCIDOL	targetBased	3	Completed	01/11/2020	https://clinicaltrials.gov/study/NCT05505253	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	polycystic ovary syndrome	ALFACALCIDOL	targetBased	2	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02656121	0.2	GoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	erectile dysfunction	SAR-407899	targetBased	2	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00914277	0.2	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Autosomal dominant polycystic kidney disease	BARDOXOLONE METHYL	targetBased	3	Terminated	29/05/2019	https://clinicaltrials.gov/study/NCT03918447	0.7	LoF	protect	Discontinuation of all bardoxolone chronic kidney disease programs
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Autosomal dominant polycystic kidney disease	BARDOXOLONE METHYL	targetBased	3	Terminated	29/05/2019	https://clinicaltrials.gov/study/NCT03918447	0.7	LoF	protect	Discontinuation of all bardoxolone chronic kidney disease programs
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Autosomal dominant polycystic kidney disease	BARDOXOLONE METHYL	targetBased	3	Terminated	29/05/2019	https://clinicaltrials.gov/study/NCT03918447	0.7	LoF	protect	Discontinuation of all bardoxolone chronic kidney disease programs
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Autosomal dominant polycystic kidney disease	BARDOXOLONE METHYL	targetBased	3	Terminated	29/05/2019	https://clinicaltrials.gov/study/NCT03918447	0.7	LoF	protect	Discontinuation of all bardoxolone chronic kidney disease programs
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Autosomal dominant polycystic kidney disease	BARDOXOLONE METHYL	targetBased	3	Terminated	29/05/2019	https://clinicaltrials.gov/study/NCT03918447	0.7	LoF	protect	Discontinuation of all bardoxolone chronic kidney disease programs
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Autosomal dominant polycystic kidney disease	BARDOXOLONE METHYL	targetBased	3	Terminated	29/05/2019	https://clinicaltrials.gov/study/NCT03918447	0.7	LoF	protect	Discontinuation of all bardoxolone chronic kidney disease programs
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	Autosomal dominant polycystic kidney disease	BARDOXOLONE METHYL	targetBased	3	Terminated	29/05/2019	https://clinicaltrials.gov/study/NCT03918447	0.7	LoF	protect	Discontinuation of all bardoxolone chronic kidney disease programs
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	Nuclear factor erythroid 2-related factor 2	Autosomal dominant polycystic kidney disease	BARDOXOLONE METHYL	targetBased	3	Terminated	29/05/2019	https://clinicaltrials.gov/study/NCT03918447	0.7	LoF	protect	Discontinuation of all bardoxolone chronic kidney disease programs
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	NFE2 like bZIP transcription factor 2, Nuclear factor erythroid 2-related factor 2	Autosomal dominant polycystic kidney disease	BARDOXOLONE METHYL	pathwayBased	3	Terminated	29/05/2019	https://clinicaltrials.gov/study/NCT03918447	0.7	LoF	protect	Discontinuation of all bardoxolone chronic kidney disease programs
Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation	WEE1	WEE1	Wee1-like protein kinase	ovarian serous surface papillary adenocarcinoma	ADAVOSERTIB	targetBased	2	Active, not recruiting	21/07/2014	https://clinicaltrials.gov/study/NCT02101775	0.2	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	premature ejaculation	EPELSIBAN	targetBased	2	Completed	23/12/2009	https://clinicaltrials.gov/study/NCT01021553	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	4	Recruiting	07/10/2019	https://clinicaltrials.gov/study/NCT04179734	1	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	4	Recruiting	07/10/2019	https://clinicaltrials.gov/study/NCT04179734	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	3	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02338960	0.7	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	3	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02338960	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	3	Recruiting	10/05/2021	https://clinicaltrials.gov/study/NCT04943068	0.7	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	3	Recruiting	10/05/2021	https://clinicaltrials.gov/study/NCT04943068	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02333071	0.7	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02333071	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf	1	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01382719	0.2	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01382719	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	2	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00425256	0.2	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE	targetBased	2	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00425256	0.2	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	OSPEMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	reproductive system disease	OSPEMIFENE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00276094	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	reproductive system disease	OSPEMIFENE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00729469	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	sexual dysfunction	OSPEMIFENE	targetBased	4	Terminated	30/06/2017	https://clinicaltrials.gov/study/NCT03018106	1		protect	Obstacles with recruitment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	menopause	OSPEMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	menopause	OSPEMIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8462d6ab-e3cd-4efa-a360-75bf8f917287	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	sexual dysfunction	OSPEMIFENE	targetBased	4	Terminated	30/06/2017	https://clinicaltrials.gov/study/NCT03018106	1		protect	Obstacles with recruitment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	sexual dysfunction	OSPEMIFENE	targetBased	4	Terminated	30/06/2017	https://clinicaltrials.gov/study/NCT03018106	1		protect	Obstacles with recruitment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	reproductive system disease	OSPEMIFENE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00276094	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	reproductive system disease	OSPEMIFENE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00276094	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	reproductive system disease	OSPEMIFENE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00729469	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	reproductive system disease	OSPEMIFENE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00729469	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Atrophic Vaginitis	OSPEMIFENE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/senshio	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	OSPEMIFENE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/senshio	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Atrophic Vaginitis	OSPEMIFENE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/senshio	1		protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	mastitis	BARICITINIB	targetBased	2	Recruiting	01/01/2023	https://clinicaltrials.gov/study/NCT05852171	0.2	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	sexual dysfunction	FISPEMIFENE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02443090	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	FISPEMIFENE	targetBased	2	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00290134	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	FISPEMIFENE	targetBased	2	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00290134	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	FISPEMIFENE	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00415571	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	FISPEMIFENE	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00415571	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	FISPEMIFENE	targetBased	2	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT01061970	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	FISPEMIFENE	targetBased	2	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT01061970	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	FISPEMIFENE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02443090	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	FISPEMIFENE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02443090	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	hypogonadotropic hypogonadism	FISPEMIFENE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02443090	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	erectile dysfunction	FISPEMIFENE	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00415571	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	erectile dysfunction	FISPEMIFENE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02443090	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	erectile dysfunction	FISPEMIFENE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02443090	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	erectile dysfunction	FISPEMIFENE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02443090	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	erectile dysfunction	FISPEMIFENE	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00415571	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	erectile dysfunction	FISPEMIFENE	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00415571	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	hypogonadism	FISPEMIFENE	targetBased	2	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT01061970	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	hypogonadism	FISPEMIFENE	targetBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00415571	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	hypogonadism	FISPEMIFENE	targetBased	2	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00290134	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	sexual dysfunction	FISPEMIFENE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02443090	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	sexual dysfunction	FISPEMIFENE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02443090	0.2		protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	DULAGLUTIDE	targetBased	4	Completed	15/05/2021	https://clinicaltrials.gov/study/NCT04876027	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	DULAGLUTIDE	targetBased	4	Completed	15/05/2021	https://clinicaltrials.gov/study/NCT04876027	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	DULAGLUTIDE	targetBased	4	Completed	15/05/2021	https://clinicaltrials.gov/study/NCT04876027	1	GoF	protect
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	Anoctamin-1	AIDS	CROFELEMER	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45584fba-8081-4cd1-a21e-3ea8237f62ff	1	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	Anoctamin-1	AIDS	CROFELEMER	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45584fba-8081-4cd1-a21e-3ea8237f62ff	1	LoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	AIDS	CROFELEMER	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45584fba-8081-4cd1-a21e-3ea8237f62ff	1	LoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	AIDS	CROFELEMER	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45584fba-8081-4cd1-a21e-3ea8237f62ff	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube transitional cell carcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube endometrioid adenocarcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube clear cell adenocarcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	fallopian tube mucinous adenocarcinoma	PACLITAXEL POLIGLUMEX	targetBased	3	Unknown status	21/03/2005	https://clinicaltrials.gov/study/NCT00108745	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Klinefelter's syndrome	SEMAGLUTIDE	targetBased	3	Recruiting	21/03/2023	https://clinicaltrials.gov/study/NCT05586802	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Klinefelter's syndrome	SEMAGLUTIDE	targetBased	3	Recruiting	21/03/2023	https://clinicaltrials.gov/study/NCT05586802	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Klinefelter's syndrome	SEMAGLUTIDE	targetBased	3	Recruiting	21/03/2023	https://clinicaltrials.gov/study/NCT05586802	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	SEMAGLUTIDE	targetBased	2	Not yet recruiting	01/03/2025	https://clinicaltrials.gov/study/NCT05646199	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	SEMAGLUTIDE	targetBased	2	Not yet recruiting	01/03/2025	https://clinicaltrials.gov/study/NCT05646199	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	SEMAGLUTIDE	targetBased	2	Not yet recruiting	01/03/2025	https://clinicaltrials.gov/study/NCT05646199	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	SEMAGLUTIDE	targetBased	4	Recruiting	09/05/2023	https://clinicaltrials.gov/study/NCT05702905	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	SEMAGLUTIDE	targetBased	4	Recruiting	09/05/2023	https://clinicaltrials.gov/study/NCT05702905	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	SEMAGLUTIDE	targetBased	4	Recruiting	09/05/2023	https://clinicaltrials.gov/study/NCT05702905	1	GoF	protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	postpartum hemorrhage	FIBRINOGEN, HUMAN	targetBased	2	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01359878	0.2		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	postpartum hemorrhage	FIBRINOGEN, HUMAN	targetBased	2	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01359878	0.2		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	postpartum hemorrhage	FIBRINOGEN, HUMAN	targetBased	4	Completed	10/04/2014	https://clinicaltrials.gov/study/NCT02155725	1		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	postpartum hemorrhage	FIBRINOGEN, HUMAN	targetBased	4	Completed	10/04/2014	https://clinicaltrials.gov/study/NCT02155725	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	endometriosis	QUINAGOLIDE	targetBased	2	Completed	19/08/2019	https://clinicaltrials.gov/study/NCT03749109	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	endometriosis	QUINAGOLIDE	targetBased	2	Completed	19/08/2019	https://clinicaltrials.gov/study/NCT03749109	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	endometriosis	QUINAGOLIDE	targetBased	2	Completed	19/08/2019	https://clinicaltrials.gov/study/NCT03749109	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	endometriosis	QUINAGOLIDE	targetBased	2	Completed	19/08/2019	https://clinicaltrials.gov/study/NCT03749109	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	endometriosis	QUINAGOLIDE	targetBased	2	Completed	19/08/2019	https://clinicaltrials.gov/study/NCT03749109	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	endometriosis	QUINAGOLIDE	targetBased	2	Completed	19/08/2019	https://clinicaltrials.gov/study/NCT03749109	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	QUINAGOLIDE	targetBased	2	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00329693	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	QUINAGOLIDE	targetBased	2	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00329693	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	QUINAGOLIDE	targetBased	2	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00329693	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	QUINAGOLIDE	targetBased	2	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00329693	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	QUINAGOLIDE	targetBased	2	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00329693	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	QUINAGOLIDE	targetBased	2	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00329693	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	QUINAGOLIDE	targetBased	2	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00665041	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	QUINAGOLIDE	targetBased	2	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00665041	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	QUINAGOLIDE	targetBased	2	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00665041	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	QUINAGOLIDE	targetBased	2	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00665041	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	QUINAGOLIDE	targetBased	2	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00665041	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ovarian hyperstimulation syndrome	QUINAGOLIDE	targetBased	2	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00665041	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	infertility	BARUSIBAN	targetBased	2	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01723982	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acromegaly	CLOMIPHENE	targetBased	2	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT02274311	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acromegaly	CLOMIPHENE	targetBased	2	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT02274311	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04870502	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04870502	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	2	Completed	19/07/2018	https://clinicaltrials.gov/study/NCT03674385	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	2	Completed	19/07/2018	https://clinicaltrials.gov/study/NCT03674385	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	2	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02775734	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	2	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02775734	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00795808	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00795808	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	3	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02255578	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	3	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02255578	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02436226	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02436226	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Terminated	02/07/2020	https://clinicaltrials.gov/study/NCT04306692	1		protect	clomiphene citrate is no longer being considered as standard treatment for polycystic ovary syndrome
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Terminated	02/07/2020	https://clinicaltrials.gov/study/NCT04306692	1		protect	clomiphene citrate is no longer being considered as standard treatment for polycystic ovary syndrome
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	3	Recruiting	12/09/2023	https://clinicaltrials.gov/study/NCT03059173	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	3	Recruiting	12/09/2023	https://clinicaltrials.gov/study/NCT03059173	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=834802c8-911f-55e7-e053-2a91aa0a5c7d	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=834802c8-911f-55e7-e053-2a91aa0a5c7d	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	3	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00427700	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	3	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00427700	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02344888	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02344888	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Unknown status	02/01/2018	https://clinicaltrials.gov/study/NCT03806036	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Unknown status	02/01/2018	https://clinicaltrials.gov/study/NCT03806036	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02479256	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02479256	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	2	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02551367	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	2	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02551367	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT03630341	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT03630341	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT02352597	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT02352597	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anovulation	CLOMIPHENE	targetBased	2	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02551367	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anovulation	CLOMIPHENE	targetBased	2	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02551367	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anovulation	CLOMIPHENE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02186782	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anovulation	CLOMIPHENE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02186782	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anovulation	CLOMIPHENE	targetBased	2	Completed	10/03/2005	https://clinicaltrials.gov/study/NCT00213148	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anovulation	CLOMIPHENE	targetBased	2	Completed	10/03/2005	https://clinicaltrials.gov/study/NCT00213148	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	CLOMIPHENE	targetBased	2	Completed	02/04/2015	https://clinicaltrials.gov/study/NCT03933618	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	CLOMIPHENE	targetBased	2	Completed	02/04/2015	https://clinicaltrials.gov/study/NCT03933618	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	CLOMIPHENE	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01904734	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	CLOMIPHENE	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01904734	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	CLOMIPHENE	targetBased	2	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00697814	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	CLOMIPHENE	targetBased	2	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00697814	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	CLOMIPHENE	targetBased	2	Terminated	01/04/2019	https://clinicaltrials.gov/study/NCT03245827	0.2		protect	not enough recruitment
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	CLOMIPHENE	targetBased	2	Terminated	01/04/2019	https://clinicaltrials.gov/study/NCT03245827	0.2		protect	not enough recruitment
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00610077	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00610077	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02186782	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02186782	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02344888	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02344888	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	2	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00796289	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	2	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00796289	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00296465	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00296465	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49860a2f-92f2-4da8-b78f-0efc005d725a	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49860a2f-92f2-4da8-b78f-0efc005d725a	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	2	Unknown status	01/07/2018	https://clinicaltrials.gov/study/NCT03549741	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	2	Unknown status	01/07/2018	https://clinicaltrials.gov/study/NCT03549741	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d544453-f6d4-45a4-9ece-2f705b32011f	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d544453-f6d4-45a4-9ece-2f705b32011f	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53eff40f-37b1-47b1-a9b8-c22360855f18	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53eff40f-37b1-47b1-a9b8-c22360855f18	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02381184	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02381184	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02436226	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02436226	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	3	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT03241472	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	3	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT03241472	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9950303-9322-4f27-9e28-f1cedaf87b20	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9950303-9322-4f27-9e28-f1cedaf87b20	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2f33ee6-0c57-45d9-b8fc-a8daf2a2185c	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2f33ee6-0c57-45d9-b8fc-a8daf2a2185c	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/02/2012	https://clinicaltrials.gov/study/NCT01529177	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/02/2012	https://clinicaltrials.gov/study/NCT01529177	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	07/08/2017	https://clinicaltrials.gov/study/NCT03309436	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	07/08/2017	https://clinicaltrials.gov/study/NCT03309436	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT02690870	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT02690870	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	2	Completed	01/10/2021	https://clinicaltrials.gov/study/NCT05846906	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	2	Completed	01/10/2021	https://clinicaltrials.gov/study/NCT05846906	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/12/2017	https://clinicaltrials.gov/study/NCT03400722	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/12/2017	https://clinicaltrials.gov/study/NCT03400722	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00835744	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00835744	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02890238	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02890238	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be399623-6400-475d-93d3-1dedd4d43017	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be399623-6400-475d-93d3-1dedd4d43017	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02575248	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02575248	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	female infertility	CLOMIPHENE	targetBased	4	Completed	15/01/2021	https://clinicaltrials.gov/study/NCT05753098	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	female infertility	CLOMIPHENE	targetBased	4	Completed	15/01/2021	https://clinicaltrials.gov/study/NCT05753098	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	female infertility	CLOMIPHENE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01791751	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	female infertility	CLOMIPHENE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01791751	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	female infertility	CLOMIPHENE	targetBased	2	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02237755	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	female infertility	CLOMIPHENE	targetBased	2	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02237755	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	azoospermia	CLOMIPHENE	targetBased	3	Not yet recruiting	01/01/2023	https://clinicaltrials.gov/study/NCT03615547	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	azoospermia	CLOMIPHENE	targetBased	3	Not yet recruiting	01/01/2023	https://clinicaltrials.gov/study/NCT03615547	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	reproductive system disease	CLOMIPHENE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02644304	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	reproductive system disease	CLOMIPHENE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02644304	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	acromegaly	CLOMIPHENE CITRATE	targetBased	2	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT02274311	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	acromegaly	CLOMIPHENE CITRATE	targetBased	2	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT02274311	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=834802c8-911f-55e7-e053-2a91aa0a5c7d	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=834802c8-911f-55e7-e053-2a91aa0a5c7d	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT02352597	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT02352597	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02344888	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02344888	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	2	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02551367	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	2	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02551367	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04870502	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	2	Completed	01/04/2019	https://clinicaltrials.gov/study/NCT04870502	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	3	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02255578	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	3	Unknown status	01/09/2014	https://clinicaltrials.gov/study/NCT02255578	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	2	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02775734	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	2	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02775734	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	3	Recruiting	12/09/2023	https://clinicaltrials.gov/study/NCT03059173	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	3	Recruiting	12/09/2023	https://clinicaltrials.gov/study/NCT03059173	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02479256	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02479256	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02436226	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02436226	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Terminated	02/07/2020	https://clinicaltrials.gov/study/NCT04306692	1		protect	clomiphene citrate is no longer being considered as standard treatment for polycystic ovary syndrome
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Terminated	02/07/2020	https://clinicaltrials.gov/study/NCT04306692	1		protect	clomiphene citrate is no longer being considered as standard treatment for polycystic ovary syndrome
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Unknown status	02/01/2018	https://clinicaltrials.gov/study/NCT03806036	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Unknown status	02/01/2018	https://clinicaltrials.gov/study/NCT03806036	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT03630341	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	4	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT03630341	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	3	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00427700	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	3	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00427700	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	2	Completed	19/07/2018	https://clinicaltrials.gov/study/NCT03674385	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	polycystic ovary syndrome	CLOMIPHENE CITRATE	targetBased	2	Completed	19/07/2018	https://clinicaltrials.gov/study/NCT03674385	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anovulation	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02186782	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anovulation	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02186782	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anovulation	CLOMIPHENE CITRATE	targetBased	2	Completed	10/03/2005	https://clinicaltrials.gov/study/NCT00213148	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anovulation	CLOMIPHENE CITRATE	targetBased	2	Completed	10/03/2005	https://clinicaltrials.gov/study/NCT00213148	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	anovulation	CLOMIPHENE CITRATE	targetBased	2	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02551367	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	anovulation	CLOMIPHENE CITRATE	targetBased	2	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02551367	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	CLOMIPHENE CITRATE	targetBased	2	Completed	02/04/2015	https://clinicaltrials.gov/study/NCT03933618	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadism	CLOMIPHENE CITRATE	targetBased	2	Completed	02/04/2015	https://clinicaltrials.gov/study/NCT03933618	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	CLOMIPHENE CITRATE	targetBased	2	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00697814	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	hypogonadotropic hypogonadism	CLOMIPHENE CITRATE	targetBased	2	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00697814	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be399623-6400-475d-93d3-1dedd4d43017	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be399623-6400-475d-93d3-1dedd4d43017	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Unknown status	07/08/2017	https://clinicaltrials.gov/study/NCT03309436	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Unknown status	07/08/2017	https://clinicaltrials.gov/study/NCT03309436	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53eff40f-37b1-47b1-a9b8-c22360855f18	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53eff40f-37b1-47b1-a9b8-c22360855f18	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	3	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT03241472	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	3	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT03241472	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	2	Completed	01/10/2021	https://clinicaltrials.gov/study/NCT05846906	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	2	Completed	01/10/2021	https://clinicaltrials.gov/study/NCT05846906	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02381184	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	2	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02381184	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2f33ee6-0c57-45d9-b8fc-a8daf2a2185c	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2f33ee6-0c57-45d9-b8fc-a8daf2a2185c	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00610077	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00610077	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d544453-f6d4-45a4-9ece-2f705b32011f	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d544453-f6d4-45a4-9ece-2f705b32011f	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00296465	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00296465	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02890238	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/08/2016	https://clinicaltrials.gov/study/NCT02890238	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02186782	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02186782	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	2	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00796289	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	2	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00796289	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02575248	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02575248	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02436226	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02436226	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9950303-9322-4f27-9e28-f1cedaf87b20	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9950303-9322-4f27-9e28-f1cedaf87b20	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02344888	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT02344888	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	2	Unknown status	01/07/2018	https://clinicaltrials.gov/study/NCT03549741	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	2	Unknown status	01/07/2018	https://clinicaltrials.gov/study/NCT03549741	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00835744	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00835744	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/02/2012	https://clinicaltrials.gov/study/NCT01529177	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4	Unknown status	01/02/2012	https://clinicaltrials.gov/study/NCT01529177	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49860a2f-92f2-4da8-b78f-0efc005d725a	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	infertility	CLOMIPHENE CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49860a2f-92f2-4da8-b78f-0efc005d725a	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	female infertility	CLOMIPHENE CITRATE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01791751	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	female infertility	CLOMIPHENE CITRATE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01791751	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	female infertility	CLOMIPHENE CITRATE	targetBased	2	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02237755	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	female infertility	CLOMIPHENE CITRATE	targetBased	2	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02237755	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	female infertility	CLOMIPHENE CITRATE	targetBased	4	Completed	15/01/2021	https://clinicaltrials.gov/study/NCT05753098	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	female infertility	CLOMIPHENE CITRATE	targetBased	4	Completed	15/01/2021	https://clinicaltrials.gov/study/NCT05753098	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	azoospermia	CLOMIPHENE CITRATE	targetBased	3	Not yet recruiting	01/01/2023	https://clinicaltrials.gov/study/NCT03615547	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	azoospermia	CLOMIPHENE CITRATE	targetBased	3	Not yet recruiting	01/01/2023	https://clinicaltrials.gov/study/NCT03615547	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	reproductive system disease	CLOMIPHENE CITRATE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02644304	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	reproductive system disease	CLOMIPHENE CITRATE	targetBased	2	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02644304	0.2		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sexual dysfunction	CP-866087	targetBased	2	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00482664	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sexual dysfunction	CP-866087	targetBased	2	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00482664	0.2	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00499005	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT02053922	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02277041	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	3	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02303418	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02391636	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	2	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT02079558	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02044549	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	4	Completed	04/01/2018	https://clinicaltrials.gov/study/NCT03755531	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	4	Recruiting	05/04/2018	https://clinicaltrials.gov/study/NCT04300452	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	4	Completed	02/07/2018	https://clinicaltrials.gov/study/NCT03556852	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02277067	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	3	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02410759	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	4	Completed	20/12/2022	https://clinicaltrials.gov/study/NCT05664659	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	3	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02216383	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	4	Completed	07/08/2018	https://clinicaltrials.gov/study/NCT03651882	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	postpartum hemorrhage	CARBETOCIN	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT03693599	1	GoF	protect
Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3)	MAPK10	MAPK10	Mitogen-activated protein kinase 10	endometriosis	BENTAMAPIMOD	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01630252	0.2	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	menopause	MF101	targetBased	2	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00454441	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	LIRAGLUTIDE	targetBased	3	Not yet recruiting	30/07/2023	https://clinicaltrials.gov/study/NCT05965908	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	LIRAGLUTIDE	targetBased	3	Not yet recruiting	30/07/2023	https://clinicaltrials.gov/study/NCT05965908	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	polycystic ovary syndrome	LIRAGLUTIDE	targetBased	3	Not yet recruiting	30/07/2023	https://clinicaltrials.gov/study/NCT05965908	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE ACETATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf	1	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	sexual dysfunction	BREMELANOTIDE ACETATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	CHIGLITAZAR	targetBased	2	Enrolling by invitation	01/11/2023	https://clinicaltrials.gov/study/NCT06125587	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	CHIGLITAZAR	targetBased	2	Enrolling by invitation	01/11/2023	https://clinicaltrials.gov/study/NCT06125587	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	CHIGLITAZAR	targetBased	2	Enrolling by invitation	01/11/2023	https://clinicaltrials.gov/study/NCT06125587	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	CHIGLITAZAR	targetBased	2	Enrolling by invitation	01/11/2023	https://clinicaltrials.gov/study/NCT06125587	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	CHIGLITAZAR	targetBased	2	Enrolling by invitation	01/11/2023	https://clinicaltrials.gov/study/NCT06125587	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	polycystic ovary syndrome	CHIGLITAZAR	targetBased	2	Enrolling by invitation	01/11/2023	https://clinicaltrials.gov/study/NCT06125587	0.2	GoF	protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.